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The development of insulin resistance (IR) in the liver is one of the key pathophysiologic events in the 
development of type 2 diabetes mellitus, but most patients do not become uniformly resistant to the 
hepatic actions of insulin. Although insulin loses its ability to blunt glucose production, it largely retains its 
capacity to drive lipogenesis. This “selective IR” results in the characteristic hyperglycemia and 
dyslipidemia of type 2 diabetes. In this thesis, we take two approaches to better understand the 
mechanisms underlying selective IR. First, the compensatory chronic hyperinsulinemia (CHI) of insulin 
resistance downregulates levels of the insulin receptor (InsR). We have therefore modeled CHI in primary 
hepatocytes to demonstrate that the reduction in InsR number results in insufficient signaling capacity to 
halt glucose production while still leaving enough residual signaling capacity to promote lipogenesis. That 
is, the two processes are inherently differentially sensitive to insulin. Second, we hypothesize that FoxO1, 
a key insulin-inhibited transcription factor, coordinately regulates both hepatic glucose and lipid 
homeostasis. We have developed a transgenic mouse model heterozygous for a knocked-in allele of DNA 
binding-deficient FoxO1 and have proceeded to dissect the mechanisms by which FoxO1 differentially 
regulates glucose and lipid handling. We found that while the former requires FoxO1 to bind to its 
consensus sequences in target-gene promoters, the latter proceeds via a co-regulatory action of FoxO1. 
Taken together, these findings reveal novel connections between the glucose and lipid “arms” of the 
insulin-signaling pathway and how they may go awry in the run-up to diabetes. 
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administered religiously and without complaint.  
Given this history, it is no coincidence that I have dedicated the entirety of my time in biomedical 
research thus far – and very likely in the future – to studying various aspects of insulin action and 
production. During my time as a PhD student, I even presented Pa’s story as a model of how much 
diabetes research has improved quality and length of life for so many to the CUMC Board of Advisors. 
Near the end of his life, however, his insulin dosage requirements dropped and neither I nor apparently 
his doctors considered the possibility that it might be a sign of a problem. We will never know if it was or 
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not, but I will never forgive myself for not thinking to question it at the time. I will take this as a lesson in 
the importance of bridging the knowledge we obtain through our work in laboratory to the lives of our 
patients and loved ones.  
Pa was living proof of the old adage that still waters run deep. He never sought to draw attention 
but it was clear that behind his smiling eyes lay the soul of somebody who not only noticed but even 
reveled in the small wonders of life. He derived happiness from living in a world in which even the 
individual flowers and birds he sketched were imbued with a quiet dignity and intricate beauty that made 
everything feel as though it were meant to hang together by some benevolent grand design. He derived 
happiness from assembling his long and rich life into carefully curated and annotated photo albums and 
collections that tell of a journey well taken. But most of all, he derived happiness from giving everything he 
could for the ones he loved. For his country, he lied about his age to be able to begin his army service 
early. For his neighbors, he was eloquent and charming; everyone he knew around town from the 
pharmacist to the manager at Wendy’s remarked that their days felt brighter for having enjoyed his 
company. For his colleagues, he led always by example of patience and grace, spurring them to keep up 
with their former boss even a quarter century into his retirement.  
As for his family, however, there is no real way to express succinctly all that he gave, and of how 
much I miss all of that now. Yes, he gave of his considerable wisdom, he gave hugs and kisses, he gave 
countless memorable Thanksgiving dinners and hunts for the afikomen. Much as I miss those things, 
however, the hole in my heart that is left by his passing would not be refilled merely were those to return. 
Rather, I miss him, my real-life example of what a true human being is. I miss his warm smile and the way 
that it made me feel as though any worries I had were not so enormous that they could not be solved by 
approaching them as he would. I miss the way that he proved that the chaos of life in the modern world 
could be wrangled into order by being proactive yet patient. I miss his gentle sense of humor and how he 
laughed in his characteristic chuckle with and never at people. I miss the way he wanted to learn about 
everything. I miss the way he seemed to deeply understand everything I told him, even when some of it 
was not explicitly spoken. I miss the way that the world felt more humane and more purposeful because 
he was there to contribute his spirit to it.  
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I want all of this to be entered into the record forever in this dissertation because this work would 
not have been possible without Pa there to keep my head held high. And, just in case it was not already 
































1.1. Hormonal Regulation of Energy Homeostasis 
The First Law of Thermodynamics implies that energy must be supplied in at least equal measure to what 
the body must expend in carrying out the myriad processes of living [1]. The monosaccharide glucose is 
the metabolic fuel favored by most cell types in the body, in particular neurons and erythrocytes. Thus 
maintaining a relatively consistent, moderate blood glucose concentration (termed euglycemia) is a matter 
of grave physiologic importance.  Evolution has devised an intricate network of hormonal signals that 
coordinate nutrient catabolism and anabolism in a variety of tissues in order to maintain euglycemia 
regardless of the time of day or feeding state [2].  
Although much of the regulatory control of carbon metabolism remains controversial, a basic 
framework underpinning bodily energy flux has emerged through years of study. Following ingestion of 
food, nutrients are absorbed across the intestinal epithelium to enter the circulation. Upon passing 
through the islets of Langerhans, the endocrine compartment of the pancreas, these nutrients – especially 
glucose – trigger the secretion of the peptide hormone insulin from islet-resident pancreatic β cells [3 pp. 
753-756]. Other mechanisms also exist to link nutrient ingestion with insulin secretion, including the 
secretion of “incretin” hormones from the gut epithelium as well as neural pathways [4].  
Insulin in the bloodstream circulates to its various target organs whose cells express the insulin 
receptor (InsR). Insulin binds to this receptor to activate its downstream signaling pathways, as will be 
discussed in greater detail. Insulin is the body’s key anabolic signal, triggering the uptake and utilization of 
glucose from the bloodstream—especially by skeletal muscle and adipose tissue—as well as its storage 
as glycogen in liver and other sites. Insulin also coordinates the metabolism of lipids, including their 
biosynthesis by liver and adipose tissue as well as their inter-organ shuttling. In keeping with this general 
anabolic drive, insulin also promotes protein synthesis in a variety of tissues [3 pp. 744-756].  
 In the hours following food intake, insulin acts to partition dietary carbohydrates and lipids among 
various tissues in order to maintain euglycemia. As the energetic demands of cellular activity remain even 
while no new nutrients are absorbed, glucose is siphoned from the circulation, resulting in a lowering of 
blood glucose termed hypoglycemia. Even slight drops in blood sugar trigger the cessation of insulin 
secretion, thus curtailing the postprandial anabolic drive in order to reallocate energy reserves for 
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catabolic use. There are several overlapping mechanisms the body uses to signal this fed-to-fasting 
transition, including secretion of the peptide hormone glucagon from endocrine pancreatic α cells and 
glucocorticoids from the adrenal cortex as well as action of the sympathetic autonomic nervous system [3 
pp. 744-756, 5 pp. 1503-1508].  
 These “counterregulatory” responses serve to buoy blood glucose levels back toward normal by 
halting glucose uptake by muscle and fat, stimulating β-oxidation of fatty acids by multiple cell types, and 
by stimulating hepatic glucose production (HGP). This latter mechanism involves both the breakdown of 
stored glycogen (glycogenolysis) and the regeneration of glucose from its glycolytic breakdown products 
and from certain amino acids (gluconeogenesis). The counterregulatory response also relieves insulin’s 
inhibition of the export of free fatty acids (FFA) and glycerol from adipose tissue to liver (the process of 
lipolysis) for use as β-oxdiative and gluconeogenic precursors, respectively. Following the next feeding 
period, the hormonal balance shifts back from counterregulatory factors to insulin [3 pp. 744-756, 5 pp. 
1503-1508]. Both insulin and glucose itself work to suppress fasting-induced HGP in addition to insulin’s 
aforementioned anabolic actions [2, 6]. 
 Under cases of prolonged fasting and starvation, the ability of the liver to produce glucose wanes 
due to diminished supply of gluconeogenic precursors. In this case, fatty acids liberated by lipolysis can 
be partially oxidized in the liver to ketone bodies, such as acetoacetate and β-hydroxybutyrate, which can 
then be further oxidized by the brain. This state, known as ketoacidosis, although meant to help fuel vital 
processes, comes at a great cost, as the disruption of acid-base balance if unchecked can result in 
altered mental status, coma, and death [3 pp. 744-756, 5 p. 1407].  
 This work focuses on metabolic regulation in the liver, arguably the most important orchestrator of 
peripheral energy homeostasis. Indeed, as mentioned, the liver acts as the body’s major rheostat for fine-
tuning levels of glucose and lipids in the blood, and thus throughout the body. As will be discussed, the 
liver is also a relatively late but indubitably substantial contributor to the development of perhaps the most 




1.2. Diabetes Mellitus Results from Functional Insulin Deficiency 
1.2.1. Overview of Diabetes Mellitus 
The hormonal control of metabolism as described above is an elegant and intricate balance carefully 
stricken between the actions of insulin and counterregulatory factors [5 pp. 1503-1509]. Perturbations in 
this delicate balance result in metabolic disease, the most epidemiologically pressing of which is diabetes 
mellitus [7]. Diabetes mellitus, however, is actually a constellation of metabolic disorders united by a 
common etiology: the failure of insulin to counterweigh the counterregulatory hormones [7, 8]. This 
imbalance is reflected in the etymology of diabetes mellitus, “honeyed discharge,” refers to the spilling of 
glucose into the urine (glycosuria) [7, 9]. Glycosuria is the result of prolonged hyperglycemia, which in turn 
is due to the inability of insulin to fulfill all of its aforementioned goals in promoting glucose storage and 
utilization [9]. Meanwhile, counterregulatory hormones continue to drive their opposing processes, 
mobilizing glucose and decreasing its peripheral catabolism [7]. Based on epidemiologic data, the medical 
community has established three bright-line diagnostic criteria for diabetes [5 p. 1330, 10]: (i) a fasting 
blood glucose reading of 126 mg/dL or greater, (ii) a random blood glucose reading of above 200 mg/dL, 
and (iii) a HbA1c value of 6.5% or greater. This last metric is based on glycosylation of hemoglobin that is 
proportional to ambient blood glucose levels; it is therefore an index of chronic glycemic control [11].  
The “insulin failure” of diabetes, in practice, arises due to two main and related causes – either an 
absolute deficiency of insulin or a relative deficiency of insulin [8] . The most common cause of the first is 
autoimmune destruction of pancreatic β cells, referred to as type 1 diabetes mellitus (T1DM) [8]; less 
common causes of insulin deficiency include mutations in genes necessary for proper β-cell function 
(maturity onset diabetes of the young, or MODY) [12], pancreatitis [13], pancreatectomy [14], and the 
development of neutralizing antibodies to circulating insulin [15]. Treatment of these disorders requires 
first and foremost replacement of insulin to physiologic levels [16].  
By far the most prevalent form of the disease, however, is type 2 diabetes (T2DM), which arises 
from relative insulin deficiency [17]. Relative deficiency relates not only to production of insulin but also to 
its action [17-19]. That is, the target cells of insulin become less responsive to its actions, a state referred 
to as insulin resistance (IR) [17, 20]. This problem can also be formulated as a particular dose of insulin 
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not triggering a particular response to its normal maximal level; reaching that usual maximum requires a 
higher-than-normal dose of insulin [17]. Pancreatic β cells are able to compensate for IR, sometimes for 
many years, by undergoing hyperplasia to produce enough insulin as necessary to maintain euglycemia 
[5 pp. 1351-1352]. Over time, however, β cells fail to keep up production of insulin sufficient to overcome 
IR. This two-hit model – IR followed by β-cell failure – encapsulates the pathogenesis of T2DM [17] .  
Treatment of T2DM is in many ways more complex than treatment of T1DM [5 pp. 1364-1365]. 
Replacing “lost” insulin bypasses the pathologic lesion of T1DM, but in T2DM insulin therapy alone does 
not solve the underlying problem of IR [21]. In fact, type 2 diabetic patients often do not require insulin 
therapy unless their disease is quite advanced [22, 23]. Instead, they can be treated with a variety of 
drugs that act as insulin “sensitizers” [24]. By decreasing the severity of IR, patients’ own β cells – which, 
unlike in T1DM, are still at least partially active – may be able to pick up the slack [21]. In reality, the ideal 
therapy for T2DM would not address IR but rather the root cause of IR itself. The literature on the causes 
of IR is extensive, but epidemiologically speaking, it appears in Western societies often to boil down to 
years of living an unhealthy lifestyle, usually manifested as diet-induced obesity (DIO) [25-27]. 
Concordantly, prescribing a “lifestyle intervention” focusing on diet and exercise in and of itself is a proven 
means of combatting T2DM, and acts in a powerful synergy with pharmacotherapy [5 pp. 1360-1364, 28].  
Problematically, however, many diabetic patients do not adhere to their prescribed therapies, and 
thus the disease’s many complications are able to rear their ugly heads. Untreated diabetes appears to 
wreak havoc in particular on blood vessels, and thereby secondarily damage the organs served by the 
affected vasculature [5 pp. 1417-1432]. The complications of diabetes have therefore traditionally been 
grouped into two main categories: microvascular and macrovascular [29]. The microvascular 
complications of diabetes arise largely due to hyperglycemia, while the macrovascular complications of 
diabetes are believed to relate more to derangements in lipid metabolism [30-34]. Because of these 





1.2.2. Consequences of Hyperglycemia – Microvascular Complications 
Persistent hyperglycemia results over time in damage to small-caliber blood vessels and by extension to 
the tissues they serve; this is referred to as the microvascular complications of diabetes [29]. Although the 
relationship between glycemia and the incidence of particular complications is not strictly linear, large 
public-health studies demonstrate a strong and continuous correlation between the two in both T1DM and 
T2DM [16, 30, 31]. In particular, the correlation between glycemia and diabetic complications becomes 
much tighter above HbA1c levels of 7%, and thus this value represents a common target for glycemic 
control [10].  
 Three sites in particular, each richly vascularized with small-caliber vessels, represent major foci 
of hyperglycemic complications: the retina, the renal glomerulus, and the peripheral nerve [5 pp. 1417-
1420]. Over time, uncontrolled diabetes at these sites results in diabetic retinopathy, nephropathy, and 
neuropathy, respectively [5 pp. 1417-1420]. Diabetic retinopathy manifests as macular edema and has 
become the leading cause of adult-onset blindness in the United States [5 p. 1432]. Diabetic nephropathy 
has become the most common cause of end-stage renal disease (ESRD) [36], typically fatal within 4 
years of diagnosis [5 p. 1417]. Over 60% of diabetic patients suffer from neuropathies [5 p. 1417], which 
includes a variety of presentations including neuropathic pain, autonomic dysfunction (e.g., urinary 
incontinence, erectile dysfunction), and impaired motor coordination [37].  
 
1.2.3. Consequences of Dyslipidemia – Macrovascular Complications 
Diabetes had historically been thought of primarily as a disorder of carbohydrate metabolism, the 
microvascular complications of the disease serving as stigmata of chronic hyperglycemia. However, 
T2DM is also a disorder of lipid metabolism, and as a result rarely occurs in isolation. It is more typically 
associated with obesity, hypertension, and atherosclerosis, a pathologic assemblage referred to as 
“metabolic syndrome” and rooted in insulin resistance [38, 39]. T2DM, as with the IR state of metabolic 
syndrome generally, brings about characteristic lipid-metabolic abnormalities termed dyslipidemia. The 
typical abnormal blood lipid profile of T2DM includes high concentrations of TG and small, dense LDL and 
low concentrations of HDL [40]. Dyslipidemia, in turn, is thought to be responsible for the accelerated 
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development of atherosclerosis in major blood vessels including coronary and carotid arteries, hence 
“macrovascular complications” [41].  
Macrovascular complications are responsible for the largest portion of diabetic morbidity and 
mortality [42]. Indeed, the leading cause of death among people with diabetes, affecting as many as 80% 
of diabetic patients, is cardiovascular disease (CVD), including heart attack and stroke [43]. In fact, 
diabetic patients are up to four times more likely to develop CVD than non-diabetics [44]. Although 
hyperglycemia can contribute to and exacerbate CVD [45], CVD arises in large part as a primary result of 
insulin resistance rather than solely secondary to derangements in glucose metabolism as do the 
microvascular complications [46]. This is not necessarily surprising, however, as insulin is a dominant 
regulator of lipid metabolism in a variety of tissues.  
 
1.2.4. Hepatic Steatosis 
Despite the importance of serum lipid profile and events at the arterial wall in the pathogenesis of CVD, 
the main focus of this thesis is on insulin action in the liver. The importance of this is not to be 
underestimated, however, as IR in the liver alone is sufficient to foment dyslipidemia and atherosclerosis 
[47]. Moreover, the liver itself is vulnerable to lipid abnormalities. Obesity and IR are strongly correlated 
with the buildup of triglyceride in the liver, a condition termed hepatic steatosis [48-50]. Although “simple” 
hepatic steatosis may be clinically benign, it can progress to increasing degrees of liver dysfunction in 
non-alcoholic steatohepatitis (NASH) and even to cirrhosis [50]. This spectrum of pathologies is 
collectively referred to as non-alcoholic fatty liver disease (NAFLD) [48]. The seriousness of NAFLD as a 
public-health problem is highlighted by the fact that NAFLD has become the leading cause of liver failure 
requiring transplant in the United States. 
 Hepatic steatosis appears to result largely from two main sources: (i) increased influx of fat from 
adipocyte lipolysis (especially in obesity) and (ii) increased de novo lipogenesis (DNL) in the liver itself 
[48, 51]. Increased TG stores in the liver may in turn give rise to increased secretion in the form of VLDL, 
contributing to dyslipidemia and atherosclerosis, and potentially to worsening IR. It is important to note, 
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however, that there is not a strictly linear relationship between liver TG content and VLDL secretion [47, 
48, 52, 53].  
Despite the strong epidemiologic correlation between IR and NAFLD, the direction of causality (if 
any) remains difficult to define. Triglycerides in and of themselves do not appear to be injurious to 
hepatocytes [54], although TG metabolites such as ceramides [55] or diacylglycerols (DAG) [56, 57] may 
interfere with insulin signaling. Consequently, TG may even be beneficial to hepatocytes as a “safe” 
storage form for lipid species that may otherwise adversely affect cellular function [58, 59]. In other words, 
histologic hepatic steatosis may represent a compensatory epiphenomenon roughly proportional in extent 
to the concentrations of the invisible “true” bad actors [60, 61]. Consistent with this interpretation, 
transgenic mice with liver-specific overexpression of enzymes catalyzing the esterification of FFA and 
DAG to TG are protected from IR despite florid hepatic steatosis [62, 63]. Even in the more clinically 
relevant model of high-fat diet feeding, hepatic steatosis did not impair the direct actions of insulin on 
isolated rat livers, implicating extrahepatic factors in the development of steatosis-correlated hepatic IR 
[64]. In addition to these models of steatosis without IR, it should also be noted that some of the most 
severe cases of IR – the insulin receptoropathies, as will be discussed in Section 1.6 – are associated 
with normal or even low liver TG levels [65].  
Taken together, this evidence suggests that, if generalized IR does precede steatosis, it may be 
secondary to unchecked WAT lipolysis that would furnish ostensibly harmful FFA to the liver and further 
hinder hepatic insulin action [51, 60, 66]. This model is consistent with the widely held idea that the 
development of IR in WAT generally antedates hepatic IR by many years in the natural history of T2DM 
[67-71]. This may be especially important in obesity due to the enormously expanded pool of releasable 
fat and potentially detrimental alterations in fat composition [51, 66, 72].  
Finally, although increased FFA flux appears to be an integral contributor to hepatic steatosis, the 
liver itself is not passive in the process. Rates of hepatic DNL have been found to be as much as fivefold 
higher than normal in NAFLD even during fasting and may be increasingly important even relative to FFA 
re-esterification as the disease progresses [48, 73, 74]. Patients with type 2 diabetes (i.e., with hepatic IR) 
also exhibit higher rates of DNL [75]. Thus, whether or not hepatic IR is causally related to the initiation of 
9 
NAFLD, it may well be relevant to the disease’s progression both as cause and effect. These issues will 
be revisited in Chapter 5. 
1.3. The Proximal Insulin Signaling Pathway 
In order to be able to understand the pathogenic mechanisms underlying insulin resistance, it is 
necessary first to consider the actions of insulin under normal circumstances (illustrated in Fig. 1.1A). 
Insulin acts by binding to the insulin receptor (InsR) on the surface of target cells. InsR is a heterodimeric 
receptor tyrosine kinase consisting of two extracellular α subunits and two integral membrane β subunits 
[76]. The α and β subunits are the product of a single precursor polypeptide that undergoes 
posttranslational cleavage followed by the association of the cleaved subunits by disulfide bonds [76].  
The binding of insulin to its receptor triggers a conformational change that is translated through 
the receptor’s transmembrane domains, ultimately resulting in the autophosphorylation and activation of 
the receptor’s intracellular tyrosine kinase domains [77]. The autophosphorylation of tyrosine residues on 
InsR itself recruits several phosphotyrosine-binding proteins including the insulin receptor substrate (IRS) 
proteins, most importantly IRS1 and IRS2 [78]. InsR is able to phosphorylate several tyrosine residues 
within IRS1/2; these phosphotyrosines are then able to serve as docking sites for several SH2 domain-
containing proteins [79, 80]. Thus, IRS1/2, which are themselves devoid of enzymatic activity, serve as 
scaffolds upon which the insulin-signaling complex can be arranged in response to the activation of InsR 
[78, 81, 82].  
Arguably the most metabolically important Irs-binding protein is phosphoinositol-3-kinase (PI3K) 
[83]. PI3K is a modular enzyme composed of a regulatory subunit for which three genes exist (PIK3R1, 
PIK3R2, PIK3R3, encoding p85α, p85β, and p55γ, respectively) and a catalytic subunit, also encoded by 
three different genes (for p110α, β, and δ) [83]. The PI3K regulatory subunit contains an SH2 domain that 
binds to phosphotyrosine residues within IRS1/2 that, in turn, releases its inhibition of the associated 
catalytic subunit [83, 84]. The PI3K catalytic subunit is then able to phosphorylate the inner-leaflet plasma 
membrane glycolipid phosphatidylinositol-4,5-bisphosphate (PIP2) to phosphatidylinositol-3,4,5-
triphosphate (PIP3) [84]. The generation of PIP3 within the vicinity of the InsR/Irs complex allows for the 
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recruitment of protein kinase B, also known as AKT, one of the principal mediators of the metabolic 
effects of insulin signaling, via its pleckstrin homology (PH) domain [85]. Once localized to the plasma 
membrane by binding to PIP3, AKT can be activated by 3-phosphoinositide-dependent kinase-1 (PDK1) 
via phosphorylation of threonine 308 within AKT’s activation loop [86]. Several studies have indicated that 
the mammalian target of rapamycin complex-2 (mTORC2) is responsible for a second phosphorylation of 
AKT at Ser 473 [87-89]. Nevertheless, Ser 473 phosphorylation is also responsive to insulin, and the 
mechanism linking insulin signaling to Ser 473 phosphorylation by mTORC2 remains unclear [88].  
Although the upstream components of the insulin-signaling pathway are able to regulate other 
pathways, such as the MAPK signaling pathway through ERK1/2 [83], the preponderance of existing 
scientific evidence suggests that AKT is the most distal step of the pathway that unites insulin’s major 
effects on glucose and lipid metabolism [90]. In other words, it appears that these pathways diverge 
downstream of AKT. Having established this basic paradigm, more detailed descriptions of the 
mechanism of insulin’s actions on glucose and lipid metabolism in the liver follow below. 
 
1.4. Insulin Regulation of Hepatic Glucose Metabolism 
1.4.1. Overview of Hepatic Glucose Metabolism 
Two major peripheral target organs of insulin, skeletal muscle and adipose tissue, generally require 
insulin signaling to stimulate glucose uptake by inducing translocation of the GLUT4 glucose transporter 
to the cell surface [91]. Liver, however, expresses a different major glucose transporter, GLUT2, whose 
subcellular localization is not directly regulated by insulin and allows for the equilibration of glucose 
concentrations within the blood and the hepatocyte [92]. In order to retain glucose within the cell for 
further metabolism, hepatocytes express glucokinase (GCK), a hexokinase unique to liver and pancreatic 
β cells, which phosphorylates glucose to form glucose-6-phosphate (G6P) [93]. G6P is not subject to 
transport by GLUT2 and thus can be efficiently shunted to the various carbohydrate-metabolic pathways 
[93].  
 The two most important roads down which G6P proceeds are (i) the synthesis of glycogen, the 
major storage form of glucose, and (ii) catabolism via glycolysis and, ultimately, either lipid biosynthesis or 
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oxidative phosphorylation to generate energy in the form of adenosine triphosphate (ATP) [3 pp. 744-
752]. In the case of glycogen synthesis, G6P is converted to glucose-1-phosphate (G1P) that reacts with 
a molecule of uridine triphosphate (UTP) to generate UDP-glucose. UDP-glucose units are then coupled 
to the growing end of a glycogen chain with the subsequent release of UDP [3 pp. 481-487]. Glycogen is 
broken down in the process of glycogenolysis by the action of glycogen phosphorylase, which re-
generates G1P from glucose monomers within the glycogen chain. G1P can then be enzymatically 
converted back into G6P, which in turn can be dephosphorylated by glucose-6-phosphatase (G6Pase, the 
catalytic subunit of which is encoded by the G6PC gene) to yield glucose that can be released into the 
circulation [3 pp. 474-481].    
 The process of glycolysis transforms one molecule of G6P ultimately into two molecules of 
pyruvate [3 pp. 428-431]. Along the way, glycolysis results in the net generation of two molecules of ATP 
and of two molecules of NADH that act to shuttle electrons to the mitochondrial electron-transport chain 
for oxidative generation of more ATP [3 p. 446]. The two molecules of pyruvate are each converted by the 
pyruvate dehydrogenase complex (PDC) into acetyl-CoA that can proceed through the citric acid cycle to 
yield the net generation of two more molecules of ATP and six of NADH [3  pp. 517-524]. Acetyl-CoA is 
also the principal building block utilized in de novo lipogenesis, as will be described later [3 pp. 650-651]. 
Gluconeogenesis represents the reverse of glycolysis – the regeneration of glucose from 
pyruvate. Although this process proceeds merely by reversing most of the steps of glycolysis using the 
same enzymes, there are three main enzymatic transformations that differ between these processes and 
therefore are ideal loci of hormonal regulation [3 pp. 500-501]. First, pyruvate is produced from 
phosphoenolpyruvate (PEP) in one highly exergonic step by the ATP-generating enzyme, liver-type 
pyruvate kinase (L-PK, encoded by the PKLR gene) [3 pp. 443-445]. The reverse reaction therefore 
requires the input of significant energy and is not merely reversible through L-PK [3 pp. 500-501]. Instead, 
pyruvate is tagged with a CO2 adduct by pyruvate carboxylase to produce oxaloacetate, which is in turn 
converted back to PEP by PEP carboxykinase (PCK1, commonly known as PEPCK), classically 
considered the main rate-limiting step of gluconeogenesis [3  pp. 502-503, 94]. The next glycolytic 
reaction requiring a gluconeogenic workaround is the conversion of fructose-6-phosphate (F6P) to 
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fructose-1,6-bisphosphate (F1,6BP) by phosphofructokinase-1 (PFK-1) [3 pp. 433-434]. F1,6BP is 
converted back into F6P in the gluconeogenic pathway by the action of FBPase-1 [3 pp. 504-507]. The 
third non-reversible reaction required to complete gluconeogenesis is the same as the final step of 
glycogenolysis: the dephosphorylation of G6P to glucose by G6Pase, the reverse reaction of Gck [3 pp. 
480-481].  
As will be described, each of these pathways can be regulated via both posttranslational and 
transcriptional mechanisms. One of the most important mechanisms of exacting this control is through the 
modulation of the relative circulating levels of insulin and glucagon [7]. As mentioned earlier, during times 
of fasting, glucagon levels rise causing the liver to switch from storage and utilization of glucose to HGP in 
order to maintain euglycemia [3 pp. 752-756]. Thus, in this scenario, glycogen synthesis (glycogenesis) is 
decreased in favor of glycogen breakdown (glycogenolysis) while glycolysis also gives way to its reverse 
pathway, gluconeogenesis [3 pp. 752-756]. The processes of glycogenolysis and gluconeogenesis that 
are stimulated by counterregulatory factors are subject to negative regulation by insulin, also both by 
posttranslational and transcriptional mechanisms [3 pp. 752-756].  
The rate of HGP is highly sensitive to changes in the relative concentrations of insulin and 
glucagon [2]. The shift to higher concentrations of insulin following a meal reduces HGP within a matter of 
minutes, suggesting a predominance of posttranslational regulation of the proteins involved; over the 
course of a physiologic fast of several hours, about 75% of HGP results from glycogenolysis in response 
to counterregulatory signaling [95-97]. It therefore makes sense that the vast majority of the HGP-
suppressing effect of insulin during physiologic fasting is due to its net inhibition of glycogenolysis in favor 
of glycogen synthesis [98-102].  
The importance of gluconeogenesis is not to be overlooked, however. The relative contribution of 
gluconeogenesis to HGP appears to be greater in humans suffering from obesity and type 2 diabetes, as 
the percentage of HGP attributable to gluconeogenesis, as well as total HGP, are positively correlated 
with fasting plasma glucose [103]. Overall, the contribution of gluconeogenesis to HGP may be 50% 
higher in diabetic patients [103-105]. In fact, using an NMR-tracer method to follow carbon flux revealed 
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that glycogenolysis may even be decreased in diabetic patients and that increased gluconeogenesis is 
the culprit behind the fasting hyperglycemia of diabetes [106]. 
 
1.4.2. Posttranslational Regulation of Glycogenolysis by Insulin 
Multiple mechanisms contribute to insulin’s ability to shut down HGP. Insulin stimulates the activity of 
protein phosphatases such as PP1 that undo the activating phosphorylation events carried out by cAMP-
dependent protein kinase (PKA) in response to glucagon [107, 108]. Targets of this form of regulation 
include glycogen phosphorylase [109] and glycogen synthase (GS) [110]. Insulin signaling also promotes 
Akt-dependent phosphorylation of glycogen synthase kinase-3α and -3β (GSK3α/β). Phosphorylated 
GSK3α/β are then unable to carry out their glucagon-stimulated inhibitory phosphorylation of GS, thus 
allowing glycogen synthesis to proceed [111]. Although insulin’s inhibition of GSK3α/β has long been 
considered a major link between InsR and glycogen synthesis, the in vivo significance of this pathway in 
liver has recently been called into question [112].   
 
1.4.3. Posttranslational Regulation of Gluconeogenesis by Insulin 
Only following a prolonged fast of 24-48 h are hepatic glycogen stores depleted in humans, thus 
rendering the liver dependent upon gluconeogenesis to maintain euglycemia [113]. The ability of insulin to 
directly suppress gluconeogenesis, however, has been controversial [2]. Indeed, glycogenolysis appears 
to be far more sensitive to inhibition by insulin than does gluconeogenesis [98, 99]. A series of studies in 
dogs undergoing portal-vein insulin infusion has demonstrated that only at very high concentrations of 
insulin is there a net inhibition of net gluconeogenic flux [94, 114]. Even when insulin does appear to 
suppress net gluconeogenesis, the effect is transient except at the highest of insulin concentrations and 
may be due more to an increase in glycolysis than to a suppression of gluconeogenesis per se [94, 114]. 
In any event, inhibition of gluconeogenesis by insulin may be somewhat beside the point, as even in the 
fed state gluconeogenesis proceeds to produce G6P from pyruvate [94, 100, 101, 114]. The key 
difference lies in the fact that this G6P is shunted into insulin-stimulated glycogen synthesis rather than 
dephosphorylated and released into the circulation [97, 100, 115, 116].  
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The major effects of insulin on the acute regulation of gluconeogenesis in vivo may therefore be 
indirect [117, 118]. Insulin strongly suppresses the secretion of glucagon from pancreatic α cells, thus 
dampening the pro-gluconeogenic signal in fasting [119, 120]. Insulin also potently inhibits adipose-tissue 
lipolysis, thereby cutting off the supply of glycerol, an HGP substrate, and free fatty acids, which have 
been shown to potentiate HGP in a variety of ways [121-126]. Finally, insulin also decreases the release 
of gluconeogenic substrates such as lactate and alanine from skeletal muscle and other organs [127, 
128]. 
Despite the foregoing, insulin has been shown to posttranslationally regulate several steps of 
gluconeogenesis [2]. As in the case of glycogenolysis, insulin triggers the activation of phosphatases such 
as PP1 that undo the pro-gluconeogenic actions of glucagon-stimulated PKA activity. Perhaps the most 
important example of this is in the regulation of fructose-6-phosphate (F6P)/fructose-1,6-bisphosphate 
(F1,6BP) balance by phosphfructokinase-1 (PFK1) and F1,6BPase (FBP1) [129, 130]. PKA stimulates the 
activity of fructose-2,6-bisphosphatase (FBP2), converting fructose-2,6-bisphosphate (F2,6BP) to F6P. 
FBP2, however, is a bifunctional enzyme that also possesses a phosphofructokinase activity that is 
stimulated by insulin-dependent dephosphorylation of FBP-2. Upregulation of FBP2’s 
phosphofructokinase activity by insulin converts F6P back to F2,6BP, which acts as an allosteric activator 
of PFK1, thus driving the equilibrium between the PFK1/FBP1 reactions toward the former and driving net 
glycolysis [129, 130]. The increase in intracellular F2,6BP concentration has been posited to be the 
principal means by which insulin does exert its acute, if minor, repressive effect on gluconeogenesis [94, 
114, 131]. Nevertheless, insulin also triggers the reversal of PKA-mediated inhibition of L-PK as well, both 
by directly activating phosphatase activity [132, 133] as well as by increasing intracellular levels of 
F1,6BP, an allosteric activator of the enzyme [129]. Finally, insulin can inhibit the activities of pyruvate 
dehydrogenase kinase-2 and -4 (PDK2/4), which serve as negative regulators of the PDC [134]. Thus, in 
effect, insulin can facilitate the conversion of pyruvate to acetyl-CoA, effectively preventing its becoming a 




1.4.4. Transcriptional Regulation of HGP by Insulin Through FoxO1 
Although insulin and glucagon are able to cause rapid changes in HGP through purely posttranslational 
modifications of the enzymes involved, signaling by these hormones is also able to alter the long-term 
program of hepatic glucose metabolism by regulating gene expression [2]. Indeed, given the evolutionary 
imperative of preventing hypoglycemia, multiple overlapping transcriptional mechanisms have arisen to 
promote HGP in the long term [2]. Moreover, perhaps in order to prevent hypoglycemia, not all of these 
pathways are inhibited by insulin. To wit, glucose production in the fed state is significantly lower than 
during fasting but is not absent; input from other hormones (e.g., adrenal corticosteroids) [135], the 
autonomic nervous system [136], and circadian factors [137] all modulate HGP independently of insulin 
signaling [138, 139].  
The forkhead box O (FoxO) proteins, in particular FoxO1, FoxO3, and FoxO4, are a widely 
expressed class of transcription factors characterized by a common forkhead DNA-binding domain [140, 
141]. We focus in particular on FoxO1 (also known as FKHR, encoded by Foxo1 in mice and FKHR in 
human), the best-characterized and most abundant FoxO family member in hepatocytes [2, 142, 143]. 
Importantly, the FoxO proteins – especially FoxO1 – appear to represent the major insulin-regulated 
transcriptional coordinator of HGP [2, 144, 145]. Akt downstream of InsR phosphorylates FoxO1 at three 
sites – Thr 24, Ser 256, and Ser 319 – causing its exclusion from the nucleus and cytoplasmic 
sequestration through interaction with 14-3-3 proteins [143, 146-150]. This inhibitory effect of insulin is 
rapid, potent, and persistent. Glucagon signaling in the postabsorptive state activates FoxO1 [151], which 
in turn upregulates the expression of several fasting-inducible genes, most notably including G6pc [152], 
IGF binding protein-1 (Igfbp1) [148, 153], Pdk4 [154], and Pck1, although the last is controversial [142, 
144, 145, 155]. FoxO1 acts on these genes through binding to conserved recognition motifs in their 
promoters termed insulin response elements (IRE). The phosphorylation and nuclear exclusion of FoxO1 
in response to insulin then shows a strong temporal correlation with the decrease in G6pc and Pck1 
mRNA [94]. 
 Whole-body knockout of FoxO1 is embryonically lethal due to the occurrence of arteriovenous 
malformations [156, 157]. Liver-specific deletion of FoxO1, dubbed the L-FoxO1 mouse model, results in 
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a significant enhancement in whole-body glucose tolerance due to decreased HGP [145]. 
Hyperinsulinemic-euglycemic clamp studies have shown L-FoxO1 livers to exhibit decreases in both 
gluconeogenesis and glycogenolysis [145]. Although blood glucose is normal in L-FoxO1 mice following a 
standard overnight fast, hypoglycemia becomes apparent following prolonged fasting [145]. Despite their 
reduced HGP, L-FoxO1 mice are not overall more sensitive to insulin; they do not show any difference in 
fasting or fed insulin levels or in insulin tolerance [145, 158]. Concomitant deletion of FoxO3 and FoxO4 in 
the liver (L-FoxO1,3,4) results in an enhancement of glucose tolerance beyond that of the L-FoxO1 
mouse due to a further reduction in HGP [144, 159]. Conversely, transgenic expression of an insulin-
insensitive mutant FoxO1 in liver results in glucose intolerance due to an inability of insulin to blunt HGP 
and tonically increases expression of G6pc [142, 160]. Similar findings were obtained with adenoviral 
overexpression of wild-type FoxO1 [161].  
Multiple lines of evidence support the primacy of FoxO1 repression in insulin’s overall regulation 
of HGP. In C. elegans, for example, deletion of the Foxo1 orthologue daf-16 rescues the developmentally 
arrested dauer phenotype of nematodes lacking the Insr orthologue, daf-2 [145, 162, 163]. In a similar 
vein, deletion of Foxo1 only in liver significantly extends the lifespan of whole-body Insr knockout mice 
[145]. Although most of these mice still die prematurely, they are spared the lethal neonatal 
hyperglycemia, ketoacidosis, and hepatic steatosis of Insr-/- mice [145, 164]. That the compound l-Foxo1 ; 
Insr-/- mice phenocopy mice lacking Insr in all tissues except the liver further suggests the centrality of 
FoxO1 in mediating insulin’s actions on hepatic metabolism [145, 165].  These striking findings of genetic 
epistasis between Insr and Foxo1 are substantiated by further mechanistic studies on the InsR signaling 
pathway. Liver-specific deletion of Irs1/2 [166] or Akt1/2 [167] both result in hyperglycemia and glucose 
intolerance due to the inability of insulin to blunt HGP, associated with constitutively increased expression 
of G6pc and Pck1 and decreased expression of Gck. In both of these cases all of these abnormalities can 
be completely reversed by concurrent liver-specific deletion of Foxo1 [166, 167].  
FoxO1 appears to represent a promising if elusive target in the treatment of diabetes; multiple 
studies have shown that inhibition of FoxO1 in insulin-resistant states has beneficial effects on glucose 
metabolism [155]. L-FoxO1 mice rendered insulin resistant by Western-type diet feeding showed a 
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significant reduction in fasting blood glucose, fasting insulin, and glucose intolerance relative to controls 
[168]. In the acute setting, anti-Foxo1 antisense oligonucleotide (ASO) therapy of insulin resistant, diet-
induced obese (DIO) mice resulted in decreased blood glucose and HGP, improving glucose tolerance 
and whole-body insulin sensitivity [169]. Similarly, infection of diabetic db/db mice with an adenovirus 
encoding the dominant-negative Foxo1-∆256 also dropped blood glucose levels and reduced expression 
of G6pc and Pck1 in liver [170].   
 
1.4.5. Transcriptional Regulation of HGP by FoxO1-Associated Proteins 
FoxO1 acts in tandem with other transcriptional effectors to regulate the HGP transcriptional program in 
mice. A particularly prominent FoxO1 co-regulator is PPARγ coactivator-1α (Pgc1α, encoded by the 
Ppargc1a gene), which is itself a FoxO1 target gene [145]. Pgc1α is induced in response to fasting, and 
adenoviral overexpression in liver activates the expression of G6pc, Pck1, and Fbp2 and consequently 
upregulates glucose production [171, 172]. FoxO1 and Pgc1α synergistically activate the expression of 
G6pc and Pck1 through a direct interaction [173] and Pgc1α, like FoxO1, can be inhibited by Akt-
mediated phosphorylation [174]. Interestingly, FoxO1 is required for Pgc1α induction of G6pc and Pck1 
but not for the action of Pgc1α on mitochondrial oxidative gene targets [145]. 
FoxO1 also coordinates gluconeogenesis through functional interactions with CREB-regulated 
transcription coactivator-2 (CRTC2, formerly known as TORC2). CRTC2 is a co-activator of cAMP-
response element binding protein (CREB), a major downstream effector of glucagon-induced 
gluconeogenic gene expression [175, 176]. CRTC2/CREB-induced gluconeogenic gene expression 
appears to predominate during very early fasting but then gives way to FoxO1 activity, through 
coordinated deacetylation of the two proteins [177]. Furthermore, CRTC2 itself can be degraded in 
response to insulin signaling, providing a FoxO1-independent means of tamping down glucagon-induced 
transcriptional activity [178]. Finally, FoxO1 has also been demonstrated to interact with hepatocyte 
nuclear factor-4α (HNF-4α) to regulate the expression of G6pc and Gck in fasting and feeding, 




1.5. Insulin Regulation of Hepatic Lipid Metabolism 
1.5.1. Overview of Hepatic Lipid Metabolism: Lipid Biosynthesis 
The influx of nutrients into the liver in the fed state results in a net production of acetyl-CoA, most 
classically following the glycolytic breakdown of glucose to pyruvate, but also from other carbohydrates as 
well as certain amino acids [180]. Acetyl-CoA can be further metabolized via the citric acid cycle to yield 
ATP and NADH, although more is produced in the immediate postprandial state than is required for the 
generation of energy [180]. The liver therefore seeks to preserve the chemical energy stored in acetyl-
CoA for use during fasting periods by polymerizing these carbons into fatty acids. This process is termed 
de novo lipogenesis (DNL) [180].  
 The liver strikes a balance between the anabolism and catabolism of fatty acids that responds to 
the metabolic conditions of the moment [3 pp. 744-747]. The liver takes into account signaling inputs from 
hormones (e.g., insulin, glucagon) as well as changes in the relative concentrations of nutrients 
themselves [3 pp. 743-784]. The main regulator responsible for setting this balance is acetyl-CoA 
carboxylase-α (ACC1, encoded in liver by the ACACA gene), which catalyzes the first committed step of 
fatty acid biosynthesis [181, 182]. As its name indicates, ACC1 transforms acetyl-CoA into its 
carboxylated adduct, malonyl-CoA [181]. Malonyl-CoA, then, serves two functions: it both serves as the 
major substrate for polymerization to fatty acids and inhibits the import of fatty acids to the mitochondrion 
in order to prevent catabolism of the newly synthesized products [181-183].  
 The major enzyme responsible for transforming individual two-carbon units of malonyl-CoA into 
fatty acids is the enzyme fatty acid synthase (FAS, encoded by the FASN gene) [3 pp. 653-658]. This 
single enzyme remarkably performs the seven different catalytic activities necessary for fatty-acid 
biosynthesis, powering these reactions through the cleavage of malonyl-CoA’s highly energetic thioester 
bond [3 pp. 653-658]. The end product of the FAS reactions is the sixteen-carbon saturated fatty acid, 
palmitate [3 p. 656]. Much as in the case of malonyl-CoA, palmitate serves both as substrate and 
allosteric regulator [3 pp. 660-662]. Palmitate can be transformed into longer-chain fatty acids through the 
action of fatty acid elongases, as well as into desaturated fatty acids by desaturases such as stearoyl-
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CoA desaturase-1 (SCD1) [3 pp. 657-658]. Palmitate also allosterically inhibits ACC1 in an example of 
negative feedback [3 pp. 660-662].  
Three individual fatty acyl-CoA esters can be esterified (or, in the case of free fatty acids derived 
from adipose-tissue lipolysis, hepatically re-esterified) with the three carbons of glycerol to form 
triacylglycerol, or triglyceride (TG), the major storage form of fatty acids [3 pp. 658-660]. Triglycerides can 
be stored in the liver or can be exported for uptake and use by other tissues. For this purpose, the liver 
packages triglycerides along with cholesterol esters and apolipoproteins into very low-density lipoproteins 
(VLDL) [184]. Insulin has been shown to inhibit the secretion of VLDL by stimulating the degradation of its 
major protein component, apoB [46, 185]. 
 In the healthy liver, DNL accounts for only about 4% of TG secreted into the circulation basally, 
although this number rises to a high of 23% at 4 h following a meal [186, 187]. By comparison, 
esterification of FFA liberated from WAT accounts for 77% and 44% of secreted TG in the fasted and fed 
states, respectively [188-190]. Meal composition also plays a role in determining the relative contribution 
of DNL to circulating TG, with high-carbohydrate foods more potently driving lipogenesis than fat- or 
protein-rich foods [189, 191-197]. However, in the pathologic state of hepatic steatosis associated with 
insulin resistance, a far greater percentage of the hepatic TG and associated VLDL secretion is derived 
from DNL [73-75]. 
 
1.5.2. Transcriptional Control of Lipid Biosynthesis 
The transcriptional control of lipid biosynthesis is largely, although not exclusively, driven by two “master” 
regulators, sterol regulatory element binding proteins (SREBP) and carbohydrate response element 







Sterol regulatory element binding protein-1c (SREBP-1c) 
The program of biosynthesis of lipids in liver is remarkably well coordinated at the transcriptional level by 
the SREBPs, a trio of transcription factors that recognize and bind to sterol-response elements (SRE) in 
the promoters of target genes [198]. There are two genes encoding SREBPs, namely Srebf1 and Srebf2; 
the latter encodes SREBP-2, which is directly responsible for the transcriptional activation of all of the 
major enzymes involved in cholesterol biosynthesis and transport [198]. SREBF1 contains two different 
transcriptional start sites to yield two isoforms, SREBP-1a and SREBP-1c, differing in their first exon 
[198]. SREBP-1c is the most abundant SREBP-1 in liver [199]. Target genes of this transcriptional 
complex include all of the major lipogenic enzymes described above, including Fasn, Acaca, Scd1 and 
the enzymes involved in the esterification of TGs from fatty acids. SREBP-1c also positively regulates its 
own expression [198]. Whole-body knockout of Srebf1 leads to embryonic lethality in a considerable 
majority of animals [200]. In those that survive, it appears that upregulation of SREBP-2 partially 
compensates for the loss of SREBP-1 at the price of markedly upregulated cholesterol synthesis [200].  
Whole-body knockout specifically of the exon unique to the -1c isoform results in blunted feeding-induced 
expression of Fasn, Acaca, Scd1, and other lipid-biosynthetic enzymes, resulting in decreased circulating 
and hepatic TG in response to re-feeding [201].  
The derangements in feeding-induced lipid synthesis underscore the fact that regulation of 
SREBP-1c is one of the principal methods of insulin’s control of liver fat metabolism [202]. Although it is a 
transcription factor, regulation of SREBP-1c by insulin occurs in large part outside of the nucleus [198]. At 
baseline, SREBP-1c is an integral membrane protein localized to the ER membrane in complex with 
SCAP, another integral membrane protein that shepherds SREBP-1c into vesicles bound for the Golgi 
apparatus [203, 204].  Preventing this translocation event are INSIG-1 and INSIG-2a [205]. Once arrived 
at the Golgi, the proteases S1p and S2p catalyze sequential cleavage events that liberate a cytosolic, N-
terminal fragment of the SREBP-1c precursor protein [206]. This cleaved SREBP-1c is then free to 
translocate to the nucleus to perform its function as a transcription factor [207]. 
Insulin affects SREBP-1c at each of these stages [208]. First, insulin promotes the packaging of 
the precursor SREBP-1c/SCAP complex into Golgi-bound vesicles at the ER [203]. Second, insulin 
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decreases protein levels of INSIG2a, presumably relieving its inhibition of SREBP-1c/SCAP translocation 
[209]. Third, insulin triggers the phosphorylation and inhibition of LIPIN-1, a negative regulator of SREBP 
activity within the nucleus [210]. Finally, insulin positively regulates Srebf1 gene expression, again at least 
in part due to positive feedback of SREBP-1c [209, 211-213].  
The intermediaries linking insulin signaling to SREBP-1c expression and cleavage have been 
elucidated in recent years. Both the cleavage and expression of SREBP-1c require signaling from InsR 
through PI3K and Akt [213]. Akt’s activation of SREBP-1c proceeds via mammalian target of rapamycin 
complex-1 (mTORC1) [214, 215]; Akt activates the mTORC1 kinase through inhibition of its inhibitors, 
TSC-1/2 [216]. Blocking hepatocellular mTORC1 via treatment with rapamycin or by deletion of TSC-1 
results in an inability of insulin to promote SREBP-1c expression or cleavage, thereby suppressing 
insulin-induced DNL and lipogenic gene expression [213, 217, 218]. Insulin’s regulation of SREBP-1c 
diverges downstream of mTORC1, however, as insulin-induced cleavage of SREBP-1c requires the 
activity of mTORC1 substrate S6 kinase (S6K) while expression of SREBP-1c in response to insulin does 
not [218]. A further potential mechanistic link between insulin and SREBP-1c is through GSK3β, which 
has been shown to phosphorylate SREBP-1c and thereby inhibit its activity [219]. The inhibition of GSK3β 
by Akt downstream of InsR, therefore, would relieve GSK3β’s inhibition of SREBP-1c, further promoting 
its activity [185, 219, 220]. A gap in our understanding persists, however, between these distal signaling 
events and the actual processing and transcription of SREBP-1c.   
Increasing our understanding of the regulation of SREBP-1c is of great clinical importance given 
its alleged role in the pathogenesis of NAFLD and potentially hepatic insulin resistance. Liver samples 
from humans with obesity [221] and NAFLD [222] have been shown to have higher expression of SREBP-
1c and its targets. Several animal models of fatty liver disease, such as the leptin-deficient ob/ob mouse 
and the sucrose-fed hamster, likewise demonstrate elevated levels of SREBP-1c in liver [223-225]. 
Supporting the importance of increased SREBP-1c levels, mice engineered to express a constitutively 
active mutant SREBP-1c in the liver developed hepatic steatosis and insulin resistance [226, 227]. 
Conversely, deletion of SCAP (resulting in an inability to cleave SREBP-1c) prevented hepatic steatosis in 
both ob/ob and sucrose-fed hamster models of NAFLD by reducing DNL [225].  
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Carbohydrate response element binding protein (ChREBP) 
In a manner similar to SREBP-1c, ChREBP is a transcription factor capable of coordinately inducing many 
genes in the lipogenic program [228]. While SREBP-1c is primarily controlled by insulin signaling, 
ChREBP activity, as its name implies, is induced following exposure to carbohydrates acting in a signaling 
capacity [228-230]. At least three metabolites of glucose, each requiring the initial action of glucokinase 
[231, 232], have been reported to induce ChREBP to stimulate glucose-induced gene expression [233-
236]. As the expression of Gck is itself strongly influenced by insulin, even ChREBP activity is indirectly 
affected by insulin signaling [202]. 
 ChREBP shares many common targets with SREBP-1c, including Fasn, Acaca, and Scd1 [228]. 
This helps to explain why livers lacking nuclear SREBP-1c, for example due to deletion of InsR, still 
demonstrate some feeding-induced expression of these lipogenic genes [201, 202, 237]. Furthermore, it 
appears that synergism between insulin-stimulated SREBP-1c activity and glucose-stimulated ChREBP 
activity is required for maximal activation of several lipogenic genes [232, 238]. On the other hand, only 
ChREBP is able to induce the expression of liver-type pyruvate kinase (Pklr), responsible for catalyzing 
the final step of the glycolytic pathway [239, 240].  
 
FoxO proteins (FoxO1, FoxO3, FoxO4) in Lipid Biosynthesis 
The importance of FoxO proteins in the regulation of HGP is now firmly established [2]. Empirical 
evidence has also mounted to implicate FoxO proteins in the control of hepatic lipid metabolism as well 
but the interpretation of these data has been more nuanced [158, 161, 168, 241-245]. Nevertheless, it 
appears overall that inhibition of FoxO proteins, in particular of FoxO1, may represent another important 
modus operandi of insulin’s control of fat anabolism in the liver.   
 Our laboratory’s initial publication of the liver-specific FoxO1 knockout mouse (L-FoxO1), though 
highly supportive of a key role for FoxO1 in the control of hepatic glucose metabolism, did not 
demonstrate any notable abnormalities in lipid parameters [145]. L-FoxO1 mice generated by another 
group (albeit using a different liver-specific promoter to drive Cre expression) did demonstrate slight but 
significant elevation in liver TG in the fed state [158]. One potential reason for the absence of a lipid 
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phenotype as dramatic as the glucose phenotype in the L-FoxO1 mice may be the fact that these 
measurements were performed in chow-reared mice. Indeed, subsequent studies done in mice subjected 
to various metabolic challenges have elicited a more robust connection between FoxO1 and hepatic lipid 
metabolism. L-FoxO1 mice rendered insulin resistant by Western-type diet (WTD) feeding show 
exacerbated hepatic steatosis compared to controls in the fed state [168]. This phenotype is due at least 
in part to an impaired ability to generate 12α-hydroxylated bile acids, which serve as endogenous 
signaling molecules that limit TG deposition, in the absence of liver FoxO1 [168].  
Gain-of-function models also have helped to uncover potential connections between FoxO1 and 
hepatic lipid handling. Compared to controls, livers from mice overexpressing a constitutively nuclear 
FoxO1 showed decreased feeding-induced DNL coupled with lower expression of lipogenic genes 
including Gck, Pklr, Fas, Acaca, and Srebf1 [160]. In keeping with an effect of FoxO1 on lipogenic gene 
expression, FoxO1 has been shown to block the activating O-glycosylation of ChREBP, reducing its 
stability and ability to transactivate expression of lipogenic genes [246]. Interestingly, mice overexpressing 
a constitutively nuclear form of FoxO1 acutely rather than congenitally show increased hepatic TG, due 
apparently to increased insulin sensitivity potentially driving SREBP-1c [247]. 
Altered TG secretion may also underlie FoxO1 regulation of hepatic lipid homeostasis, although it 
is important to note that secreted (i.e., circulating) TG levels are not necessarily reflective of hepatic TG 
storage [63, 248-251]. FoxO1 has been shown to induce expression of microsomal TG transfer protein 
(MTP), which in turn regulates lipid loading onto apoB for secretion as VLDL [242, 243]. Mice 
transgenically overexpressing a constitutively nuclear FoxO1 exhibited increased TG secretion 
proportional to increased MTP levels while acute knockdown of FoxO1 expression by siRNA led to the 
opposite [243], although other studies on the constitutively nuclear mutant have shown decreased TG 
secretion [160]. Some data have suggested that FoxO1 can directly regulate the expression of apoB [243, 
252] and apoC-III [244] as well, in both cases leading to accumulation of TG in plasma. On the other 
hand, in the context of insulinopenic hyperglycemia, L-FoxO1 mice exhibit increased VLDL secretion 
leading to higher serum TG without an effect on liver TG content [241]. 
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Most of these models have attempted to cast FoxO1’s ostensible regulation of hepatic lipid 
metabolism as mechanistically separate from its canonical regulation of HGP. However, recent studies in 
our laboratory have argued in favor of a unified, parsimonious explanation for FoxOs’ dual effects on 
glucose and lipid handling in the liver [253]. L-FoxO1,3,4 mice show significantly higher levels of liver TG 
attributable to higher rates of DNL [245, 253] and potentially to lower rates of fatty acid oxidation [245]. 
The significant increase in DNL in these mice is not, however, associated with increased expression of 
most classical lipogenic enzymes (e.g., Fasn, Acaca) [253]. Rather, it appears that a robust and 
reproducible increase in Gck expression independent of feeding state coupled with decreased G6pc in the 
absence of FoxO may be responsible [253]. This constitutively decreased G6pc:Gck ratio results in 
significantly increased flux through glycolysis and DNL regardless of feeding state [253].  
Thus, FoxOs may be the key to the transcriptional control of the fasting/feeding transition [253]. 
During fasting, when insulin signaling is low, active FoxO orchestrates an increase in G6pc expression 
while inhibiting the expression of Gck, thereby shunting carbons into HGP at the expense of DNL [253]. In 
the fed state, when insulin signaling inhibits FoxO activity, these effects are reversed, favoring DNL over 
HGP [253]. These mechanisms may also be at play in L-FoxO1 mice, which also show increased Gck 
expression with decreased G6pc [144, 145, 167], but may be, as in the case of glucose metabolism by 
FoxO, partially compensated for by intact FoxO3 and FoxO4 [144, 159, 160, 179, 254].  
The establishment of Gck as a FoxO target gene is a seminal contribution given its utter centrality 
in insulin’s control of carbon flux through the hepatocyte [255-258]. Although its vaunted insulin 
responsiveness had previously been thought to be due to regulation by SREBP-1c [211, 259], this view is 
no longer generally accepted [258] leaving an explanatory void now filled by FoxO. Indeed, mice with 
liver-specific deletion of Akt1/2 show a near total loss of Gck, but concomitant knockout of Foxo1 restores 
Gck levels nearly to normal (presumably knockout of Foxo3 and Foxo4 would result in a complete rescue) 
[167]. Thus, insulin signaling appears to orchestrate DNL at least partially in parallel through regulation of 
FoxO à Gck and SREBP-1c à Fasn/Acaca/etc. [253]. Naturally, the coordinated control of G6pc vs. Gck 
expression also need not be mutually exclusive with FoxO regulation of other lipid-regulatory pathways 
(e.g. bile acid metabolism, etc.).  
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1.5.3. Overview of Hepatic Lipid Metabolism: Fatty Acid Oxidation 
During times of fasting the liver and other tissues produce glucose in order to maintain euglycemia. This is 
not the only mechanism for fueling the processes of life in the absence of dietary nutrients, however. In 
the post-absorptive state, as insulin levels fall, the inhibition of adipocyte lipolysis decreases, allowing for 
adrenergic signaling to stimulate the release of free fatty acids for transport back to the liver where they 
can be oxidized to provide energy [183]. 
 The process of fatty acid oxidation (FAO) occurs in the mitochondrial matrix [3 pp. 636-637]. In 
order to enter the mitochondrion, however, the fatty acid must first be “activated” through coupling to 
acetyl-CoA, forming an acyl-CoA. The energy stored in the acyl-CoA thioester bond can then be 
expended in coupling the fatty acid to carnitine through the action of carnitine palmitoyltransferase-1 
(CPT-1). The fatty acyl-carnitine adduct is then whisked through to the mitochondrial matrix where the 
carnitine moiety is removed by carnitine palmitoyltransferase-2 (CPT-2) and the fatty acid is recoupled to 
acetyl-CoA. The mitochondrial fatty acyl-CoA is then free to undergo oxidation. Fatty acids are oxidized 
through the removal of two-carbon acetyl-CoA units (i.e., the exact reverse of the process of DNL) 
proceeding from the β (carboxyl) end of the fatty acid chain. A series of four enzymatic reactions are 
necessary to catabolize saturated fatty acid chains. Catabolism of unsaturated fatty acids requires 
additional enzymes [3 pp. 636-642]. 
Each of the acetyl-CoA units removed from a fatty acid chain can then be further metabolized by 
the citric acid cycle and oxidative phosphorylation, both of which also take place inside the mitochondrion, 
just as for acetyl-CoA derived from glycolysis [3 pp. 660-662, 182]. Fatty acids are therefore able to 
provide fuel for the liver as it engages in energetically costly processes of HGP, as the brain and 
erythrocytes are themselves unable to oxidize fatty acids and strongly “prefer” to metabolize glucose [3 
pp. 649-662, 744-752]. Fatty acids themselves, however, are unable to be converted to glucose in 
animals due to the net loss of the lipid-derived carbons as CO2 during the irreversible steps of the citric 
acid cycle [3 pp. 535-538]. Fatty acids do not only provide the fuel for gluconeogenesis, however; they 
also allosterically prevent glucose oxidation and promote gluconeogenesis, thus sparing glucose for the 
brain [125]. During times of prolonged fasting or starvation, acetyl-CoA derived from FAO can be used 
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directly to provide energy to the brain. That is, the liver is able to condense two molecules of acetyl-CoA 
to generate acetoacetate, which can be further metabolized to acetone and to β-hydroxybutyrate. These 
three “ketone bodies” can then be converted back to acetyl-CoA in other tissues and used in place of 
pyruvate-derived acetyl-CoA [3 pp. 649-650]. 
A key transcriptional coordinator of the FAO program is peroxisome proliferator-activated 
receptor-α (PPARα) [260, 261]. PPARα is a nuclear hormone receptor that, in conjunction with retinoid X 
receptor (RXR), responds to a variety of fatty acid species by inducing FAO genes [262] including lipid 
transporter Cd36 [263], Cpt1, various acyl-CoA dehydrogenases (e.g., Acadm), and acyl-CoA oxidase-1 
(Acox1).  In addition to its role in promoting HGP, PGC-1α also stimulates FAO at least in part by serving 
as a co-activator of PPARα [174, 264]. Interestingly, it appears that the hypolipidemic action of PPARα 
may also include transrepression of FoxO1, particularly with respect to its induction of apoC-III expression 
[252]. 
No liver-specific PPARα knockout model has yet been published. Whole-body PPARα-knockout 
mice show decreased fasting β-oxidation of long-chain fatty acids [265-267], although these mice are also 
protected from the development of obesity-induced insulin resistance [268]. Nevertheless, the relatively 
easy activation of PPARα with synthetic ligands such as the fibrate class of drugs has allowed it to be 
harnessed as a therapeutic avenue in the treatment of hyperlipidemia [269]. 
 
1.5.4. Regulation of Hepatic Fatty Acid Oxidation by Insulin 
In an oft-quoted article from 1992, J. Denis McGarry posited that Oskar Minkowski, who is credited with 
linking diabetes mellitus to the pancreas, had focused too much on the sweet taste of his 
pancreatectomized dog’s urine and not sufficiently on the acetone scent of the dog’s breath in pondering 
the pathogenesis of diabetes [270]. Had Minkowski instead been more attuned to olfactory stimuli, 
McGarry argued, he and his successors would have come to think of diabetes as primarily a disorder of 
fatty acid metabolism [270]. Insulin deficiency, as in type 1 diabetes, results in unchecked lipolysis that 
leads to extremely high levels of FFA in the blood [183]. FFAs exacerbate hyperglycemia at multiple 
levels, including by hindering glycolysis and promoting gluconeogenesis in liver [121, 125, 126, 270]; 
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reducing FFA levels has been shown to ameliorate hyperglycemia [271]. Furthermore, the skyrocketing 
FFA levels also drive very high rates of FAO and ketone body production, hence the aroma of nail polish 
remover that Minkowski was meant to have noticed emanating from his dog [270]. In patients with type 1 
diabetes, this buildup of ketone bodies can result in radical alterations in blood pH, termed diabetic 
ketoacidosis (DKA), and results in short order in coma and death [5 p. 1407].    
The exact mechanism of insulin’s suppression of FAO however, has not garnered as much 
experimental attention in recent years as has its promotion of DNL. It is apparent from what has been 
heretofore discussed that insulin exerts indirect control over the process. Insulin inhibits adipose tissue 
lipolysis, thereby cutting off the supply of ketogenic precursors to the liver [270]. Insulin also stimulates 
the uptake of glucose directly by promoting Glut4 translocation in muscle and adipose tissue and 
indirectly by “trapping” glucose as G6P in hepatocytes through its induction of Gck and posttranslational 
regulation of various steps of glycolysis [3 pp. 749-755]. Insulin-stimulated glycolytic flux in liver and 
skeletal muscle generates acetyl-CoA that, through mass action, will be metabolized to malonyl-CoA by 
ACC1 for DNL [3 pp. 744-750]. Malonyl-CoA is a potent inhibitor of CPT-1, preventing the import of fatty 
acids into the mitochondrion for FAO [181]. Insulin is also able to regulate ACC1 activity by promoting the 
removal of inhibitory phosphates placed by PKA in response to glucagon or epinephrine. This, then, also 
stimulates the production of malonyl-CoA to inhibit FAO [3 pp. 660-662]. 
The above means of insulin control of FAO at the global level require contributions from 
extrahepatic tissues. Whether hepatocyte insulin signaling per se controls FAO more proximally than 
solely by altering malonyl-CoA production outside of the mitochondrion [272] remains unclear. Mice 
lacking InsR specifically in hepatocytes (LIRKO) show elevated plasma ketones in the fed state, 
associated with increased expression of Cpt1 and Hmgcs2, the latter a ketogenic enzyme [202], 
suggesting a transcriptional element of regulation. One way in which insulin signaling may influence FAO-
related gene expression is via Akt phosphorylation of PGC-1α at Ser 570, which has been shown to 




1.6. Molecular Mechanisms of Insulin Resistance 
1.6.1. Insulin Receptoropathies as a Model of Pure Insulin Resistance 
Insulin resistance is a sine qua non of type 2 diabetes mellitus; fasting hyperglycemia results from 
inadequate insulin signaling. While hyperglycemia is thought to account for the microvascular 
complications of diabetes, it is insufficient to explain the characteristic dyslipidemia and attendant 
atherosclerosis associated with the disease [5 pp. 1420-1421, 46]. Thus, dysregulated insulin action per 
se may drive such lipid abnormalities. Moreover, as the liver is one of the principal regulators of bodily 
glucose and lipid metabolism, it is thought to be central to the pathophysiology of insulin resistance. 
 Based on our understanding of the hepatic insulin-signaling pathway as described earlier, we can 
formulate predictions as to the consequences of impaired insulin action (illustrated in Fig. 1.1B). We can 
consider, for instance, the case of the liver InsR knockout (LIRKO) mouse, in which all insulin signaling is 
curtailed specifically in the liver [273]. In this case, the hepatocyte is indifferent to the presence of insulin. 
As a result, there is no activation of the insulin-signaling cascade (e.g., phosphorylation of Irs or Akt). If 
we first consider the glucose arm of the pathway, the inability to activate Akt in response to insulin results 
in the inability to phosphorylate and thereby inactivate FoxO proteins. FoxOs therefore remain largely 
nuclear in localization and promote glucose production, perhaps by inducing the expression of 
gluconeogenic enzymes. Insulin also is unable to engage in its normal posttranslational regulation of 
enzymes involved in glucose flux. Thus, on the whole, the hepatocyte moves to release glucose through 
glycogenolysis and gluconeogenesis, contributing to the characteristic hyperglycemia of diabetes. This 
prediction is borne out by the glucose intolerance exhibited both by the LIRKO mouse prior to liver failure 
[273, 274] and, more importantly, in humans with insulin receptoropathies due to Insr mutations or 
acquired autoantibodies against InsR [65].  
 We also predict that dysfunction of InsR would abrogate the stimulatory effect of insulin on 
hepatic lipid biosynthesis. Specifically, insulin-stimulated cleavage of SREBP-1c downstream of Akt would 
be impaired, thus resulting in decreased expression of lipogenic enzymes. In addition, as in the case of 
the glucose arm, insulin would not be able to engage in posttranslational regulation of lipid partitioning, 
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such as its normal inhibition of VLDL secretion. Thus, on the whole, insulin-stimulated lipid biosynthesis 
would be expected to be low.  
Again, these mechanistic predictions are validated both in mouse and human models of insulin 
receptoropathy. The LIRKO mouse liver shows significantly reduced SREBP-1c processing in response to 
re-feeding, thus resulting in defective induction of Fasn and Scd1 expression [47], which in turn translates 
into decreased DNL [202]. Interestingly, liver TG content is normal at steady state in the LIRKO mouse, 
potentially due to homeostatic compensation by ChREBP [202]. Human insulin receptoropathy patients 
likewise exhibit low to normal liver fat content and normal rates of DNL, the latter value not frankly low 
perhaps due to minor residual signaling capacity of the defective receptors or hyperglycemia-associated 
ChREBP activity [65]. Diminished TG biosynthesis by InsR-deficient livers both in mouse and man also 
results in low to normal plasma TG levels, although this often translates into pro-atherogenic small, dense 
VLDL enriched in cholesterol relative to TG [47, 65, 275].  
 
1.6.2. Garden-Variety Insulin Resistance Is Selective in Nature 
Although the phenotype of patients with insulin receptoropathies tidily comports with our basic 
understanding of the hepatic insulin-signaling pathway, it partially contradicts the prevailing epidemiologic 
picture of IR. All type 2 diabetic patients by definition manifest fasting hyperglycemia due to impaired 
insulin action, but the vast majority of these patients do not exhibit the benign triglyceride profiles of 
insulin-receptoropathy patients [40, 41]. Instead, these individuals, who often have developed IR 
associated with diet-induced obesity, are prone to dyslipidemia including elevated circulating triglycerides 
and LDL cholesterol as well as excessive deposition of triglyceride in the liver (hepatic steatosis) [40, 41, 
248]. As aforementioned, this radically altered lipid phenotype is thought to account for the increased risk 
of cardiovascular disease in IR and diabetic patients [40, 41]. Thus, understanding the connection 
between garden-variety IR and defective lipid homeostasis is of paramount clinical importance.  
 In an influential essay [276], Brown and Goldstein argued that the underlying abnormality in the 
garden-variety IR leading to most cases of type 2 diabetes is actually an uncoupling of insulin’s normal 
actions on the glucose and lipid arms of the pathway. In this paradigm (illustrated in Fig. 1.1C), the 
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glucose arm (including downstream of the FoxOs) becomes resistant to insulin, both as predicted and 
empirically verified in diabetic patients. On the other hand, the excessive hepatic lipogenesis exhibited by 
most IR patients may actually represent some preservation of insulin’s normal stimulation of this process. 
In other words, the lipogenic pathway including SREBP-1c remains relatively sensitive to insulin 
compared to the glucose arm. IR in these patients is “selective,” unlike the “pure” IR of insulin 
receptoropathy. 
Chronic hyperinsulinemia (CHI) may represent a primary etiologic linkage between the combined 
excessive glucose production and excessive lipogenesis of the insulin-resistant liver. That is, excessive 
glucose released by the liver triggers compensatory secretion of insulin, resulting in the well-documented 
hyperinsulinemia of all forms of IR [276, 277]. In the case of insulin receptoropathies, InsR itself is 
defective and so is minimally responsive to any concentration of insulin [65]. In common forms of IR, 
however, InsR itself is not necessarily qualitatively defective, and thus the heightened levels of insulin can 
continue to activate its signaling cascade in the hepatocyte [276]. Evidently this compensatory 
hyperinsulinemia is sufficient to drive the lipid arm of the pathway, thus resulting in excessive lipid 
deposition, but is not able to adequately affect the glucose arm, hence excessive glucose production 
[276]. The mechanism of this CHI-induced IR, which is likely to result from downregulation of InsR [278], 
will be discussed at greater length below. 
 
1.6.3. Differential Sensitivity to Insulin May Drive Selective IR 
The most important question, then, is the biochemical mechanism underlying this apparent uncoupling of 
the glucose and lipid arms. One possibility with considerable support in the literature is that the glucose 
and lipid arms are inherently differentially sensitive to insulin. Specifically, a greater degree of insulin 
signaling is ordinarily required to blunt glucose production (i.e., less sensitive) than to stimulate 
lipogenesis (i.e., more sensitive). In biochemical terms, the ED50 for insulin’s action on lipogenesis is 
expected to be lower than the ED50 for insulin’s action on HGP (Fig. 1.2). 
Based on this idea, we propose that pure IR and selective IR do not necessarily represent a 
paradox. Rather, as illustrated in Fig. 1.2, we hypothesize that they represent different stages along a 
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single continuum of insulin action. In either case, IR can stem from a quantitative defect in InsR signaling 
that alters the effective concentration of insulin “seen” by the hepatocyte rather than arising solely from 
some postreceptor defect as some have posited. At one end of the IR spectrum, as indicated by the blue 
shading in Fig. 1.2, lies the effective absence of InsR that leads to pure IR. In this region, the effective 
insulin concentration lies below the ED50 of both the glucose and lipid arms. Thus, pure IR would 
represent a state with too few functional InsR available to transduce any metabolic signals efficiently, 
resulting in the expected defects in both pathways. 
On the other hand, in garden-variety (selective) IR, some degree of signaling through InsR 
remains intact. As indicated by the pink shading in Fig 1.2, the effective insulin concentration experienced 
by the cell is less than the ED50 for the glucose arm but is greater than the ED50 for the lipid arm. Thus, in 
practical terms, the residual capacity for transducing the insulin signal would be sufficient to drive the 
more-sensitive lipid arm relative to its effect on the less-sensitive glucose arm. This model implies that, if 
one’s degree of hepatic insulin action were hypothetically to deteriorate, one could in theory proceed from 
selective toward pure IR. In other words, were signaling through InsR to worsen, insulin would 
progressively lose its ability to drive lipogenesis. Any residual ability to properly regulate HGP that were 
retained in the partially IR state – albeit insufficient to keep blood glucose levels below the clinical cutoff 
for diabetes – would then be completely lost in pure IR, further exacerbating glucotoxicity.  
This theoretical construct presents two major questions. First, what is the mechanism behind the 
loss of functional InsR? Second, how does incremental loss of InsR differentially affect downstream 
signaling pathways? 
 
1.6.4. Downregulation of InsR Signaling by Hyperinsulinemia 
The reason behind the effective absence of InsR is clear in the case of pure IR, but what causes this loss 
of functional InsR in selective IR? We suspect that the mechanism responsible for diminished InsR 
signaling in selective IR is the same as that driving the inappropriate deposition of lipid: hyperinsulinemia.  
 As described above, hyperinsulinemia results from the attempt of pancreatic β cells to 
compensate for excessive HGP. Chronic hyperinsulinemia per se, however, is a known cause of IR, even 
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in the absence of inchoate IR preceding the development of hyperinsulinemia [277]. For example, patients 
with insulinoma, a benign insulin-secreting tumor, can be considered a model of primary 
hyperinsulinemia. These patients often exhibit reduced insulin action (e.g., by hyperinsulinemic-
euglycemic clamp) in proportion to their hyperinsulinemia that is reversed following removal of the tumor 
[277, 279]. Moreover, mice engineered to express 8 or 32 copies of the human insulin gene (resulting in 
circulating insulin levels 2 or 4 times control) display marked glucose intolerance along with 
hypertriglyceridemia, characteristic of selective IR. Studies of first-degree relatives of patients with T2DM 
provide further evidence of a more “physiologic” primary hyperinsulinemia as an early event in the 
development of IR [270]. Even though these supposedly healthy people showed completely normal 
glucose tolerance test (GTT) profiles, their insulin levels both before and during the test were twice as 
high as controls [280]. This finding appears to dovetail with an apparent genetic predisposition toward 
primary hyperinsulinemia in these family members [281], suggesting that the GTT findings may actually 
have been inappropriately normal for the high insulin and thus reflective of early IR [270]. It merits 
reemphasizing that the physiologic importance of CHI to IR need not be limited to rare case of primary 
hyperinsulinemia, as CHI is a cardinal feature of all forms of IR prior to β-cell failure. 
 CHI is believed to induce IR at least in part by causing a functional downregulation of InsR, an 
example of negative feedback employed by numerous receptor-ligand pairs [277, 278, 282, 283]. The 
extent of IR downregulation in the face of CHI would be expected to dampen signaling through InsR in a 
dose-dependent manner [284, 285]. Thus, in a patient experiencing mounting IR, the steady rise in insulin 
levels over time would result in a progressive loss of hepatic InsR function such that the effective 
hepatocyte “insulinization” falls in parallel [286]. Were garden-variety IR to deplete InsR such that the 
effective insulin concentration were delimited to the pink-shaded region in Fig. 1.1, the clinical stigmata of 
selective IR would arise. Again, in the case of pure IR, the severe defect in InsR function renders the 
hepatocyte utterly indifferent even to the extreme hyperinsulinemia described in such patients.   
 The paradigm described above suggests that most IR patients should show a partial loss of 
functional InsR [287]. Specific binding of insulin to purified human liver plasma membranes isolated during 
liver biopsy was found to be significantly decreased—but not absent—in both non-diabetic and diabetic 
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obese patients compared to non-obese controls [288, 289]. Several studies provide evidence of InsR 
downregulation in a variety of other human cell types as well [290-293]. Such studies have not, however, 
directly assessed the simultaneous effect of partial InsR downregulation on the differential insulin 
signaling to lipid vs. glucose metabolism. 
The biochemical mechanism behind CHI-induced InsR downregulation is complex and involves 
both alterations in receptor numbers and affinity for insulin. Hormone-bound InsR, as in the case of other 
receptor tyrosine kinases, is internalized and degraded in a variety of cell types including liver, thereby 
decreasing the total population of InsR. CHI may also modulate InsR number by decreasing levels of Insr 
mRNA [294], although others have not found such an effect [295]. Second, CHI decreases insulin’s 
affinity for its receptor. Each InsR has two insulin binding sites, the second of which is only occupied at 
high concentrations of insulin. Binding of a second insulin to InsR occurs at a lower affinity than the first, 
decreasing the overall average affinity of insulin binding [296]. CHI also alters the splicing of Insr mRNA to 
favor the lower affinity long form (InsR-B) versus the higher affinity short form (InsR-A) [297], although the 
significance of this mechanism in liver, where InsR-B predominates under normal circumstances, is 
unclear [298]. 
 
1.6.5. Insulin Signaling Diversity Results from Isoform Combinations 
The second major question posed by our model is how a functional loss of InsR translates into differential 
effects on residual insulin signaling to downstream pathways. In other words, what is the molecular 
mechanism behind the phenomenological dose-response curve difference between glucose and lipid 
metabolism?  
Thus far, the only documented cause of the pure IR phenotype is insulin receptoropathy. This 
suggests that the various defects that result in selective IR lie at the postreceptor level. It is convenient to 
think of insulin signaling in a streamlined fashion (e.g., InsR à Irs à PI3K à Akt), a model that is difficult 
to reconcile with selective IR. However, in reality, each of these upstream steps in the pathway is actually 
represented by a group of effectors. There are, in fact, four IRS isoforms, three catalytic and five 
regulatory PI3K subunit isoforms, and three Akt isoforms. Consequently, activation of the singular InsR 
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can actually engage many different, albeit related, downstream signaling pathways that can generate the 
signaling diversity needed to account for inherent differences in the insulin sensitivity of metabolic 
pathways [83].   
In order for this model to be plausible, there must exist demonstrable differences in the ability of 
isoforms of each of these upstream signaling “nodes” to transduce the insulin signal to downstream 
metabolic pathways [83]. Transgenic mouse models manipulating these signaling intermediates show this 
indeed to be the case. Below we consider the cases of the Irs and Akt isoforms, although similar work has 
also been done with regard to the various PI3K subunit combinations. 
Insulin-receptor substrates (IRS) 
There are two major IRS isoforms in liver, IRS1/2. Deletion of both of these isoforms in the liver results in 
glucose and insulin intolerance due to increased HGP that can be rescued by concomitant deletion of 
FoxO1 [166]. As in the LIRKO model, although hepatic TG levels are normal on a chow diet, liver-specific 
Irs1/2-deficient mice show a significant decrease in induction of Srebf1c expression and its lipogenic gene 
program in response to re-feeding as well as reduced serum TG [166]. The liver phenotypes of the whole-
body knockouts of IRS1 and IRS2 are confounded by detrimental effects on other tissues [299].  
Loss of IRS1/2 together resembles a total loss of insulin signaling [166]. On the other hand, loss 
of individual Irs isoforms result in different phenotypes, consistent with the idea of isoform-specific 
signaling driving differential insulin responsiveness. Liver-specific deletion either of IRS1 or IRS2 resulted 
in decreased insulin sensitivity under hyperinsulinemic-euglycemic clamp conditions due to a complete 
loss of insulin inhibition of HGP [300] but a similar study found no difference in these parameters in IRS2 
liver knockout mice [301]. Although there was no difference in liver TG content on chow diet, deletion of 
Irs1 decreased the degree of steatosis in the livers of HFD-fed mice compared to control while liver 
deletion of Irs2 had no effect [300]. This was mirrored by dampened feeding-responsive expression of 
lipogenic genes such as Fasn and Gck that are more dramatic in the IRS1- versus IRS2-deficient liver 
[300]. An RNAi-based approach to acute silencing of Irs1 and/or Irs2 expression in adult liver, however, 
suggested that IRS1 is more integral to insulin’s control of glucose metabolism and IRS2 to the lipid arm, 
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although this conclusion was largely based on gene-expression patterns rather than on physiologic 
readouts [302].  
Although reconciling such data may be difficult due to acute versus chronic effects of IRS 
knockdown, they emphasize the overall possibility that insulin signaling may differentially regulate far-
downstream aspects of glucose and lipid metabolism through differential activation of IRS isoforms. This 
interpretation is bolstered by mechanistic data from primary rat hepatocytes demonstrating that CHI-
induced insulin resistance specifically leads to decreased mRNA and protein levels of IRS2 but not of 
IRS1 [295]. Insulin-stimulated tyrosine phosphorylation of IRS2 and association of IRS2 with PI3K in 
response to insulin are abrogated in CHI-treated cells [295]. On the other hand, these parameters are 
preserved with respect to IRS1, in addition to insulin-induced expression of Srebf1c [295]. (Similar 
experiments performed in rat hepatoma cells have, however, found decreased protein levels of IRS1 in 
response to CHI [303].) While these experiments suggest that SREBP-1c is more under the control of 
IRS1 than IRS2, generally consistent with the transgenic mouse data, experiments in cultured MEFs 
suggest that IRS2 more efficiently affects the phosphorylation of FoxO proteins [304]. 
Akt 
As in the case of IRS, there are two major isoforms of Akt operating in liver, Akt1/2. Liver-specific 
deletion of both major isoforms, in a fashion again similar to both the LIRKO and liver-specific IRS1/2-
knockout mice, develop glucose intolerance due to the inability of insulin to suppress HGP. This 
phenotype is associated with increased expression of G6pc and Pck1 and these abnormalities can be 
rescued by concomitant deletion of FoxO1 [167]. Although the effect of liver-specific Akt1/2 knockout on 
hepatic or plasma lipids has not been reported, insulin-stimulated expression of Srebf1c and Gck were 
significantly decreased relative to controls [167]. Again, prior experimental evidence suggests the 
possibility of differential regulation of metabolism by Akt1 versus Akt2. In cultured adipocytes, for 
example, CHI treatment suppressed insulin-stimulated glucose uptake by Glut4 but did not prevent the 
blunting of lipolysis downstream of FoxO1 because the latter process is controlled by both Akt1 and 
Akt2 while the former is regulated only by Akt2 [305].   
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In the context of liver, tissue-specific elimination of Akt2 results in a significant impairment of 
insulin inhibition of HGP (specifically of glycogen synthesis and catabolism) without effects on G6pc or 
Pck1 expression [112]. Hepatic Akt2-knockout livers do not manifest obvious deficiencies in lipid 
metabolism in the chow-fed state, although short-term feeding with a high-carbohydrate diet unmasks a 
significant lowering of DNL in the Akt-deficient liver [158, 306]. Moreover, induction of metabolic stress 
through various genetic (e.g., leptin deficiency) and dietary (e.g., Surwit HFD feeding) manipulations 
reduced steatosis in the Akt2-deficient livers due to decreased lipogenic gene expression and 
coordinately lower rates of DNL [306]. Interesting, subsequent experiments demonstrated that the 
decreased rates of DNL in HFD-fed Akt2-null livers occurs alongside decreased expression of Fasn and 
Gck despite normal induction of Srebf1c [158]. Thus, on the whole, Akt2 plays a role in hepatic lipid 
metabolism under conditions of metabolic stress but is a prime regulator of hepatic glucose metabolism 
under normal physiologic conditions.  
There has been no study to date focusing solely on liver-specific Akt1 deficiency. Whole-body 
Akt1 knockout mice, unlike global Akt2 knockouts, are susceptible to perinatal mortality and exhibit growth 
defects but, also unlike Akt2-/- animals, do not demonstrate notable perturbations in glucose metabolism 
[307-309]. This suggests that the bulk of insulin’s effects on metabolism are mediated through Akt2 while 
Akt1 is more important in mediating mitogenic aspects of insulin and growth factor signaling [310-313]. It 
is important, however, to note these studies did not explore aspects of whole-body or hepatic lipid 
metabolism in depth in the Akt1 knockout mice. 
Signaling diversity may be generated through the Akt “node” not only through the unique activities 
of Akt1 versus Akt2 but also through differential activating phosphorylation of Akt1/2. Both Akt1 and Akt2 
are phosphorylated in response to insulin signaling on two main residues, Thr 308 (in Akt1)/Thr 309 (in 
Akt2) and Ser 473 (in Akt1)/Ser 474 (in Akt2). Again, although both of these sites are phosphorylated in 
response to insulin signaling, the individual kinases responsible for phosphorylating these two residues 
differ. In the case of Thr 308/309, the phosphate transfer is catalyzed by PDK1 following PI3K activation 
within the classical upstream insulin-signaling paradigm [86, 314]. On the other hand, Ser 473/474 does 
not appear to be phosphorylated by PDK1, but rather by mTOR complex 2 (mTORC2) [87-89]. A number 
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of other kinases have also been implicated in the phosphorylation of Ser 473 [315]. Although some have 
speculated that phosphorylation of Thr 308 is dependent on an initial “gatekeeping” phosphorylation at 
Ser 473, the two phosphorylation events have been shown to be capable of independent regulation and 
are both required for full activation of Akt activity [88, 316-318].  
Experimental evidence suggests that differential phosphorylation of Thr 308 versus Ser 473 
results in selective regulation of downstream signaling pathways [316]. Liver-specific deletion of rictor 
(LiRiKO), the defining constituent of mTORC2, abrogates Ser 473 phosphorylation in response to insulin 
signaling while leaving Thr 308 phosphorylation intact [88]. This manipulation results in the loss of Akt’s 
ability to phosphorylate and inhibit FoxO1 and GSK3β but not of its ability to trigger the activation of 
mTORC1 and its substrates, S6K1 and 4EBP1 [88]. Interestingly, however, despite the preservation of 
mTORC1 activation, LiRiKO mice exhibit defects in insulin regulation of both HGP and DNL [88]. Cells 
from whole-body rictor knockout mice have also demonstrated defects in phosphorylation of FoxO but not 
of TSC2 à mTORC1 à S6K1 [89]. On the other hand, liver-specific deletion of Pdk1 (L-Pdk1KO) resulted 
in deficient phosphorylation of FoxO1 and S6K1 but not of GSK3β [319]. In both LiRiKO (i.e., phospho-
Ser 473-deficient) and L-Pdk1KO (i.e., phospho-Thr 308-deficient) livers there was a significant decrease 
in Gck expression [88, 319]. Moreover, in both of these models, rescuing Gck expression via adenovirus 
rescues the expression of some or all of the classical ChREBP-inducible lipogenic genes but not Srebf1c 
[88, 319]. Interestingly, in the LiRiKO mouse, even the restoration of glucose flux and lipogenic gene 










1.7. Hypotheses and Specific Aims 
Although we know a great deal about how insulin acts and how resistance to those actions can contribute 
to metabolic disease, a great many questions remain outstanding. Perhaps principal among these stands 
the phenomenon of selective IR, as the unfavorable combination of escalated HGP and DNL give rise to 
the mutually reinforcing hyperglycemia and dyslipidemia of T2DM. A great part of our problem in 
elucidating the pathogenesis of selective IR is the fact that we still do not completely understand the 
intimate relationship between insulin’s actions on hepatic glucose and lipid metabolism even in the 
healthy liver. However, I have identified two promising avenues of investigation that may lend us greater 
insight into these pressing questions. 
 First, as discussed at length above, I hypothesize that chronic hyperinsulinemia drives 
selective IR due to inherent differences in the insulin responsiveness of the glucose and lipid 
arms of the pathway. Thus, in Chapter 3, I describe a model of chronic hyperinsulinemia in isolated 
primary hepatocytes that does indeed recapitulate selective IR. I further substantiate InsR downregulation 
as a potential mechanism of CHI-induced selective IR by demonstrating that acute titration of InsR levels 
per se differentially affects insulin’s ability to halt glucose production versus stimulating de novo 
lipogenesis. 
 Second, although I make reference to the glucose and lipid “arms” of the insulin-signaling 
pathway, this is merely shorthand based in part on the largely historical portrayal of these pathways as 
divergent downstream of Akt. Aside from the evident allosteric and thermodynamic coordination of HGP, 
DNL, and FAO, insulin appears to exert long-term control over these processes at the transcriptional level 
as well through FoxO proteins, particularly FoxO1. Indeed, no other insulin-regulated protein downstream 
of Akt has been so extensively validated as essential to the regulation of both glucose and lipid 
metabolism. Yet most of the evidence linking FoxO1 to control of glucose and lipid metabolism, though 
convincing in a phenomenological sense, does not adequately explain how this transcription factor can 
affect metabolic processes outside of the nucleus. In other words, we do not know which of FoxO1’s 
hundreds of purported target genes are truly essential for fulfilling its clear roles in metabolic control. 
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In Chapter 4, I describe an unbiased first step in this direction by taking a genetic approach. 
Specifically, I hypothesize that determining whether FoxO1 acts as a direct transcription factor or as 
a transcriptional co-regulator with respect to a particular physiologic parameter will allow us to 
rule out or rule in subsets of its target genes as responsible for that effect. To that end, I will 
describe the L-DBD mouse, which expresses only a DNA binding-deficient form of FoxO1 in its liver. By 
comparing the L-DBD mouse to L-FoxO1 and control animals, I have determined the primary “mode” of 
FoxO1’s action on hepatic glucose and lipid metabolism. I have then coupled this physiologic information 
with transcriptomic analysis of each of these mouse models to drastically narrow down the list of 
candidate target genes for each metabolic process. 
Finally, in Chapter 5, I attempt to integrate the information learned from these two systems to 














































Figure 1.2. Theoretical Continuum of Insulin Action!
!































2.1. In Vivo Studies 
2.1.1. Mice and Diets 
Male and female C57Bl6/J mice aged over 8 weeks were used for all experiments in Chapter 3. Male 
mice aged 12-20 weeks were used for all experiments in Chapter 4 with the exception of L-FoxO1,3,4 
mice and associated Cre- controls, aged 8-10 weeks. L-FoxO1 mice have been previously described 
[145]. Heterozygous DBD knock-in mice were generated by two previous postdoctoral fellows in the lab, 
Tadahiro Kitamura and Alex Banks, through homologous recombination by recombinase-mediated 
cassette exchange (RMCE) [157, 320] (Fig. 2.1). Breeding for the L-DBD colony was begun by Kyoichiro 
Tsuchiya before the author joined the lab. All L-FoxO1, L-DBD, and respective Cre- control mice were 
bred on to the C57Bl6/J background. Genotyping was performed by Thomas Kolar; primer sequences are 
listed in Table 2.1. Mice were weaned at 3 weeks of age to standard (chow) diet (Harlan; 4% fat). 
Western-type diet (Harlan; 21% anhydrous milk fat, 34% sucrose, 0.2% cholesterol) was fed to animals 
as indicated beginning at 6 weeks of age for 10 weeks. L-FoxO1,3,4 mice and Cre- controls, all on a 
mixed genetic background, were furnished by Rebecca Haeusler and Samuel Lee. The Columbia 
University IACUC approved all animal procedures.  
 
2.1.2. Metabolic Testing 
Overnight fasts were conducted for 16 hr, from 17:00 to 09:00. Mice to be re-fed were then given ad 
libitum access to chow from 09:00 to 13:00. Blood glucose measurements were made from tail vein blood 
using OneTouch glucose monitor and strips, immediately before sacrifice for terminal procedures 
(Lifescan). Intraperitoneal glucose and pyruvate tolerance tests were performed in overnight-fasted mice 
using a dose of 2 g/kg dextrose (aq) or sodium pyruvate (aq). Insulin tolerance test was performed in 5-
hr-fasted mice using a dose of 0.8 U/kg Novolog insulin. Oral lipid tolerance test (OLTT) and TG secretion 
experiments were performed in mice fasted for 5 h. OLTT was performed using olive oil administered 
orally at 10 μL/g body weight. TG secretion was measured following intraperitoneal injection of Poloxamer 
407 (aq) at 10 μL/g. In both cases tail vein blood was collected at indicated time points and TG content 
measured by colorimetric assay (Wako). Tolerance tests were performed by Ana Flete-Castro. 
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2.1.3. In Vivo Insulin Signaling 
Mice for in vivo insulin signaling assessment were fasted for 5 hr, anesthetized, and injected in the inferior 
vena cava with 0.5 mU/g NovoLog insulin (Novo Nordisk). After 3 min, samples of liver, soleus muscle, 
and epididymal white adipose tissue were snap frozen using liquid nitrogen.  
 
2.1.4. Biometrics and Indirect Calorimetry 
Body composition of ad libitum-fed adult male mice was performed via MRI (Bruker Optics) by Ana Flete-
Castro and percent composition was calculated based on total body weight. Indirect calorimetry and 
measurement of activity was performed as previously described [157, 321] using a TSE Labmaster 
Platform (TSE Systems). Mice were acclimated to metabolic cages for 24 h before beginning 
measurements. Measurements were carried out for 72 h and averages were calculated over the three 
light cycles and three dark cycles of that period. Illustration of cumulative food intake over 24 h reflects the 
second day of measurement.  
 
2.1.5. Tissue Sample Collection 
Mice were sacrificed using CO2 in accordance with the laboratory animal protocol. Blood was drawn by 
cardiac puncture immediately after sacrifice. After being allowed to clot, bloods were centrifuged and 
serum withdrawn. Measurements of serum insulin were made by ELISA (Mercodia) and lipids by 
colorimetric assays (Wako for non-esterified fatty acids and cholesterol, Thermo for TG), respectively. 
Tissue samples were removed within 3 min following sacrifice and snap frozen on liquid nitrogen except 
for liver samples used for histology, which were preserved in formalin. Histology procedures were 
performed by the Pathology Core in the Naomi Berrie Diabetes Center. 
 
2.1.6. Hepatic Lipid Measurement 
Hepatic lipids were extracted from ~50 mg snap-frozen tissue samples using a modified method of Folch 
[322]. Briefly, tissue samples were homogenized in PBS via bead mill and were then extracted 
successively in 2:1 chloroform:methanol and then 86 chloroform:14 methanol:1 water. The hydrophobic 
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phases of each extraction were pooled in glass scintillation vials and blown to dryness under N2 gas. 
Dried lipids were then resuspended and solubilized in 8.5:1.5 chloroform:Triton X-100. Solubilized lipids 
were then blown to dryness again and resuspended in water. TG and cholesterol content were assayed 
colorimetrically and normalized to sample weight.  
 
2.2. Primary Hepatocyte Studies 
2.2.1. Primary Hepatocyte Isolation and Culture 
Primary hepatocytes were isolated from anesthetized mice using a collagenase perfusion protocol. A 
vascular clip was placed over the supradiaphragmatic inferior vena cava. A 24G¾ Exel Safelet catheter 
was then inserted into the inferior vena cava at the level of the left renal vein and connected to a 
peristaltic pump to infuse 40 mL perfusion solution (HBSS with 0.5 mM EGTA) following cutting of the 
portal vein. Next we infused 100 mL collagenase solution (Medium 199 containing 1% BSA, 20 mM 
HEPES, and type 4 collagenase [Worthington] at 3 mg/g body weight). The liver was then excised and 
finely minced in plating medium (Medium 199 with 10% FBS, and antibiotics [100 U/mL 
penicillin/streptomycin (Invitrogen), 50 µg/mL gentamicin (Sigma)]). The hepatocyte suspension was 
filtered through a 100-µm nylon mesh (BD). Following a series of low-speed centrifugations followed by 
medium replacements, cells were plated at a density of 400,000/mL on collagen-coated cultureware (BD). 
90 min after plating, cells were washed with PBS and plating medium was replaced. For most 
applications, 3 h later cells were washed twice again with PBS and incubated overnight in serum-free 
medium (Medium 199 supplemented with 1% fatty acid-free BSA and antibiotics). For cells treated with 
the chronic hyperinsulinemia (CHI) protocol in Chapter 3, medium was supplemented with 100 nM 
Novolog insulin at every step from plating onward, including during overnight serum starvation. 
 
2.2.2. Glucose Production Assay 
For glucose production assay, cells were washed twice with PBS and serum-free medium was replaced 
with glucose production medium (glucose- and phenol red-free DMEM supplemented [Sigma] with 1% 
BSA, 3.3 g/L sodium bicarbonate, 20 mM calcium lactate, 2 mM sodium pyruvate, and antibiotics). Cells 
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were incubated with 100 µM 8-chlorophenylthio-cAMP (Sigma) with or without 1 µM dexamethasone 
(Sigma) or vehicle for 5 hr. In experiments in which acute insulin was employed, cells were pre-treated for 
1 h with insulin before adding glucose-production cocktails. For experiments with S961 (Novo Nordisk) or 
Akti-1/2 (Akt inhibitor VIII, Sigma), inhibitor or vehicle (DMSO for Akti-1/2) was added at the indicated 
concentrations 30 min before the insulin pre-treatment and was continued throughout the experiment. At 
indicated time points, aliquots of medium were sampled, centrifuged, and glucose content was measured 
via peroxidase-glucose oxidase assay (Sigma) and normalized to protein content. 
 
2.2.3. De Novo Lipogenesis 
Following overnight serum starvation, medium was changed to serum-free medium with or without 10 nM 
insulin. For experiments with S961 (Novo Nordisk), inhibitor was added at the indicated concentrations 30 
min before the insulin pre-treatment and was continued throughout the experiment. After 2 hr, the medium 
was spiked with 0.6 µCi/mL [1,2-14C]-acetic acid (PerkinElmer Life Sciences) and incubated for an 
additional 3 hr. Lipids were extracted twice using 3:2 hexane:isopropanol and pooled extracts were dried 
in glass scintillation vials under N2 gas. For measurement of total DNL, lipids were resuspended in 2:1 
chloroform:methanol and were then counted using a liquid scintillation counter (PerkinElmer). For specific 
measurement of TG synthesis, dried lipids were resuspended in 2:1 chloroform:methanol and transferred 
onto TLC plates using a SpotOn TLC Sample Applicator (Analtech). TLC was performed using a mobile 
phase of 70:30:1 hexane:diethyl ether: acetic acid. Areas of silica containing TG, as identified by staining 
with iodine vapor, were scraped into glass scintillation vials and counted as above. In both cases, CPM 
readings were normalized to total cellular protein. 
 
2.2.4. Fatty Acid Oxidation 
Primary hepatocytes were cultured overnight in plating medium (i.e., not serum starved). Cells were 
washed three times with PBS and incubated for 4 hr in Medium 199 supplemented with 1.5% fatty acid-
free BSA, 0.2 mM unlabeled oleic acid, and 1 µCi/mL [1-14C]-oleic acid. Media from each well were 
transferred to glass Erlenmeyer flasks sealed with rubber plugs containing a suspended center well 
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(Kontes) holding grade 4 filter paper (Whatman) alkalinized with 1N potassium hydroxide. 70% (v/v) 
perchloric acid was then injected into each flask followed by agitation of the flasks at room temperature 
for 1 hr. Radiolabeled CO2 content of each filter paper was then assessed by scintillation counting and 
normalized to total cellular protein after correcting for specific activity of the original labeling medium in 
each well. 
 
2.3. Gene and Protein Expression Analyses 
2.3.1. mRNA Studies 
Samples of frozen liver (~10 mg) were homogenized in QiaZOL (Qiagen) using an electric homogenizer 
(Fisher Scientific, Model 500). Lysates were extracted with chloroform and the aqueous phase 
precipitated with 70% ethanol. Primary hepatocytes were lysed in Buffer RLT (Qiagen) supplemented with 
10 µL/mL β-mercaptoethanol. Samples were processed using the RNeasy Mini Kit (Qiagen) following 
manufacturer’s instructions, including on-column digestion with DNase-I (Qiagen). RNA concentrations 
were measured using a NanoDrop Spectrophotometer (Thermo). 1 µg of RNA was reverse transcribed 
using the GoScript Reverse Transcription System (Promega) following manufacturer’s instructions. 
cDNAs were diluted 1:10 and RT-PCR was performed using a DNA Engine Opticon 2 System (Bio-Rad) 
with SYBR Green (Promega). Primers were synthesized by Invitrogen; sequences are available in Table 
2.2. Gene expression levels were normalized by TATA-binding protein (Tbp) using the 2-∆∆Ct method. 
 
2.3.2. Western Blotting 
Frozen livers (~50 mg) were homogenized in or primary hepatocytes directly lysed in ice-cold lysis buffer 
(20 mM Tris-HCl, 150 mM sodium chloride, 10% glycerol, 2% NP-40, 1 mM EDTA, 20 mM sodium 
fluoride, 30 mM sodium pyrophosphate, 0.2% SDS, 0.5% sodium deoxycholate) supplemented with 
protease/phosphatase inhibitors (Cell Signaling). Protein concentration was assessed by bicinchoninic 
acid assay against a standard solution of albumin (Sigma). Electrophoresis was performed using 
homemade 8% polyacrylamide gels at 125 V for 2 h in a running buffer of 25 mM Tris base, 0.192 mM 
glycine, and 0.1% SDS. Precision Plus Protein Kaleidoscope Standards (Bio-Rad) were used as 
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molecular weight marker. Gels were transferred at 4ºC to PVDF membranes (Bio-Rad), sandwiched 
between Whatman paper, at 100 V for 2 h in a transfer buffer of 25 mM Tris base, 0.192 mM glycine, and 
10% methanol. Following transfer, membranes were stained with a solution of Ponceau Red S and cut 
into strips covering appropriate molecular weight ranges. The membrane strips were then destained in 
TBS-T (1X Tris-buffered saline with 0.05% Tween-20 [Sigma]) and blocked for 1 h at room temperature in 
blocking buffer (TBS-T with 5% nonfat dry milk [Parmalat]). Incubation with primary antibody was carried 
out overnight at 4ºC in a solution of 2.5% BSA in TBS-T. A list of antibodies used is available in Table 2.3. 
The next morning, membrane strips were washed several times in TBS-T followed by incubation with 
secondary antibody (1:2000 in blocking buffer). Following several additional washed with TBS-T, 
membrane strips were treated with Pierce Enhanced Chemiluminescent (ECL) Western Blotting Substrate 
(Thermo) and were exposed to radiography film (Fisher). Films were developed using an X-OMAT 
Developer (Kodak). Densitometric analysis was performed using ImageJ software (NIH). 
 
2.3.3. Luciferase Assay 
Luciferase assays were performed by Dr. Michihiro Matsumoto, a former postdoctoral fellow in the 
laboratory. HEK293 cells were transiently transfected with plasmids encoding either Foxo1wt, Foxo1dbd, or 
empty vector as well as 3X IRE-luc reporter plasmid or empty vector using Lipofectamine 2000 
(Invitrogen) in DMEM supplemented with 10% FBS. 36 h after transfection of plasmids, media was 
changed to serum-free DMEM/PCSM. 12 h after serum starvation, cells were lysed and luciferase assay 
was performed using the Dual Luciferase Reporter Assay System (Promega) in a Monolight 310 
luminometer (PharMingen).  
 
2.4. RNA-Seq 
2.4.1. Physical Procedures 
mRNA samples from three fasted and three re-fed mice of each genotype (control, L-FoxO1, L-DBD) and 
purified as described above were submitted to the Columbia University Molecular Pathology Core for 
assay using an Agilent Bioanalyzer 2100. All mRNA samples submitted demonstrated RNA integrity 
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number (RIN) values of greater than 8.0. Samples were then submitted to the Columbia Genome Center 
(CGC). The CGC prepared the RNA-seq library via poly(A) pulldown using TruSeq RNA Sample Prep Kit 
v2 (Illumina). Libraried cDNA was then sequenced using a HiSeq 2000/2500 sequencing system 
(Illumina) at a read depth of 30 million over 100 bp fragments.  
 
2.4.2. In Silico Analysis 
Sequence alignment, statistical analysis, and heat mapping were performed by Dr. Bin Fang of the 
University of Pennsylvania. Statistical significance was defined more stringently by q < 0.05 or less 
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Figure 2.1. RMCE Strategy for Generating Foxo1dbd!
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Foxo1 (flox)! GCTTAGAGCAGAGATGTTCTCACATT! CCAGAGTCTTTGTATCAGGCAAATAA!
Foxo1 (dbd)! TGCACATGTCTCCATACTTGTTA! TGTAATCACACTCTGCCGAGGT!
Foxo1 (het)! ACTTCCAGTTCAACATCAGCCG! TTCCCGCTTCAGTGACAACGTC!
Cre (univ.)! ACCTGAAGATGTTCGCGATTATCT! ACCGTCAGTACGTGAGATATCTT!
Table 2.1. Primers Sequences Used for Genotyping!
!











Foxo1 (total)! GCGTGCCCTACTTCAAGGATAA! TCCAGTTCCTTCATTCTGCACT!
Foxo1 (wt)! GAAGAATTCAATTCGCCAC! CTGCACTCGAATAAACTTGC!













Table 2.2. Primers Sequences Used for qPCR!
!




Species/Clonality! Manufacturer! Product no.!
R mAb! Cell Signaling! 4970S!
R pAb! Cell Signaling! 9272S!
R mAb! Cell Signaling! 13038S!
R mAb! Cell Signaling! 4060S!
R mAb! Cell Signaling! 3180S!
R mAb! Cell Signaling! 2880S!
R pAb! Cell Signaling! 9461S!
S pAb! N/A*! N/A*!
R mAb! Cell Signaling! 9315S!
R mAb! Cell Signaling! 9322S!
M mAb! Novus Biologicals! 06349-64!
R mAb! Cell Signaling! 3024S!
R mAb! Cell Signaling! 3407S!
R mAb! Cell Signaling! 3089S!
R mAb! Cell Signaling! 2983S!



















SREBP-1c (2A4)! M mAb! Novus Biologicals! NB600-582!
Table 2.3. Primary Antibodies Used for Western Blotting!
!
M = mouse, R = rabbit, S = sheep; mAb = monoclonal, pAb = polyclonal!
































Our hypothesis for the genesis of selective IR in liver suggests that it is at least in part hepatocyte 
autonomous. We therefore aim to recapitulate selective IR by modeling CHI in primary mouse 
hepatocytes as described previously [247, 295, 305]. The ability to demonstrate that this model works 
would substantiate the idea that CHI per se can contribute to the development of selective IR, rather than 
CHI merely representing an epiphenomenon coinciding with selective IR.  
The kinetics of CHI-induced InsR downregulation in cultured hepatocytes is well described [284, 
285, 288, 323-326]. Incubation of primary hepatocytes with 100-nM insulin results in a ~50% decrease in 
InsR numbers by 24 h that remains steady up to 72 h. Removal of insulin from the culture medium after 
24 h results in a nearly complete rebound in InsR number to the level of untreated cells within hours [285]. 
InsR downregulation can be demonstrated in primary hepatocytes chronically exposed even to lower, 
more physiologic insulin concentrations [324].  
Precedent also exists to suggest the possibility of recapitulating selective IR in isolated cells in 
response to CHI. For example, a model of CHI in primary rat hepatocytes that resulted in significantly 
increased insulin-stimulated de novo lipogenesis compared to control cells in spite of significantly 
decreased InsR binding and insulin-stimulated uptake of 3-aminoisobutyrate [325]. Increased lipogenesis 
in this system may be due to persistent activation of the SREBP-1c pathway despite markedly reduced 
insulin-stimulated PI3K activity [295]. These studies, though consistent with our hypothesis, do not speak 




3.2.1. Model of Chronic Hyperinsulinemia Recapitulates Selective IR 
We treated mouse primary hepatocytes with or without 100-nM insulin (“chronic hyperinsulinemia,” 
henceforth CHI) for 24 h followed by acute (30 min) treatment with or without 10-nM insulin. CHI treatment 
results in an approximately 50% reduction in InsR protein levels, indicating InsR downregulation (Fig. 3.1). 
In keeping with reduced InsR signaling, insulin-stimulated phosphorylation of Akt at Thr 308 and Ser 473 
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is markedly reduced, although the basal level of Akt phosphorylation at both sites is higher than in control 
(Fig. 3.1). This is consistent with findings in the published literature.  
As Akt is generally considered the “branch point” between the glucose and lipid arms of hepatic 
insulin action [213], we assessed major downstream indices of insulin action on these processes. 
Phosphorylation of FoxO1, as indicated by an upward electrophoretic mobility shift, parallels that of its 
insulin-responsive kinase, Akt, as expected (Fig. 3.1). That this electrophoretic mobility shift in FoxO1 is 
completely lost in CHI-treated cells is consistent with the hypothesis that the glucose arm has been 
rendered resistant to the acute effects of insulin. On the other hand, cleavage of SREBP-1c, a surrogate 
measure of the activation of the lipid arm, appears to be relatively more intact in the CHI-treated cells (Fig. 
3.1). That is, although SREBP-1c cleavage appears to lose much of its acute responsiveness to insulin as 
well, the absolute amount of cleaved SREBP-1c is comparable between insulin-treated control cells and 
CHI-treated cells treated acutely with or without insulin (Fig. 3.1). The preservation of cleaved SREBP-1c 
levels in the CHI-treated cells is likely attributable to increased levels of precursor (uncleaved) SREBP-1c 
that had accumulated in response to high-dose insulin over the 24-h exposure period (Fig. 3.1). CHI-
treated primary hepatocytes interestingly exhibited sharp decreases in protein levels of IRS1/2 (Fig. 3.1 
and data not shown). We confirmed these findings in rat Fao hepatoma cells as well (data not shown). 
Although these indices of insulin action are consistent with our expectations, it is necessary to 
test functional readouts of both arms of the insulin-signaling pathway. We therefore performed glucose 
production (GP) assays in mouse hepatocytes subjected to the CHI paradigm described above (Fig. 
3.2A). As expected, treatment with a cell-permeable cAMP analogue (CPT-cAMP) resulted in a ~35% 
induction of GP over 5 h that was completely reversed by concomitant treatment with insulin. On the other 
hand, although CHI treatment did not affect maximal induction of GP by cAMP, the inhibitory effect of 
insulin was completely lost. qPCR analysis of key enzymes involved in GP were congruent with the 
glucose-production findings (Fig. 3.2B-C). mRNA levels of G6pc and Pck1 were induced 30- and 15-fold, 
respectively, by treatment with cAMP; this effect was, as expected blocked by co-treatment with insulin. 
CHI-treated cells consistently exhibited an attenuated response of G6pc and Pck1 expression to cAMP 
treatment, but again even this blunted response was completely unresponsive to insulin (Fig. 3.2B-C). 
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Thus, we can state that CHI treatment does indeed induce insulin resistance in the glucose arm of the 
pathway.  
 In order to determine whether the IR evoked by CHI is truly selective, we assessed de novo 
lipogenesis (DNL) in the context of the CHI model (Fig. 3.3A). CHI treatment tended to increase basal 
lipogenesis by 23%. Nevertheless, acute insulin treatment still significantly induced DNL by 38%, 
although this was decreased relative to the effect of acute insulin in control cells (53%). Expression of 
Srebp1c and Gck were both increased at baseline in CHI-treated cells, although there was no significant 
effect of acute insulin treatment on expression of these genes in either control or CHI-treated cells (Fig. 
3.3B-C). These observations were confirmed at the protein level as well (Fig. 3.1). Overall, CHI treatment 
renders primary hepatocytes incapable of inhibiting cAMP-induced GP even as they remain able to 
activate lipogenesis in response to the same dose of insulin, hence selective IR.  
 
3.2.2. Variable InsR Antagonism Results in a Spectrum of IR 
The recapitulation of selective IR in response to CHI treatment is consistent with the empirical findings in 
hyperinsulinemic humans and mice. The ex vivo model of CHI, however, is associated with certain 
limitations. First, the reduction in InsR protein levels by ~50% represents only a snapshot of InsR 
impairment that does not allow us to understand at which point the two metabolic arms actually diverge. 
Next, CHI involves exposure of the cells to insulin as a matter of course. Thus, before IR sets in, cells 
would respond to the treatment as they would an acute bolus of insulin. This is reflected, for example, in 
the higher baseline phosphorylation of Akt and protein levels of precursor SREBP-1c and Gck, and may 
therefore mask subtle defects in the acute response of DNL to insulin. Lastly, CHI-induced IR may 
actually represent only one particular even of selective IR and we therefore aimed to take a parallel 
approach to investigating selective IR. 
 We have therefore taken an acute approach to manipulating the insulin sensitivity of hepatocytes 
by employing S961, a peptide competitive inhibitor of InsR derived from insulin [327]. By treating cells with 
a range of concentrations of S961, we expect to generate a spectrum of insulin resistance that will allow 
us to better visualize the differential insulin sensitivities of the glucose and lipid arms [327, 328]. To this 
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end, we have treated mouse primary hepatocytes with or without S961 for 30 min prior to and then along 
with acute treatment with insulin. S961 treatment dose-dependently inhibits the phosphorylation of IRS1, 
Akt (Thr 308), GSK3β (Ser 9), and FoxO1 in response to insulin (Fig. 3.4A).  On the other hand, there is 
no discernible effect on either total or cleaved SREBP-1c levels (Fig. 3.4A). As expected, there is also no 
effect on total InsRβ levels (Fig. 3.4A). By plotting the percentage of maximal insulin action on Akt or 
GSK3β phosphorylation as a function of the logarithm of antagonist concentration, we can calculate the 
IC50 of S961 as an index of the relative IR of these components of the proximal insulin-signaling pathway 
(Fig. 3.5). The calculated IC50 for the response of phosphorylation of Akt Thr 308 to 10-8 M insulin is -9.06 
(0.87 nM), for Akt Ser 473 is -8.57 (2.69 nM), and for GSK3β Ser 9 is -9.01 (0.98 nM) (Fig. 3.5). 
Antagonism of InsR also results in dose-dependent defects in the insulin responsiveness of 
glucose production (Fig. 3.4B). Acute treatment of cells with 10-8 M insulin results in a 31% reduction of 
cAMP-stimulated GP. Co-treatment with S961 at 10-6 and 10-7 M S961 completely blocks this effect of 
insulin, while 10-8 M S961 allows for a 9% reduction of GP by insulin. Treatment with 10-9 and 10-10 M 
S961 allowed for 21% and 24% reductions of glucose production, respectively, by insulin. Thus, even at 
an antagonist concentration 100-fold lower than that of insulin, the cells still are unable to completely 
suppress GP in response to insulin. Treatment even with the maximal dose of S961 did not affect 
maximal GP in response to cAMP. By plotting the percentage of maximal insulin action on GP as a 
function of the logarithm of antagonist concentration, we can calculate the IC50 of S961 as an index of the 
relative IR of the glucose arm (Fig. 3.6). The calculated IC50 for the response of the glucose arm to 10-8 M
insulin is -8.63 (2.3 nM). 
The insulin-responsive lowering of mRNA levels of G6pc and Pck1 is likewise dose-dependently 
inhibited by S961 (Fig. 3.4C). cAMP-induced expression of G6pc and Pck1 were decreased by 96% and 
92%, respectively, by insulin. Surprisingly, G6pc mRNA decreased by about a third in response to insulin 
even at the highest concentration of S961, and was suppressed maximally by insulin in the presence of 
10-9 M S961. Pck1 expression, on the other hand, was not decreased by insulin in the presence of 10-6 or 
10-7 M S961, although, as for G6pc, was fully suppressed at 10-9 M S961. The calculated IC50 for
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suppression of cAMP-induced G6pc and Pck1 expression by 10-8 M insulin are -7.60 (25.1 nM) and -7.79 
(16.2 nM), respectively (Fig. 3.7). 
Variable InsR antagonism resulted in a distinctly different dose-response curve for DNL (Fig. 
3.4E). Treatment with 10-8 M insulin stimulated DNL by 67% in control hepatocytes. This effect was fully 
suppressed by S961 at 10-6 and 10-7 M but treatment with even the highest dose of S961 did not alter 
basal DNL. Treatment with 10-8 M S961 permitted a 29% increase in DNL in response to insulin, roughly 
44% of the maximal response. At 10-9 and 10-10 M the rates of DNL exceeded even that in the insulin-
treated control cells, rising by about 78% in each case. The slightly higher rates of DNL in these cells was 
not, however, statistically significant compared to insulin-only control. The calculated logarithmic IC50 for 
S961 inhibition of DNL in response to 10-8 nM insulin, an index of the relative IR of the lipid arm, is -8.07 
(8.51 nM) (Fig. 3.6).  
We can directly compare the IC50 values obtained for GP and DNL, as each represents the 
relative IR of its respective metabolic process within the same experimental context (Fig. 3.6). Again, the 
IC50 for GP was calculated as -8.63 (i.e., 10-8.63 M, or 2.3 x 10-9 M S961) while that for DNL is -8.07 (i.e.,
10-8.07 M, or 8.5 x 10-9 M S961). Thus, an InsR antagonist concentration of nearly four times greater than 
that needed to half-maximally suppress insulin’s effect on GP is required to half-maximally suppress 
insulin’s effect on DNL. This outcome strongly supports our hypothesis that modulation of effective InsR 
number per se can produce selective IR. 
3.2.3. Inhibition of Akt1/2 Results in Pure IR 
Previous studies have suggested that Akt represents the most distal element of the InsR signaling 
cascade that unites insulin’s effects on glucose and lipid metabolism. We therefore tested the effect of 
inhibition of Akt on GP and DNL in primary hepatocytes. Akti-1/2 is a chemical inhibitor of Akt that 
prevents its phosphorylation. Accordingly, Akti-1/2 treatment completely blocked phosphorylation of Akt in 
response to insulin, and thereby also markedly decreased phosphorylation of FoxO1, GSK3β, and mTOR 
without affecting upstream IRS2 (Fig. 3.8A). Of note, treatment with the inhibitor was without notable 
effect on SREBP-1c cleavage. Akti-1/2 treatment also blocked the ability of insulin to decrease GP in 
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response to cAMP (Fig. 3.8B). Similar to the effect of CHI treatment, Akt inhibition decreased the maximal 
cAMP-induced expression of G6pc and Pck1 (Fig. 3.8C-D). Although Akti-1/2 prevented the lowering of 
G6pc expression to normal by insulin, it did allow for an approximately 50% repression, while Akti-1/2 did 
not prevent the lowering of Pck1 expression to basal levels by insulin (Fig. 3.8C-D). Finally, Akti-1/2 
treatment completely abrogated insulin’s induction of DNL (Fig. 3.8E). These data support the idea that 
Akt signaling unites insulin’s effects on GP and DNL in the context of primary hepatocytes, and thus 
interfering with its action recapitulates a form of pure IR [90]. 
 
3.3. Discussion 
3.3.1. Overview of Findings 
Classical biochemistry teaches that insulin acts in the liver to shift its anabolic activity away from glucose 
production and toward glycogen synthesis and lipogenesis. Accordingly, patients with inactivating 
mutations in Insr cannot suppress glucose production or stimulate lipogenesis in response to insulin. A 
persistent conundrum facing clinical endocrinology, however, has been the selective IR exhibited by so 
many garden-variety type 2 diabetic patients. This study supports the idea that pure and selective IR lie 
along a single spectrum in which decreasing InsR activation differentially alters glucose and lipid 
metabolism because of inherent differences in the relative insulin responsiveness of each process. 
Specifically, as we have shown using a peptide competitive inhibitor of InsR, a greater degree of intact 
InsR is required to properly halt HGP than to stimulate DNL. Thus, at intermediate levels of InsR 
activation, DNL can proceed while HGP fails to respond. At very low levels of intact InsR, neither process 
can go forward.  
This loss of InsR may stem from downregulation due to the chronic hyperinsulinemia that is 
common to those in the run-up to T2DM. Indeed, modeling of CHI in primary hepatocytes shows that 
these cells can be rendered selectively resistant to insulin’s lowering of GP while remaining able to 
engage in insulin-stimulated DNL. In other words, the co-occurrence of CHI and selective IR in garden-
variety pre-diabetic patients may not merely represent an epiphenomenon; rather, the two may be 
etiologically linked.  
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3.3.2. Qualitative and Quantitative Impact of CHI on InsR  
 As discussed extensively in Chapter 1, CHI has been shown to induce IR. That CHI may precede 
the development of hepatic IR is supported by the general consensus that IR in skeletal muscle and WAT, 
the combination of which would induce compensatory CHI, precedes hepatic IR by many years in the 
natural history of T2DM [67-71, 329]. This is manifested clinically in the observation that post-prandial 
hyperglycemia, which in part reflects failure of glucose disposal in muscle, precedes fasting 
hyperglycemia, a reflection of HGP [69, 71, 329]. Much evidence supports the idea that CHI-induced IR is 
due to downregulation of InsR in the hepatocyte, thereby producing a quantitative defect in insulin 
signaling. Indeed, a similar study in rat hepatocytes demonstrated CHI treatment resulting in a ~50% 
reduction in InsR number affected only the maximal rates of insulin-stimulated lipogenesis and glycogen 
synthesis and not their inherent sensitivities to insulin (i.e., ED50) [285]. The studies described here are 
concordant with this paradigm, as ex vivo modeling of CHI in primary mouse hepatocytes also results in a 
~50% reduction in InsR protein levels. Of note, specific binding of insulin to membrane preparations of 
liver from obese humans was also decreased by about 50% relative to non-obese controls, further 
supportive of the physiologic relevance of this model [289].  
It is important to note that this thesis has only shown a decrease in total hepatocellular InsR 
levels, however, which does not necessarily reflect the relative contributions of intracellular vs. cell-
surface receptors. Indeed, cell-surface InsR may even represent a minority of total cellular InsR levels 
[288, 323, 326, 330] but even this pool of InsR has been shown to be reduced in diabetic and non-
diabetic obese livers [288]. Moreover, insulin binding in the short term can reversibly alter subcellular 
localization of InsR [330-333] even if not total InsR number [291], adding another layer of complexity to 
the problem and perhaps accounting for some of the observed variability in the degree of InsR 
downregulation between different studies. Yet another intriguing, albeit controversial possibility behind 
InsR downregulation is the activation of a cell-surface protease following CHI exposure that cleaves the 
extracellular α domain of InsR, thereby abolishing the ability of the residual receptor to bind to insulin 
[334]. Corroborating the potential clinical relevance of this mechanism is the observation that diabetic 
patients exhibit elevated levels of soluble InsR in their circulation [335]. 
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The fact that insulin can and does alter both cellular InsR content and localization may help to 
explain why pulsatile rather than continuous delivery of insulin to the liver leads to a more robust acute 
insulin response and prevents desensitization [277, 336-339], even in primary hepatocytes [333]. 
Prolonged infusion even of supraphysiologic doses of insulin in humans does not result in loss of insulin 
responsiveness if supplied in a pulsatile fashion; in fact, this may even enhance insulin sensitivity [340].  
These observations dovetail with the empirical finding that pancreatic β cells of patients with type 2 
diabetes as well as obese non-diabetic patients exhibit a more continuous, or at least less regularly 
pulsatile, release of insulin, underscoring the “chronic” aspect of CHI [341-345], although some conflicting 
evidence exists [346]. Moreover, first-degree relatives of T2DM patients have been found to show 
impaired pulsatility in insulin secretion, further suggesting a primary role of altered insulin secretion in the 
pathogenesis of selective IR [347]. That incretin-modulating drugs augment insulin secretion in a pulsatile 
fashion [348, 349], as opposed to the continuous effect of sulfonylureas [350], may help to explain their 
ability to improve insulin sensitivity as opposed merely to insulin secretion [4]. Taken together these 
findings suggest that, although patients developing IR are hyperinsulinemic, insulin levels per se do not 
need to be all that high to induce IR. In other words, a loss of normally pulsatile insulin delivery 
experienced by these patients, even if not resulting in frank hyperinsulinemia, would still be tantamount to 
CHI in terms of inducing InsR desensitization.     
Previous studies also suggest that CHI induces post-binding defects that contribute to the overall 
cellular IR, a possibility that is not mutually exclusive with a coincident wholesale downregulation of InsR. 
For example, in primary hepatocytes isolated from diabetic patients, not only were insulin binding per 
surface area and total InsR protein levels decreased but so was insulin-stimulated InsR kinase activity 
even when normalized for amount of insulin bound [288]. In other words, the defect in InsR function is 
disproportionate to the extent of InsR downregulation [351-355]. This is also reflected in the findings of 
this study, as CHI-treated cells show a complete loss of Akt phosphorylation in response to acute insulin 
despite the reduction of InsR by only about 50% (Fig. 3.1). Similarly, acute insulin treatment completely 
curtails the hormone’s ability to suppress G6pc and Pck1 expression (Fig. 3.2B-C). Also consistent with a 
qualitative effect of CHI on InsR function, treatment with increasing doses of S961, which does not alter 
 65 
total InsR levels at least in the acute setting (Fig. 3.4A), resulted in roughly proportional changes in InsRβ 
and Akt phosphorylation (Fig. 3.4A, Fig. 3.5).  
It is also important to consider potential confounding effects of the high doses of insulin used in 
this study. First, CHI treatment may risk “specificity spillover” through activation of the IGF-1 receptor 
(Igf1R) by insulin. This possibility may not be as problematic in our system as in other cell types, however, 
as adult liver and isolated primary hepatocytes have been found to express little or no Igf1R [356, 357], 
although it may be induced in regenerating liver [358]. Second, hepatocytes may contain spare receptors 
for insulin. One study in isolated rat hepatocytes found that only 35% of maximal insulin binding was 
required for full stimulation of glycogen synthesis [359], although other studies in primary hepatocytes 
[285] and whole liver [64] did not find evidence of spare receptors. The presence of spare InsR would be 
problematic for our study in two ways. First, it suggests a priori that the ~50% reduction we observe in 
total InsRβ protein levels is not sufficient to explain the defects in Akt phosphorylation and inhibition of 
GP. Potential explanations for this apparent discrepancy include (i) that some portion of the InsRβ 
detected in Fig. 3.1A has been internalized and/or (ii) that post-binding defects in InsR (e.g., reduced 
kinase activity) may account for a greater share of the loss of insulin action than reduced receptor binding 
per se. Direct assessment of insulin binding to InsR in our model of CHI would address these possibilities. 
A second potential drawback of the presence of spare receptors is that it might mask subtle defects in 
acute insulin action, especially as we have chosen to use somewhat supraphysiologic 10 nM insulin as 
our standard dose for acute treatment. For example, although on average we found that insulin lost the 
ability to significantly blunt GP following CHI treatment, the data from the three individual experiments 
demonstrated some heterogeneity; some wells responded better to acute insulin inhibition of GP than 
others. This is reflected in the residual ~12% average decrease in GP in response to insulin even in CHI-
treated cells. The single-well data in insulin-inhibited GP between control and CHI may have been tighter 
had we used a lower dose of insulin. In the experiment illustrated in Fig. 3.8B, 1 nM insulin was able to 
reduce cAMP-induced GP by about 20%. 
 Finally, CHI treatment, although resulting in IR in the longer term, activates insulin signaling over 
the first several hours of treatment. Thus, it is possible that the acute effects of CHI treatment may reset 
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the baseline for later measures of insulin action. For example, we found that CHI treatment blunted 
maximal cAMP-induced expression of G6pc and Pck1. Similarly, as discussed in Section 3.3.4, we found 
basal IRS1 and IRS2 levels to be decreased following CHI. IRS1 and IRS2 are known to be positively 
regulated by FoxO proteins, suggesting that their decrease may reflect inactivation of FoxO by insulin 
[145, 360]. These concerns would endorse waiting longer than 24 h for any residual acute effects of 
insulin to dissipate. However, mouse primary hepatocytes rapidly begin to lose their hepatocyte character 
following culture ex vivo. We found, for example, that maximal cAMP-induced GP was reduced by over 
half 48 h after isolation vs. the usual 24 h (data not shown). We therefore have attempted to strike a 
balance between preserving the integrity of the isolated hepatocytes and ensuring sufficient time to 
engender IR. Nevertheless, although we cannot prove that residual acute effects of insulin account for the 
peculiar observations listed above, we have reason to believe that this is not the case. Despite decreases 
in cAMP-induced G6pc and Pck1 expression, basal (untreated) expression of these genes is not 
decreased on average in CHI-treated cells, and in some experiments was even increased (Fig. 3.2B-C). 
More importantly, both basal and maximal cAMP-induced GP are identical in control and CHI-treated 
cells (Fig. 3.2A). Finally, despite the decrease in IRS1/2 protein levels, Irs2 mRNA was unchanged in the 
basal or stimulated states (data not shown). It is therefore likely that these observations genuinely reflect 
the CHI-induced IR state. 
3.3.3. Mechanism of Insulin-Stimulated DNL in Primary Hepatocytes 
Although the topic of cell autonomous vs. non-autonomous effects in DNL (as well as GP) will be 
discussed more extensively in Chapters 4-5, it merits an introduction here. A key finding of these studies 
is the preservation of DNL in the face of CHI-induced IR, consistent with our expectations based on 
garden-variety clinical IR. However, our system on its face does not completely support the model that 
compensatory hyperinsulinemia in insulin resistance drives DNL through a preservation of insulin 
signaling through the Akt à mTORC1 à SREBP-1c branch of the pathway [213, 215, 217, 218, 276]. In 
our studies, SREBP-1c expression and cleavage do not generally correlate well with observed rates of 
DNL, probably because SREBP-1c cleavage is reported not to be particularly sensitive to insulin in 
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isolated mouse hepatocytes (see Chapter 5). Indeed, we found quite a variable responsiveness of 
SREBP-1c cleavage in response to acute insulin treatment (cf. Fig. 3.1 vs. Fig. 3.4A and Fig. 3.8A).  
It is important to bear in mind in the discussion of selective IR that even though we refer to the 
lipid arm as remaining “sensitive” to insulin, it may well not be as sensitive as in a healthy liver. 
Lipogenesis is relatively more sensitive to insulin than is GP, and in selective IR operates under the aegis 
of hyperinsulinemia. Even though we found that SREBP-1c cleavage is not especially sensitive to insulin 
in our system, we did consistently find an increase in both SREBP-1c mRNA and precursor protein levels 
following CHI treatment (Fig. 3.1, 3.3C). This finding has been previously reported in rat primary-
hepatocyte models of CHI [209, 295]. Thus, the steady-state level of cleaved SREBP-1c is likely higher 
than in control cells, especially as basal SREBP-1c cleavage appeared higher following CHI treatment. 
This is consistent with our finding of higher mRNA and protein levels of key SREBP-1c lipogenic target 
gene Fasn (Fig. 3.1, 3.3C). So, even if the acute insulin responsiveness of SREBP-1c cleavage and 
activity is decreased, it is still expected to remain high overall relative to insulin-stimulated FoxO1 
phosphorylation and effects on GP. On the other hand, acute inhibition of insulin signaling, either directly 
by S961 treatment or indirectly by Akt inhibition, may uncouple DNL from SREBP-1c expression, as these 
treatments hindered DNL without systematically affecting SREBP-1c cleavage. We suspect that, due to 
the far shorter time course of these experiments versus the CHI model, changes in basal SREBP-1c 
expression would not be expected to play a dominant role in DNL. However, we cannot make this 
statement conclusively as we did not measure insulin-stimulated mRNA expression of SREBP-1c and its 
targets in S961- or Akti-1/2-treated cells.  
Taken together with the CHI data (and data from Chapter 4, to be discussed at greater length in 
Chapters 4-5), we speculate that, although both “chronic” (i.e., CHI) and “acute” (i.e., S961, Akti-1/2) 
inhibition of InsR signaling betray selective IR, the mechanisms underlying the relative preservation of 
insulin signaling to DNL may be distinct. We therefore have formulated a hypothesis regarding our DNL 
results in CHI-treated vs. control cells that separates out effects on basal (i.e., chronic insulin-stimulated) 
vs. acute insulin-stimulated DNL. In the case of acute insulin treatment (and the effects of S961 or Akti-
1/2 on it), we see no differences in expression of classic lipogenic genes (Fig. 3.3B-D), consistent with 
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previous observations in primary mouse hepatocytes. Thus, the increase in DNL likely occurs via 
posttranslational mechanisms (see Chapters 1 and 5). If this hypothesis is true, then even these 
posttranslational mechanisms of insulin-stimulated DNL are relatively more sensitive to insulin than those 
inhibiting GP (also likely to be largely posttranslational, as discussed in Chapter 5).  
On the other hand, as stated above, long-term treatment with high-dose insulin increases mRNA 
and protein levels of SREBP-1c, Fasn, and Gck, and decreases mRNA levels of G6pc. This essentially 
represents the Brown and Goldstein model of CHI-driven increased DNL [276]. The increased expression 
of lipogenic genes in the basal state may account for the increased basal DNL of CHI-treated cells. That 
the levels of these genes still trend higher than control in the acute insulin-stimulated state therefore may 
also explain the persistent trend of higher rates of DNL even with insulin treatment. This possibility is 
concordant with our finding that the increase in DNL in response to acute insulin is only slightly decreased 
in CHI-treated cells (38%) to that in control cells (53%). This suggests that the posttranslational effect of 
acute insulin treatment is nearly normal in CHI-treated cells.  
In summary, we propose a model whereby CHI (e.g., in the post-absorptive state) increases 
basal expression of lipogenic genes and proportionally increases rates of DNL. Moreover, CHI does not 
impair acute insulin-stimulated DNL (e.g., in the postprandial state) relative to GP even on top of the 
increase in basal DNL. This model is oversimplified, as it does not account for other mediators of DNL in 
response to fasting and feeding in whole liver. For instance, cultured hepatocytes are exposed to a 
constant ambient level of glucose that is uncoupled from insulin levels. In vivo, however, an influx of 
insulin would normally be preceded by an increase in glucose levels, which in turn could drive lipogenic 
gene expression through ChREBP independently of SREBP-1c [63, 202]. In the case of selective IR, 
therefore, decreased control of HGP would be expected to increase ChREBP-driven lipogenesis. 
Carbohydrates can also directly drive lipogenesis via allosteric activation of glycolytic enzymes including 
glucokinase [180, 361, 362]. In our system, increased Gck expression in CHI would be expected to further 
accentuate ChREBP signaling as well [232]. Thus, even though there may be a slight decrement in the 
ability to increase DNL in response to acute insulin post-CHI treatment, this may not manifest in vivo due 
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to increased carbohydrate-driven lipogenesis [202, 325]. Indeed, even in LIRKO mice, re-fed expression 
levels of several lipogenic genes are normal or nearly so due to ChREBP and other factors [202]. 
In spite of these caveats, however, our finding that CHI-induced IR spares DNL even in isolated 
hepatocytes represents an important conceptual step forward in our understanding of the connection 
between IR and hepatic steatosis. That is, our findings suggest that processes autonomous to the 
hepatocyte can contribute to steatosis independently of alterations in WAT-liberated FFA, namely both 
transcriptional and posttranslational changes in insulin-stimulated DNL [48]. Although previous studies 
investigating expression of lipogenic genes in primary hepatocytes suggested this possibility, these 
studies did not generally measure DNL directly [209, 213, 218, 295]. On the other hand, older studies that 
also provide evidence that DNL continues unabated in the face of CHI did not correlate these data with 
lipogenic gene expression or compare them to GP [285, 288, 325]. 
Overall, the idea that the development of steatosis requires some participation of hepatic insulin 
signaling is consistent with data indicating that humans with pure IR due to Insr mutations do not develop 
fatty liver even though their fasting FFA levels may be somewhat elevated [65]. Nevertheless, although 
the fractional contribution of DNL to hepatic TG is increased in IR states, the contribution of re-esterified 
WAT released by lipolysis is still significant, especially in the fasting state [48, 363]. For instance, mice 
lacking hormone-sensitive lipase (HSL), which are unable to liberate FFA from WAT, show increased 
hepatic insulin sensitivity and reduced hepatic TG [364, 365]. Thus, the combination of selective IR in 
WAT and liver may together drive the development of NAFLD [48]. The potential mechanisms of selective 
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Figure 3.1. Modeling Chronic Hyperinsulinemia in Primary Hepatocytes 
Western blots demonstrating alterations in InsR signaling cascade components in response to acute 
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Figure 3.2. Effect of CHI Treatment on Glucose Production 
Relative glucose production (A) and gene expression (C-D) in control or CHI-treated primary hepatocytes 
incubated for 5 h with vehicle, 100 µM CPT-cAMP, or 100 µM CPT-cAMP + 10 nM insulin. Data are 
normalized to vehicle-treated control. In (A) data are mean ± SEM of three independent experiments 
performed in quadruplicate; in (B) data are mean ± SEM of one representative experiment of three 
performed in triplicate. 

























































































Figure 3.3. Effect of CHI Treatment on De Novo Lipogenesis 
(A) De novo lipogenesis in control or CHI-treated primary hepatocytes. Following overnight serum 
starvation cells were treated with vehicle or 10-nM insulin for 2 hr and then 14C-labeled acetic acid was 
added for an additional 3 hr. Data are presented as mean ± SEM normalized to vehicle-treated control of 
five independent experiments performed in triplicate. 
(B-D) Gene expression in control or CHI-treated primary hepatocytes incubated for 5 h with vehicle or 10 
nM insulin. Data are presented as mean ± SEM normalized to vehicle-treated control and are 
representative of three independent experiments performed in triplicate.  
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Figure 3.4. Dose-Response Study of InsR Antagonism 
(A) Western blots demonstrating alterations in InsR signaling cascade components in response to 
treatment with 10 nM insulin and/or the indicated concentration of S961. Each lane represents pooled 
samples of equivalent amounts of lysate from three independent experiments.  
(B-D) Relative glucose production (B) and gene expression (C) in primary hepatocytes incubated for 5 h 
with 100 µM CPT-cAMP with or without 10 nM insulin and the indicated concentrations of S961.  
(E) De novo lipogenesis in control or S961-treated primary hepatocytes. Following overnight serum 
starvation cells were treated with or without S961 and with or without insulin for 2 hr and then 14C-labeled 
acetic acid was added for an additional 3 hr.  
Data are normalized to insulin-/S961-untreated control and represent mean ± SEM of three independent 
experiments performed in triplicate. * p < 0.05 vs. vehicle-treated control by Bonferroni’s post-hoc analysis 
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Figure 3.5. Relative Insulin Responsiveness of Akt and GSK3β  Phosphorylation 
(A) % maximal insulin response of phosphorylation of Akt T308, Akt S473, and GSK3β S9 as a function of 
S961 concentration. Figures are calculated from densitometric analysis of the Western blots shown in Fig. 
3.4A as the percentage of the departure from baseline at the indicated S961 concentration relative to the 
maximal change with insulin in the absence of antagonist.  
(B) Graphical representation of calculations in (A) for Akt and GSK3β phosphorylation IC50 is calculated 
as log10 of the S961 concentration at which each dose-response curve intercepts 50% maximal insulin 
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Figure 3.6. Relative Insulin Responsiveness of GP and DNL 
(A) % maximal insulin response of Akt T308 phosphorylation, glucose production, and de novo 
lipogenesis as a function of S961 concentration. Figures are calculated from the data in Fig. 3.2 as the 
percentage of the departure from baseline at the indicated S961 concentration relative to the maximal 
change with insulin in the absence of antagonist.  
(B) Graphical representation of calculations in (A) for glucose production and de novo lipogenesis. IC50 is 
calculated as log10 of the S961 concentration at which each dose-response curve intercepts 50% maximal 
insulin response. Data are derived from Fig. 3.2 and represent mean ± SEM of three independent 
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Figure 3.7. Relative Insulin Responsiveness of GP and gene expression 
(A) % maximal insulin response of glucose production and expression of G6pc and Pck1 as a function of 
S961 concentration. Figures are calculated from the data in Fig. 3.2 as the percentage of the departure 
from baseline at the indicated S961 concentration relative to the maximal change with insulin in the 
absence of antagonist.  
(B) Graphical representation of calculations in (A) for glucose production and gene expression. IC50 is 
calculated as log10 of the S961 concentration at which each dose-response curve intercepts 50% maximal 
insulin response. Data are derived from Fig. 3.2 and represent mean ± SEM of three independent 
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Figure 3.8. Effect of Akt Inhibition on Glucose Production and Lipogenesis 
(A) Western blots demonstrating alterations in InsR signaling cascade components in response to 
treatment with 0, 1, 10, or 100 nM insulin with or without pre-treatment with 5 µM Akti-1/2. Blots are 
representative of three independent experiments. Data are representative of mean ± SEM of three 
independent experiments. 
(B-D) Relative glucose production (B) and gene expression (C-D) in primary hepatocytes pre-treated with 
Akti-1/2 or vehicle and incubated for 5 h with 100 µM CPT-cAMP with or without 1 nM insulin. Data are 
representative of of mean ± SEM three independent experiments performed in triplicate. 
(E) Relative de novo lipogenesis in primary hepatocytes pre-treated with Akti-1/2 or vehicle and incubated 
for 5 h with or without 1 nM insulin. Data are mean ± SEM of one representative experiment of two 
performed in triplicate. 
* p < 0.05 by Bonferroni’s post-hoc analysis following two-way ANOVA. $ p < 0.05 relative to control by































As discussed in Chapter 1, several mechanisms have been proposed to explain FoxO1’s effects on 
hepatic glucose and lipid metabolism. While these models, even if all true, are not mutually exclusive, 
some may trump others in controlling a specific metabolic process; their relative control strengths have 
never been simultaneously tested. If we are to push forward in developing therapeutics aimed at FoxO1, 
which by itself represents a relatively poor drug target in liver, it will be of paramount importance to 
understand which of its many target genes would be most suited to pharmacologic manipulation. We 
therefore took an unbiased approach to parsing out which of FoxO1’s multiple actions are most directly 
responsible for its observed phenotypic outputs. 
An under-appreciated aspect of FoxO1 biology that we believe an ideal inroad into our question is 
its ability to act both dependently and independently of direct binding to its DNA consensus sequence, the 
insulin-response element (IRE). In other words, FoxO1 can act both as a transcription factor (“TF mode”) 
and as a transcriptional co-regulator (“CR mode”). Crystallographic analysis of FoxO1 bound to an IRE 
has identified two residues within its forkhead domain – Asn 208 and His 212 – as essential for sequence-
specific DNA binding [366]. Alteration of these residues to Ala and Arg, respectively, produces a mutant 
that retains proper nucleocytoplasmic partitioning in response to insulin but is incapable of binding to the 
IRE [147, 367]. Importantly, this mutant FoxO1 is not merely a hypomorphic variant of wild-type FoxO1; 
microarray analysis of a carcinomatous cell line has revealed a distinct subclass of genes that are 
induced to a greater extent by overexpressed FoxO1-HRAA than by wild-type FoxO1 [368].  
Thus, a logical step toward better understanding of FoxO1 action is to take a genetic approach in 
parsing out the metabolic effects of hepatic FoxO1 that proceed via its action as a transcription factor 
versus those in which FoxO1 plays a co-regulatory role. We have accomplished this goal by generating 
the L-DBD mouse, whose liver expresses only DNA binding-deficient FoxO1, and comparing it to control 
and L-FoxO1 mice completely lacking FoxO1 in the liver. By complementing metabolic phenotyping 
studies with transcriptomic analysis by RNA-seq, we can effectively home in on a uniquely delimited pool 
of candidate genes whose differences in expression among the three groups best correlate with observed 
phenotypic differences. 
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The pattern of differential findings between genotypes – whether in terms of metabolism or gene 
expression – implies the mechanistic basis of FoxO1’s regulation of those processes. For example, a 
process significantly altered in L-FoxO1 mice but not in L-DBD mice must require FoxO1 to act in CR 
mode. We therefore could suppose that the process is most dominantly controlled by gene(s) whose 
expression would be regulated by FoxO1 independent of DNA binding. In this way our strategy builds 
upon previous studies that have compared control mice only to those completely lacking FoxO1 in the 
liver; such an approach can only yield information as to whether FoxO1 plays a net activating or inhibiting 
role in a given process. Using these insights, we can evaluate the relative importance of previously 
proposed means of FoxO1 action as well as potentially uncovering novel mechanisms to boot. 
 
4.2. Results 
4.2.1. Generation and Analysis of L-DBD Mice 
We have developed a mutant allele of Foxo1 (Foxo1dbd) containing the N208A and H215R mutations 
described above in addition to the naturally occurring variant K219R (Fig. 4.1A). We confirmed that 
FoxO1-DBD, unlike wild-type FoxO1, is incapable of driving luciferase activity from a reporter-gene 
construct containing canonical FoxO1 consensus binding sites (Fig. 4.1B). We have then employed 
recombinase-mediated cassette exchange (RMCE) to insert a cDNA cassette encoding Foxo1dbd  into the 
Foxo1 locus by homologous recombination. These transgenic mice therefore are of the genotype 
Foxo1wt/dbd. Homozygosity for alleles encoding FoxO1-DBD results in embryonic lethality. Although we did 
not determine the cause, we presume that it results from arteriovenous malformations, as in the case of 
global Foxo1 knockout [369].  
To dissect the role of the transcriptional vs. co-regulatory functions of FoxO1 in liver, we 
introduced the Foxo1dbd allele in mice bearing a floxed allele of Foxo1 (Foxo1fl). This breeding strategy 
(Fig. 4.1C) generates mice in which each cell contains one copy of Foxo1fl and one copy of Foxo1dbd 
(Foxo1fl/dbd) henceforth termed DBD-het, as well as Foxo1fl/fl mice as controls. By breeding controls and 
DBD-hets with mice bearing a Cre recombinase transgene driven by the liver-specific α1-antitrypsin (AT) 
promoter we can generate two additional genotypes for study, as illustrated in Fig. 4.1C. First, the AT-
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Cre+ Foxo1fl/fl (L-FoxO1) mouse lacks all FoxO1 specifically in liver. Second, the AT-Cre+ Foxo1fl/dbd 
(henceforth, L-DBD) mouse lacks all floxed (i.e., wild type) FoxO1 in liver, thus leaving only DNA binding-
deficient FoxO1-DBD. In all non-hepatocyte cells the mice have one allele of Foxo1fl and one allele of 
Foxo1dbd, as do DBD-het mice. 
Quantitative RT-PCR with allele-specific primers demonstrated the generation of the desired 
genotypes (Fig. 4.1D). Western blot analysis verified the absence of FoxO1 protein in liver extracts from 
L-FoxO1, but of the retention of about half of the normal complement of FoxO1 in L-DBD mice (Fig. 4.1E), 
indicating that L-DBD mice express purely DNA binding-deficient FoxO1 in liver.  
 
4.2.2. Metabolic Features of Heterozygous Foxo1dbd Mice and Hepatocytes 
To rule out extra-hepatic metabolic effects of Foxo1dbd heterozygosity per se, we compared adult male 
controls (Foxo1fl/fl) and DBD-hets (Foxo1fl/dbd) with mice heterozygous for a null allele of Foxo1 (FoxO1fl/–; 
henceforth, FoxO1-het) (Fig. 4.1C-D, 2E). We found no differences in fasting or re-fed glucose or insulin 
levels, glucose, pyruvate, or insulin tolerance tests, body weight and composition (Fig. 4.2A-D, Table 4.1), 
or in the expression of known hepatic FoxO1 target genes following an overnight fast (Fig. 4.2E). These 
data are consistent with prior findings in FoxO1-het [142, 370]. Primary hepatocytes from control, FoxO1-
het, and DBD-het mice showed no impairment of basal or cAMP/dexamethasone-stimulated glucose 
production (Fig. 4.3A-B) in spite of decreased G6pc expression in mice of both heterozygous genotypes 
(Fig. 4.3C), although Igfbp1 and Ppargc1a expression were normal (Fig. 4.3D-E). Thus, we conclude that 
Foxo1dbd heterozygosity per se does not result in a metabolic phenotype that might confound the 
interpretation of data from the L-DBD mouse.  
 
4.2.3. Metabolic Characterization of L-DBD Mice 
We analyzed the metabolic features of adult L-DBD male mice. They gained weight at the same 
rate as L-FoxO1 and control mice (Fig. 4.4A and data not shown), and showed no differences in body 
composition (Fig. 4.4B). Indirect calorimetry revealed no significant differences in food intake, energy 
expenditure, oxygen consumption, or respiratory quotient (RQ) (Fig. 4.4C-G), further suggesting that 
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Foxo1dbd heterozygosity alone does not perturb whole-body metabolism. Likewise, there were no 
differences between L-DBD and control mice in glucose or insulin levels following an overnight fast or a 4-
hr re-feed, whereas L-FoxO1 mice showed a modest decrease in re-fed insulin levels compared to 
controls (Fig. 4.5A-B).  
L-DBD mice exhibited an enhancement of glucose tolerance (GTT) identical to L-FoxO1 mice 
(Fig. 4.5C) [144, 145], suggesting that Foxo1dbd is effectively a null mutant with respect to glucose 
tolerance. These results were borne out by pyruvate tolerance tests (PTT), showing superimposable 
curves in L-FoxO1 and L-DBD mice (Fig. 4.5D) [145]. Intraperitoneal insulin tolerance tests (ITT) on 
fasted animals failed to reveal differences between control and L-FoxO1, in accordance with previous 
data [145], but showed a modest enhancement in L-DBD mice (Fig. 4.5E). Quantitative analyses of the 
areas under the curve (AUC) from experiments on multiple cohorts confirmed these conclusions (Fig. 
4.5F). Moreover, qPCR analysis of RNA extracted from livers of overnight-fasted mice showed decreased 
G6pc and Igfbp1 (Fig. 4.5G). As we have previously reported [145], Pck1 expression was not significantly 
decreased in the absence of FoxO1 (Fig. 4.5G). These results indicate that deletion of hepatocellular 
FoxO1 results in decreased HGP.
FoxO1 regulates insulin sensitivity in part through a homeostatic loop with Akt. That is, we have 
found that a constitutively nuclear mutant form of FoxO1 is capable of increasing basal Akt 
phosphorylation, partially through upregulation of Irs2 expression (see Section 5.3.1)  [247, 371]. 
However, we detected no genotypic differences in the activation of Akt and its substrates, FoxO1 and 
GSK3β, in liver (Fig. 4.6A), skeletal muscle (Fig. 4.6B), or white adipose tissue (Fig. 4.6C) following 
intravenous administration of insulin in 5-hr-fasted mice. We saw a subtle decrease of Akt and GSK3β 
phosphorylation in L-FoxO1 mice in the more physiologic context of re-feeding (Fig. 4.7A-C). However, 
the effect may be attributable to lower insulin levels in re-fed L-FoxO1 mice since the difference 
disappeared when we compared mice matched for insulin levels (Fig. 4.7D-F). As a prototypical FoxO1 
target gene involved in the regulation of insulin sensitivity, we measured levels of Irs2 [371], and saw a 
significant reduction in livers from fasted L-FoxO1 and L-DBD animals (Fig. 4.7G). Taken together, these 
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data indicate that insulin signaling is similarly preserved in L-FoxO1 and L-DBD mice, and that Irs2 
expression requires FoxO1 to act in transcription factor mode. 
4.2.4. Impaired Glucose Production in Hepatocytes from L-DBD Mice 
Next, we isolated primary hepatocytes from control, L-FoxO1, or L-DBD mice and assessed their ability to 
generate glucose from pyruvate and lactate either basally or in the presence of CPT-cAMP and 
dexamethasone (cAMP/dex). Glucose production nearly doubled in control hepatocytes in a time-
dependent manner following the addition of cAMP/dex (Fig. 4.8A-B). In contrast, primary hepatocytes 
from L-DBD mice showed a nearly 30% decrease in basal and cAMP/dex-stimulated glucose production, 
similar to L-FoxO1 hepatocytes (Fig. 4.8A-B). Consistent with these findings, L-FoxO1 and L-DBD 
primary hepatocytes showed a >80% decrease in the effect of cAMP/dex on G6pc and a ~40% decrease 
of Pck1, as a result of which the suppressive effect of insulin on both genes was virtually abolished (Fig. 
4.8C-D). In contrast, neither L-FoxO1 nor L-DBD hepatocytes showed substantial effects on the 
expression of Ppargc1a, another gene implicated in FoxO1’s control of HGP (Fig. 4.8E) [372]. This finding 
is consistent with data indicating that FoxO1 is required for the effect of Ppargc1a on glucose production 
[145]. Nevertheless, there was a small but significant decrease in the expression of Ppargc1a in L-FoxO1 
hepatocytes versus L-DBD (Fig. 4.8E), mirroring a similar though non-significant trend in fasted liver (Fig. 
4.5G), suggesting that Ppargc1a is a co-regulatory target of FoxO1. 
4.2.5. Hepatic Triglyceride Metabolism in L-DBD Mice 
We then examined features of hepatic lipid metabolism in L-DBD mice. We found no differences in 
circulating levels of FFA, TG, or cholesterol among mice of different genotypes (Table 4.2) [145, 168]. 
Liver weight was modestly increased in re-fed, but not in overnight-fasted L-FoxO1 mice (Fig. 4.9A). This 
difference was due at least in part to increased TG content (Figure 4.9B) but surprisingly was not 
observed in L-DBD mice. There was no difference in liver cholesterol content among genotypes in the 
fasted or re-fed states (Table 4.2). 
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We analyzed different aspects of hepatic lipid handling in order to parse out the mechanism 
underlying differential liver triglyceride content. Oral lipid tolerance tests and hepatic TG secretion were 
normal (Fig. 4.9C-E). In contrast, β-oxidation of radiolabeled oleic acid decreased by ~40% in L-FoxO1 
hepatocytes, and by ~60% L-DBD hepatocytes (Fig. 4.9F). Analysis of de novo lipogenesis (DNL) using 
radiolabeled acetic acid demonstrated a non-significant ~35% increase in 14C incorporation into the TG 
pool of primary hepatocytes from L-FoxO1 mice under basal as well as insulin-stimulated conditions. 
Hepatocytes of L-DBD mice showed an even greater increase of ~75% (Fig. 4.9G). The inability of L-DBD 
hepatocytes to restore lipid oxidation and lipogenesis to their control levels indicates that these cell-
autonomous effects require FoxO1 to bind directly to DNA. 
To determine the mechanism of the alteration in DNL, we measured expression of several 
lipogenic genes (Fig. 4.10A-F). There were significant elevations in fasting levels of glucokinase (Gck) 
and stearoyl-CoA desaturase-1 (Scd1) in L-FoxO1, but not L-DBD mice compared to controls. On the 
other hand, fasting levels of pyruvate kinase (Pklr), a target of the lipogenic transcription factor Chrebp 
[373], were significantly lower, while those of acetyl-CoA carboxylase-1 (Acaca) were unchanged in L-
FoxO1 and L-DBD livers compared to controls. We also measured the expression of four key bile-acid 
metabolic genes (Fig. 4.10G-J), as we have previously attributed some of FoxO1’s ability to regulate 
hepatic TG to alterations in bile-acid pool composition [168]. This study replicates the decreased 
expression of Cyp8b1 and Cyp27a1 but not of Cyp7a1 in L-FoxO1 mice. That the expression pattern of 
these genes in L-DBD mice parallels that of L-FoxO1 mice indicates that this particular role of FoxO1 
requires its action as transcription factor.  
As our laboratory’s work has implicated Gck as a link between FoxO1 and DNL, we also 
measured its expression in primary hepatocytes in parallel with our DNL assay. Unlike in whole liver, we 
did not detect any significant differences in Gck expression between genotypes or in response to insulin 
(Fig. 4.11A), although expression did trend higher in L-DBD hepatocytes. For the sake of comparison, 
Gck expression was significantly increased by up to 78 times control levels in primary hepatocytes from L-
FoxO1,3,4 mice (Fig. 4.11B). In keeping with higher Gck expression, total de novo lipogenesis was 
increased 2.5-fold in vehicle-treated L-FoxO1,3,4 primary hepatocytes compared to control but unlike 
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control did not further increase with insulin treatment (Fig. 4.11C).  Although this is a measure of total 
DNL rather than specifically of TG synthesis, we have found the two to be interchangeable in this system.  
We also sought to determine whether the significant increase of DNL in insulin-treated L-DBD 
hepatocytes was due to enhanced insulin signaling. However, phosphorylation of Akt (T308) and Gsk3β 
(S9) in response to insulin was rather decreased in primary hepatocytes from L-FoxO1 and L-DBD mice 
(Fig. 4.11D). These experiments indicate that loss of FoxO1 function increases lipogenesis and 
decreases FFA oxidation, and that FoxO1-DBD fails to restore these functions. We conclude that FoxO1 
physiologically inhibits these processes in a DNA binding-dependent manner. 
 
4.2.6. Lipid Metabolism in WTD-Fed L-DBD Mice 
We have previously demonstrated that FoxO1 ablation increases hepatic TG deposition in mice fed a 
Western-type diet (WTD) [168]. We therefore placed L-DBD, L-FoxO1, and control mice on WTD for ten 
weeks and analyzed them in either the ad libitum-fed or 5-hr-fasted state. At the completion of the diet 
there were no significant differences among genotypes in body weight or circulating levels of glucose, 
insulin, FFA, TG, and cholesterol in either state (Table 4.3). Liver weight increased by ~25% in fed L-
FoxO1 and L-DBD mice (Fig. 4.12A), accompanied by a near doubling of liver TG, although this 
difference did not reach statistical significance owing to large individual variance (Fig. 4.12B). Histologic 
examination of liver sections taken from these mice confirmed the presence of hepatic steatosis in L-
FoxO1 and L-DBD mice (Fig. 4.12C). These findings were accompanied by coordinate increases in levels 
of mRNA encoding Fasn, Gck, and Scd1 (Fig. 4.12D-G). 
Finally, we analyzed whether FoxO1-DBD modified the effects of WTD feeding on insulin 
signaling in liver and primary hepatocytes. Fasting levels of p-Akt (Thr 308 and Ser 473) and p-GSK3β 
(S9) were uniformly increased in WTD-fed mice of all genotypes, blunting the increase in response to 
feeding (Fig. 4.13A-D). This is probably due to hyperinsulinemia [185]. We investigated this process by 
pre-incubating primary hepatocytes with insulin as a surrogate of in-vivo hyperinsulinemia (Fig. 4.11C), as 
previously described. Following this treatment, basal (i.e., “fasted”) phosphorylation levels of Akt and 
GSK3β increased relative to non-exposed cells, but were not further augmented by acute insulin 
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treatment (“fed” state). As in fed livers, L-FoxO1 and L-DBD hepatocytes exhibited a trend toward lower 
levels of Akt and GSK3β phosphorylation following acute insulin challenge. Thus, it appears that FoxO1-
DBD does not exert independent effects on insulin signaling in this context. 
 
4.2.7. Transcriptomic Profiling of L-DBD Mice 
To dissect the mechanistic basis of FoxO1’s actions, we first investigated the phenotypic consequences 
of Foxo1dbd hemizygosity, then turned to transcriptomic analyses to understand changes in gene 
expression that correlate genotypically with metabolic parameters. We performed RNA-seq analysis from 
liver samples from fasted or re-fed Control, L-FoxO1, and L-DBD mice. We found considerable overlap 
with respect to genes significantly altered in L-FoxO1 and L-DBD livers versus control (Fig. 4.14A). Thus, 
it appears that the largest share of FoxO1 target genes are regulated by direct DNA binding of FoxO1 
(i.e., as a transcription factor). Nevertheless, there is indeed a small but distinct pool of target genes that 
are differentially altered in L-FoxO1 vs. L-DBD mice – that is, genes toward which FoxO1 acts in a co-
regulatory manner (Fig. 4.14A-B, 4.15B-C). Analysis of the relative differences in the expression of these 
genes indicates that the FoxO1-DBD acts both as a co-activator and co-repressor toward these target 
genes in roughly equal measure in both the fasted and re-fed states  (Fig. 4.14B, 4.15B-C). In some 
cases, the ostensible mechanism of FoxO1’s regulation of a particular target gene appears to vary 
depending on feeding state (data not shown). We validated the expression patterns of selected genes 
(i.e., toward which FoxO1 acts as co-regulator vs. transcription factor) by qPCR (Fig. 4.15A-C).    
The complete phenotypic concordance between L-FoxO1 and L-DBD mice in terms of glucose 
production indicates that Foxo1dbd represents a complete loss-of-function allele and that FoxO1’s role in 
promoting hepatic glucose production proceeds via a mechanism requiring direct binding to DNA. This 
allows us to focus our transcriptomic analysis on genes that are significantly altered in both L-FoxO1 and 
L-DBD mice relative to control but not to each other as particularly attractive candidates for the major 
effectors of FoxO1’s influence on hepatic glucose production (Fig. 4.14A). In our RNA-seq data, 297 
genes are significantly different in fasted L-FoxO1 mice versus control and 307 are different between 
fasted L-DBD and control. However, those that are significantly altered relative to control but not to each 
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other in both of these sets number only 159. Thus, through our study of the L-DBD mouse, we have 
approximately halved the number of candidate genes that we would have obtained based on merging 
glucose-tolerance and gene-expression data from control vs. L-FoxO1 alone.  
We can apply a similar line of reasoning to the “lipid arm” of hepatic metabolism. We have shown 
that, unlike their L-FoxO1 littermates, chow-reared L-DBD mice retain normal control of hepatic 
triglyceride metabolism in the re-fed state. This demonstrates a relevant metabolic function for FoxO1 as 
a transcriptional co-regulator rather than as a transcription factor. Based on our transcriptomic analysis 
(Fig. 4.14A), we can cut down a list of candidate genes from 275 for refed Control vs. L-FoxO1 only to 44, 
those significantly altered in refed L-FoxO1 vs. control and L-DBD, but not in control vs. L-DBD. If the 
more important changes occur instead in the fasting state, our analysis cuts down the list of candidates 
from 298 (L-FoxO1 vs. control alone) to 31. We have therefore simplified our list of theoretical candidates 
by over 80% by first gating the analysis on the basis of FoxO1’s mode of action with respect to hepatic 
TG metabolism.  
Gene ontology analysis indicates that the genes that differ significantly between L-FoxO1 and L-
DBD livers vary in functional categorization between the fasted and re-fed states (Table 4.4). In the fasted 
state, the ontological categories most highly altered by the presence of FoxO1-DBD relate to metabolism 
of steroids, particularly steroid hormones. On the other hand, in the refed state, those most affected by 
FoxO1-DBD relate to both innate and adaptive immune processes. Selected candidate genes will be 
discussed in Section 4.3.5. 
 
4.3. Discussion 
4.3.1. Overview of Findings 
This study demonstrates that the pleiotropic effects of FoxO1 on hormone- and nutrient-dependent gene 
expression require binding to DNA. There is another, less recognized mode of action, whereby FoxO1 
engages in non-DNA-based interactions with components of the transcriptional complex to regulate gene 
expression. Examples of this mode of action include FoxO1 binding to Maml1 and Csl, central elements in 
Notch signaling [370, 374]. However, the present study indicates that this mode of action does not 
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contribute to the main cell-autonomous effects of FoxO1 on hepatic glucose and lipid metabolism. In fact, 
we show that reconstitution of a FoxO1 DNA-binding-deficient allele in liver of mice that lack endogenous 
FoxO1 fails to restore HGP, lipogenesis, and FFA oxidation. While the conclusion that FoxO1 controls 
HGP by binding to consensus sites on target promoters was predicted by previous work [152, 372] the 
finding of increased lipogenesis in L-DBD mice is surprising, as the inhibition of this process by FoxO1 is 
more easily reconciled with a co-repressor function [375]. Another important finding of the present study is 
the heretofore-unrecognized effect of FoxO1 ablation, mimicked by the DBD mutant, to reduce FFA 
oxidation [158, 166, 167, 245]. 
The segregation of different functional outputs of a transcription factor on the basis of DNA 
binding-dependent vs. independent actions has been observed in other contexts. For instance, it appears 
to be a feature of bHLH transcription factors, including Hand2 and Scl [376, 377]. Prior evidence in this 
vein exists for FoxO1 as well. For instance, FoxO1-DBD can suppress myogenic differentiation of C2C12 
myoblasts as efficiently as FoxO1-WT [374]. Likewise, constitutively nuclear FoxO1-DBD retains the 
ability to enhance basal phosphorylation of Akt in liver [247] (see Section 5.3.1). Overall, FoxO1 has been 
shown to engage in protein-protein interactions with at least a dozen distinct transcriptional regulators, 
although the physiologic significance of many of these interactions has not previously been validated 
[378]. 
 
4.3.2. FoxO1 Regulation of Hepatic Glucose Metabolism 
The centrality of FoxO1 in insulin’s control of HGP is beyond question. This study further cements this 
certainty, as we have found that hepatocyte-specific deletion of FoxO1 results in enhanced glucose 
tolerance due to decreased HGP. As mentioned earlier, however, despite the robust reproducibility of this 
result, the mechanism underlying it is relatively unknown. The well-known regulation of G6pc expression 
by FoxO1, and perhaps also of Fbp2, Pdk4, Ppargc1a, and Pck1, has been essentially taken for granted 
as the explanation. 
 Despite the appealingly straightforward nature of this hypothesis, however, multiple lines of 
evidence suggest that G6pc and Pck1 expression may not be directly responsible for FoxO1’s empirical 
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role in HGP. Complete loss of G6pc or of Pck1 in the liver, far more dramatic than the decrease in 
expression due to FoxO1 deficiency, do not result in a physiologic impairment in glucose production due 
to indirect actions of other tissues on this process, for example through FFA flux from adipose tissue and 
vagal control by the CNS, as well as compensatory increases in glucose production by intestine and 
kidney [379, 380]. Moreover, while concomitant knockout of all three FoxO proteins in the liver results in a 
further enhancement of glucose tolerance, it is not accompanied by any apparent defect in Pck1 
expression [144], and thus we can assume that it is not responsible for FoxO1-associated HGP. Real-
time hyperinsulinemic-euglycemic clamp studies have cast doubt on the temporal correlation between 
physiologic changes in G6pc/Pck1 expression/activity and the blunting of HGP by insulin [94, 114]. 
Finally, type 2 diabetic patients, a group exhibiting inappropriately high FoxO1 activity, do not necessarily 
exhibit increased hepatic expression of G6pc or Pck1 despite inappropriately high HGP [381]. Taken 
together, these observations indicate that although the InsR à FoxO1 axis is crucial to proper regulation 
of HGP, the precise mechanism linking FoxO1 to HGP remains unclear [2].   
 In this study we have taken a first step by demonstrating that L-DBD mice phenocopy L-FoxO1 
mice in terms of glucose-metabolic parameters. That is, direct binding of FoxO1 to the IRE is required for 
its regulation of HGP. Of note, G6pc expression was reduced similarly in L-DBD and L-FoxO1 mice, thus 
still not allowing us to rule out the importance of this gene to overall HGP. The fact that G6pc expression 
does correlate well with FoxO-associated HGP while Pck1 expression does not implies that the effect of 
FoxO1 deficiency on glucose metabolism may reflect more on alterations in glycogen metabolism than in 
gluconeogenesis, consistent with hyperinsulinemic-euglycemic clamp data in L-FoxO1 mice as well as the 
finding that L-FoxO1 livers engage in inappropriately high glycogen storage [2, 145]. Moreover, although 
the significant enhancement of pyruvate tolerance exhibited by L-FoxO1 and L-DBD mice suggests a 
primary change in gluconeogenesis, this effect may also result from increased glycogen synthesis from 
G6P and/or decreased glycogenolysis in the absence of FoxO1. In this case, low G6pc expression would 
prevent the conversion of G6P to releasable glucose. The in vivo change in G6pc expression is only 
about 25%, casting doubt on its physiologic primacy and raising the possibility that other contributors are 
necessary for the effect. Nevertheless, a potential limitation of this study is that it did not assess glycogen 
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content in L-DBD livers, although it is expected that they would demonstrate inappropriately high glycogen 
storage similar to L-FoxO1 mice. Excess glycogen in L-DBD livers may account for the slight, albeit non-
significant elevation in liver weights in L-DBD mice in spite of their normal TG levels.  
 A pertinent negative highlighted by this study is PGC-1α, which we show here to be a bona fide 
co-regulatory target of FoxO1. That is, although L-FoxO1 primary hepatocytes express significantly lower 
levels of Ppargc1a when stimulated with cAMP/dex, gene expression is completely normal in L-DBD 
hepatocytes (Fig. 4.8E) – despite the inability of FoxO1-DBD to activate glucose production above the 
level of L-FoxO1 cells (Fig. 4.8A-B). Thus, although its importance as a FoxO1 co-activator has been 
much touted [155, 372], FoxO1-mediated HGP actually proceeds largely independently of PGC-1α. That 
L-DBD primary hepatocytes also show deficient FAO suggests that FoxO1’s regulation of the process 
does not proceed through PGC-1α regulation of mitochondrial oxidation [145, 174]. 
 We also can consider candidate genes brought to the fore by RNA-seq. As mentioned earlier, the 
conclusion that FoxO1 regulation of HGP requires it to act in TF mode means that we can eliminate nearly 
half of the genes significantly altered in the absence of FoxO1 in fasted liver. The remaining list of 159 
genes includes several intriguing possibilities. Perhaps the most obvious possibility is Pdk4 [134], which 
inhibits the pyruvate dehydrogenase complex to spare pyruvate for glucongeogenesis and has already 
been shown to be regulated by FoxO1 [154]. Another logical candidate, Nr0b2, which encodes small 
heterodimer partner (SHP), also has already been implicated in FoxO1 control of HGP [2]; it acts as a 
nuclear co-repressor to block FoxO1-associated G6pc, Pck1, and Pdk4 gene expression through 
negative feedback [382-384]. In fact, we have already studied Nr0b2 in the context of its negative 
regulation of bile-acid metabolic enzymes Cyp7a1 and Cyp8b1 and shown that its expression is 
decreased in WTD-fed L-FoxO1 livers [168], suggesting another level of coordination of glucose and lipid 
metabolism by FoxO1. Finally, Slc37a4, which encodes the G6P transporter that carries G6P from the 
cytosol into the ER lumen where it can be acted upon by G6Pase [385], is decreased nearly by half in 
both L-FoxO1 and L-DBD samples. This is consistent with decreased glucose release and conceptually is 
reconcilable with a cell-autonomous model of FoxO1 action. Our laboratory has previously found that 
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Slc37a4 mRNA is significantly decreased in L-FoxO1,3,4 livers even though it is not strongly regulated by 
fasting/feeding [253].  
 
4.3.3. FoxO1 Regulation of Hepatic Lipid Metabolism 
The most notable physiologic parameter influenced by hepatic FoxO1 in its co-regulatory capacity is 
triglyceride metabolism. To wit, L-FoxO1 liver TG levels were significantly higher than controls following 
re-feeding; L-DBD mice, on the other hand, had normal re-fed liver TG levels (Fig. 4.9B). Therefore, we 
can conclude that the overall regulation of liver TG storage by FoxO1 proceeds via a co-regulatory 
mechanism rather than through binding to IREs in target-gene promoters. Although our original study of L-
FoxO1 mice did not find any significant alteration in liver TG, it focused only on the fasted and ad libitum 
fed states rather than under the strong lipogenic drive of re-feeding [145]. Indeed, a subsequent study did 
find a trend toward increased liver TG in re-fed L-FoxO1 mice that we now have found to reach statistical 
significance [241].    
We have attempted to dissect the phase of hepatic lipid handling that is defective in L-FoxO1 
livers but not in L-DBD. We detected no differences in oral lipid tolerance (i.e., lipid absorption from the 
gut) or in TG secretion from the liver (Fig. 4.9C-E). Ex vivo experiments in primary hepatocytes 
demonstrate that loss of hepatocellular FoxO1 increases de novo lipogenesis and decreases fatty acid 
oxidation (Fig. 4.9F). These alterations in hepatocellular metabolism would increase liver TG, as observed 
in vivo. Data collected from L-DBD primary hepatocytes, however, appear less straightforward, possibly 
owing to indirect control on the liver. Fatty acid oxidation by L-DBD cells does not differ from L-FoxO1, 
indicating a requirement for direct transcriptional activation by FoxO1.  
While previous in vivo studies of L-FoxO1 mice have not reported abnormalities of ketone bodies 
[145, 241], a relatively specific marker of β-oxidation, direct in vivo measurement in mice lacking all three 
liver FoxO isoforms (L-FoxO1,3,4) show decreased fatty acid oxidation rates relative to control [245]. 
These observations suggest that non-cell-autonomous mechanisms compensate for the ex vivo defect in 
fatty acid oxidation in the absence of functional FoxO1, an interpretation supported by the absence of any 
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difference in oxygen-consumption rate or respiratory quotient between genotypes (Fig. 4.4F-G). However, 
these apparent compensatory mechanisms are insufficient when all liver FoxO genes are knocked out. 
Ex vivo assessment of DNL by measuring the incorporation of radiolabeled acetic acid into TG 
also revealed a requirement for direct DNA binding (Fig. 4.9G). The rate of DNL in L-FoxO1 primary 
hepatocytes was approximately 35% greater than control, both in the basal and insulin-stimulated states. 
It appears that FoxO1-DBD may even stimulate DNL in a gain-of-function capacity beyond the apparent 
ability of wild-type FoxO1 to inhibit it, as L-DBD primary hepatocytes tended to exhibit greater rates of 
DNL even than L-FoxO1 hepatocytes (about 75% higher than control). This may result, for example, from 
FoxO1-DBD sequestration of co-regulators from other FoxO proteins [386-388] and is consistent with 
previous data documenting increased rates of DNL in L-FoxO1,3,4 mice [245, 253]. Taken together, 
therefore, cell-autonomous regulation of de novo lipogenesis and fatty acid oxidation by FoxO1 requires 
direct binding to DNA. 
It is important to emphasize, however, that L-DBD mice did not phenocopy the exaggerated liver 
TG levels of the L-FoxO1 mouse in the re-fed state in spite of its inability to properly control de novo 
lipogenesis and fatty acid oxidation in hepatocytes. We can therefore conclude that the predominant 
mechanism by which FoxO1-DBD regulates TG metabolism in the healthy liver is not solely at the level of 
cell-autonomous TG deposition or FFA oxidation. Again, we did not detect any differences between L-
FoxO1 and L-DBD mice with respect to oral lipid tolerance or TG secretion. However, FoxO1-DBD may 
regulate non-cell-autonomous mechanisms that impact on lipid synthesis or oxidation. Indeed, several 
non-hepatocyte-autonomous mechanisms of controlling hepatic lipid metabolism have been identified to 
date with which hepatic FoxO1 may interact [168, 389-392]. Our laboratory, for example, previously 
demonstrated an ability of FoxO1 to regulate hepatic TG through altered bile acid signaling [168]. In this 
study, however, we did not note any discordance between expression of bile acid metabolic enzymes in 
L-FoxO1 vs. L-DBD mice (Fig. 4.10G-J).  
As opposed to the chow-fed state, WTD-fed L-DBD mice exhibit the same increase of hepatic 
steatosis as L-FoxO1 mice, indicating this type of diet does not alter the balance between the DNA 
binding-dependent and -independent actions of FoxO1. It is possible that the insulin resistance 
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associated with WTD, which would be expected to lead to unrestrained FoxO1 activity, unmasks the 
apparent gain of function exhibited by FoxO1-DBD in primary hepatocytes with respect to de novo 
lipogenesis. In keeping with this possibility, both L-FoxO1 and L-DBD livers present lower levels of Akt 
and GSK3β phosphorylation than controls in spite of similar insulin levels (Fig. 4.13, Table 4.3), 
suggesting that FoxO1-DBD is less restrained by insulin signaling than wild-type FoxO1. This is 
consistent with the fact that steatotic liver derives a much greater percentage of its stored lipid from de 
novo lipogenesis than does healthy liver [73, 74, 306]. That dysregulated bile-acid metabolism appears to 
affect liver TG levels to a greater extent following WTD feeding [168] may also help to explain the lack of 
difference in liver TG between WTD-fed L-FoxO1 and L-DBD mice, as FoxO1 appears to regulate bile 
acid metabolism primarily as a transcription factor (Fig. 4.10G-J).  
The RNA-seq-derived shortlist of genes that may account for FoxO1’s actions on triglyceride 
metabolism in the re-fed state does not include any classical lipogenic enzymes. It does, however, 
contain other types of candidates previously linked to hepatic lipid metabolism, such as the fatty acid 
transporter Cd36 [393], the secreted peptide adropin (Enho) [394], and cell death-inducing DFFA-like 
effector C (Cidec, also known as Fsp27) [395]. Finally, it is important to note that the main effect of FoxO1 
on triglyceride metabolism in the re-fed state may be based at least in part on changes in gene 
expression during fasting. Genes regulated by FoxO1 in a co-regulatory manner that are altered in the 
fasted state and may contribute to an altered lipogenic response to refeeding include 6-phosphofructo-2-
kinase/fructose-2,6,-bisphosphatase (Fbp2), described in Chapter 1, and lipin-1 (Lpin1) [396]. We believe, 
however, that glucokinase (Gck), a gene already well studied by our laboratory is primarily responsible for 
FoxO1’s effects on hepatic lipid metabolism. 
 
4.3.4. FoxO Regulation of Glucokinase May Underlie Effects on DNL  
Data from our laboratory indicate that FoxO proteins are intimately involved in orchestrating the transition 
between fasting and feeding [253]. One potential mediator of this phenomenon is glucokinase, a central 
regulator of glucose flux in the liver and previously demonstrated to be repressed by FoxO1 [144, 167]. 
Compared to controls, expression of Gck is significantly increased by over three-fold in the livers of fasted 
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L-FoxO1 mice as expected but expression of Gck in L-DBD livers is intermediate between Control and L-
FoxO1 (Fig. 4.10C). (There is no difference in Gck expression between groups four hours after re-
feeding.) Higher levels of Gck expression in the L-FoxO1 mice at the onset of re-feeding may result in a 
more efficient accumulation of liver triglyceride than in control and L-DBD, as observed [232, 397, 398]. 
This would also explain the elevated liver TG of L-FoxO1,3,4 mice even relative to L-FoxO1, in line with 
the relative increment in Gck expression in the absence of FoxO3 and FoxO4 [144]. Thus, FoxO1’s 
repression of Gck expression in the fasted state – again, when FoxO1 is most active – proceeds at least 
in part by a co-regulatory mechanism.  
A mechanism based on Gck regulation of the fasting-feeding transition may also help to explain 
the discrepancy between ex vivo DNL and liver TG levels. Insulin has both direct and indirect effects on 
the liver, and therefore primary hepatocytes can only capture some of this complexity. As mentioned 
above, L-DBD livers partially retain the ability to suppress Gck expression in the fasted state while L-
FoxO1 livers show a significant increase in fasting Gck expression. However, in primary hepatocytes, 
there is no significant difference between genotypes in Gck expression (Fig. 4.11A), although the general 
pattern of expression interestingly mirrored that of DNL with a trend toward increased Gck expression in 
L-DBD cells. By comparison, Gck expression was at least fourfold higher in primary hepatocytes from L-
FoxO1,3,4 mice compared to control (Fig. 4.11B and data not shown) and total DNL was accordingly 
increased as well (Fig. 4.11C). This suggests that the regulation of Gck expression by FoxO proteins is 
multifaceted. FoxO3 and FoxO4 are evidently able to compensate for the loss of a cell-autonomous 
inhibitory effect of FoxO1. Meanwhile, some external stimulus modulates regulation of Gck expression by 
FoxO1 in particular in vivo. 
  A further potential clue lies in our observation that Gck expression does not significantly 
increase with insulin treatment alone in mouse primary hepatocytes, as has been previously reported. 
This indicates that the insulin-stimulated (and thus potentially FoxO1-inhibited) Gck expression, for 
example in response to re-feeding, requires the participation of factor(s) beyond hepatic insulin action 
alone. Supporting this conclusion is the finding that LIRKO mice still experience a significant, albeit 
attenuated increase in hepatic Gck expression in response to feeding [202]. Moreover, blockade of insulin 
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signaling specifically in the hypothalamus has been shown to depress the induction of liver Gck 
expression in response to portal insulin infusion [399]. Factors altogether distinct from insulin may also be 
required. We and others have found, for example, that co-treatment of primary hepatocytes with 
dexamethasone can enable insulin responsiveness of Gck expression [400-402]. That normal FoxO1-
mediated expression of Igfbp1 appears to be in part dependent on glucocorticoid signaling opens the door 
to similar requirements for FoxO1 regulation of Gck expression [145], especially as FoxO1 has been 
shown to be capable of functional interactions with the glucocorticoid receptor, potentially independently 
of IRE binding [378].  
Taken together, these data suggest a model in which FoxO1 inhibits DNL at multiple levels, 
depicted graphically in Fig. 4.16. First, in a cell-autonomous fashion, FoxO1 represses DNL via a method 
requiring direct binding to DNA. One possibility lies in the fact that FoxO1 retains the ability to normally 
regulate expression of Gck, unlike G6pc, in primary hepatocytes. Work from our laboratory has shown 
that the ratio of G6pc to Gck expression is a reliable indicator of the direction of glucose flux (i.e., of 
gluconeogenesis/glycogenolysis à HGP vs. glycolysis à DNL) [253]. Thus, in both L-FoxO1 and L-DBD 
primary hepatocytes, a defect in G6pc expression in the absence of a change in Gck would decrease the 
G6pc:Gck ratio. This, in turn, would impede gluconeogenesis, as observed in this study, while increasing 
the availability of acetyl-CoA for use in DNL, especially in the presence of insulin [253]. Again, in L-
FoxO1,3,4 primary hepatocytes, Gck expression is frankly increased and G6pc decreased, consistent 
with the dramatic elevation in DNL compared to control [253]. 
The importance of G6PC in the indirect regulation of lipogenesis is illustrated quite starkly in the 
case of G6PC deficiency. Patients with mutations in the gene, termed von Gierke disease (GSD type Ia), 
demonstrate florid hypertriglyceridemia [403]. Even acute inhibition of G6Pase activity has been shown to 
result in the development of hepatic steatosis associated with increased DNL [404]. Although the above 
discussion has called into question the importance of physiologic fluctuations in hepatic G6pc expression, 
the relative importance of transcriptional control of G6pc to glucose production may be greater in isolated 
hepatocytes. This supposition is based on the far greater reduction in G6pc expression in FoxO1-deficient 
hepatocytes ex vivo compared to whole liver as well as the absence of extrahepatic tissues (e.g., 
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intestine, kidney) to contribute to compensatory glucose production. Even if altered expression of G6pc 
per se is not directly responsible, the process of gluconeogenesis is certainly decreased in L-FoxO1 and 
L-DBD hepatocytes and thus, as in the case of decreased G6Pase action, would be expected to promote 
increased lipogenesis. Indeed, reducing gluconeogenic flux via liver-specific deletion of Pck1, for 
example, also results in significantly increased liver TG accumulation [379, 405]. 
Unlike in primary hepatocytes, fasting and feeding regulation of Gck expression via FoxO1 can 
proceed as normal in whole liver. Thus, by the end of an overnight fast, L-FoxO1 livers have accumulated 
significantly more Gck mRNA than controls. At the onset of re-feeding, these livers are thereby better 
primed for efficient TG synthesis, hence the increase in re-fed liver TG [253]. (During fasting, relatively 
low rates of DNL are eclipsed by re-esterification of FFAs liberated by WAT lipolysis in terms of overall 
liver TG levels [363].) On the other hand, L-DBD livers retain a partial ability to suppress Gck expression, 
thus not allowing these livers as much of a “head start” on DNL after re-feeding. That the expression of 
Gck is elevated to the same extent in both L-FoxO1 and L-DBD livers in the WTD-fed state therefore may 
explain the lack of difference in liver TG levels between these mice, especially given the heightened 
contribution of DNL to hepatic TG in this state. Evidently the apparent ability of haplosufficient FoxO1-
DBD to regulate Gck expression in the chow-fed state is lost in the WTD-fed state, thus altering the 
G6pc:Gck ratio similarly in these mice. Given this hypothesis, it would be of interest to assess whether the 
difference in liver TG levels would be magnified at earlier time points in re-feeding.  
Evidence of a co-regulatory action of FoxO1 on Gck expression already exists in the literature 
[179, 406, 407]. For example, in addition to being able to bind directly to the Gck promoter, FoxO1 has 
also been previously reported to disrupt the activation of Gck expression by HNF-4α by interfering with 
the latter’s binding to the promoter [179, 406]. This dual ability of FoxO1 to regulate Gck expression as 
both transcription factor and co-regulator may be reflected in the intermediate expression of Gck in L-DBD 
between control and L-FoxO1. However, all such studies have been conducted in cultured cells and 
therefore the potential contribution of a FoxO1—HNF-4α interaction to liver triglyceride levels in vivo 
remains unknown.  
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Overall, this model is not necessarily mutually exclusive with other hypotheses regarding FoxO1 
control of hepatic TG, such as via modulation of bile acid metabolism [168]. Indeed, this model alone is 
not sufficient to explain the augmentation in DNL observed in L-DBD primary hepatocytes even relative to 
L-FoxO1. Thus, it is likely that other mechanisms also come into play. One enticing possibility, as 
mentioned above, is a partial dominant-negative effect of FoxO1-DBD on FoxO3/4, especially as Gck 
expression trends slightly higher in L-DBD cells.  
 
4.3.5. Other Potential Co-Regulatory Actions of FoxO1 
The mechanistically complex nature of FoxO1’s regulation of target-gene expression also is not limited to 
glucose- and lipid-metabolic transcriptional programs. Gene-ontology analysis of transcriptomic data from 
L-FoxO1 and L-DBD livers has, in fact, uncovered a variety of cellular processes influenced differentially 
by co-regulatory versus direct transcriptional effects of FoxO1. Furthermore, the transcriptomic signature 
of FoxO1-DBD differs greatly in the fasted and refed states. In the refed state, surprisingly, nearly all of 
the most significantly altered biological processes relate to the immune system. These include elements 
both of innate immunity, such as the acute-phase response and Toll-like receptor signaling, as well as 
adaptive immunity, such as antigen processing and presentation. Although hepatocytes are the source of 
many acute-phase reactants, including serum amyloid A proteins [408], two of the genes for which are 
significantly altered in L-FoxO1 vs. L-DBD livers, the changes noted in expression levels of class II 
histocompatibility-complex components are less easily explained. As the RNA samples used for RNA-seq 
were drawn from whole liver, it is possible that hepatocellular FoxO1 activity influences the population 
and/or behavior of immune-system cells in the liver [409, 410]. However, it has also been reported that 
select populations of hepatocytes can induce expression MHC class II under stress conditions and 
function as antigen-presenting cells [411]. FoxO1 has indeed previously been implicated in the regulation 
of inflammatory pathways in the hepatocyte [412] and other cell types [413, 414]. Whether these actions 
of FoxO1 represent co-regulatory activities, and whether they relate in particular to adaptive immunity in 
the liver, however, have not previously been studied. 
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With respect to the fasted state, the majority of significantly different gene-ontological categories 
relate directly or indirectly to the metabolism of sterols and their hormonal derivatives. As previously 
mentioned, we already have elucidated FoxO1’s role in the regulation of bile acid and cholesterol 
metabolism [168]. Very little prior evidence exists, however, linking FoxO1 to the metabolism of other 
sterol derivatives. Nine of the genes significantly altered in L-FoxO1 vs. L-DBD are represented in the 
KEGG steroid hormone metabolism pathway: Cyp17a1, Cyp2b10, Cyp2c70, Cyp7b1, Hsd17b6, Hsd3b5, 
Sc4mol, Ugt2b37, and Ugt2b38. A potentially notable candidate gene among these is Hsd3b5, 3β-
hydroxysteroid dehydrogenase, type 5. The regulation of the expression of this gene by FoxO1 appears 
multifaceted, for although its expression is increased in L-FoxO1 liver relative to control, it is also strongly 
repressed in L-DBD liver, suggesting that FoxO1-DBD acts to repress it, perhaps even to a greater extent 
than can FoxO1-WT. Hsd3b5, which is expressed only in the male liver, is able to catalyze the catabolism 
of the potent androgen 5α-dihydrotestosterone, but little else is known about its role in vivo [415, 416]. 
Despite the mystery surrounding this gene and its product, however, various lines of evidence suggest a 
potentially important place for it in the regulation of nutrient metabolism in the liver. For example, in a 
comparison of the transcriptomic profile of diabetic (db/db) versus control liver by RNA-seq, Hsd3b5 was 
the second most highly downregulated of all transcripts meeting the study’s inclusion criteria [417].  
If FoxO1 does indeed act as a co-repressor of Hsd3b5, it would be expected that heightened 
FoxO1 activity in the diabetic liver would serve to suppress its expression even more strongly than usual. 
Evidence of this sort of regulation can be found in a microarray study of livers deficient in Akt1 and Akt2 
(“DLKO” mouse) and Akt1/2 as well as FoxO1 (“TLKO” mouse) [167]. Hsd3b5 was by far the most 
strongly suppressed gene in the absence of Akt1/2 in the fed state (500-fold decreased relative to control) 
and was the fourth most highly suppressed in the fasting state (15-fold decreased relative to control). 
Concomitant deletion of FoxO1, however, completely normalized Hsd3b5 expression in the fed state; in 
the fasted state, Hsd3b5 became the fourteenth most highly upregulated gene. Thus, it appears that not 
only does FoxO1 serve dominantly to inhibit the expression of Hsd3b5, but also that FoxO1 mediates this 
inhibition in a co-regulatory fashion. That Hsd3b5 expression is evidently so tightly controlled by insulin 
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signaling via an Akt-FoxO1-dependent pathway substantiates the potential importance of this heretofore-









































































Figure 4.1. Generation and Characterization of the Foxo1dbd Allele 
(A) Schematic diagram of the FoxO1 primary sequence identifying the residues mutated in Foxo1dbd.  
(B) Reporter-gene assay in 293 cells transfected with either Foxo1wt, Foxo1dbd, or empty vector as well as 
with either 3X IRE-Luc reporter construct or control. Data represent mean ± SEM. * p < 0.05 relative to 
control by Tukey’s post-hoc analysis following one-way ANOVA.  
(C) Schematic diagram of mouse models used in this study. 
(D) Liver qPCR using allele-specific primers for total Foxo1, Foxo1wt or Foxo1dbd. Data represent mean ± 
SEM.  
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Figure 4.2. Metabolic Characterization of FoxO1- and DBD-het Mice 
(A-B) Glucose (A) and pyruvate tolerance tests (B) in overnight-fasted mice (N≥7 for all genotypes). 
(C) Insulin tolerance test in 5-hr-fasted mice (N = 5-6 for all genotypes). 
(D) Quantification of the area under the curve (AUC) for the results in A-C. 
(E) Gene expression levels in fasted livers assessed by qPCR. 
All mice were reared on a chow diet and studies were performed at 16-20 weeks of age, Data represent 
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Figure 4.3. Glucose Production in Foxo1- and DBD-Het Primary Hepatocytes    
Glucose production assay performed in medium containing either vehicle or 0.1 mM CPT- cAMP + 1 μM 
dexamethasone (cAMP/dex).  
(A) Aliquots of medium were collected at the indicated time points and assayed for glucose content as 
indicated in the experimental procedures. 
(B) Area under the curve quantified from the data in panel A. 
(C-E) Expression of fasting-inducible genes in primary hepatocytes treated as either above, or including 
100 nM insulin with cAMP/dex. 
Data in (A-B) represent mean ± SEM and in (C-E) are representative of three independent experiments 











































































































































Figure 4.4. Study of Whole-Body Metabolism by Indirect Calorimetry 
(A-B) Body weight (A) and body composition (B) in fed mice 
(C-D) Cumulative 24-h food intake (C) broken down by light vs. dark cycles (D), normalized to lean body 
weight. 
(E) Energy expenditure normalized to lean body weight 
(F) Oxygen consumption rate normalized to lean body weight 
(G) Respiratory quotient (RQ), calculated as VO2/VCO2 
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Figure 4.5. Glucose Metabolism in L-FoxO1 and L-DBD Mice 
(A-B) Glucose (A) and insulin (B) in mice fasted overnight or re-fed for 4 hr. 
(C-D) Glucose (C) and pyruvate (D) tolerance tests in overnight-fasted mice. 
(E) Insulin tolerance test in 5-hr-fasted mice. 
(F) Quantification of the area under the curve (AUC) for the results in (C-E). 
(G) Gene expression levels in fasted livers assessed by qPCR. 
All mice were reared on a chow diet and studies were performed at 16-20 weeks of age, N ≥ 9 for all 
genotypes in all experiments. Data represent mean ± SEM. * p < 0.05 by Tukey’s post-hoc analysis 
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Figure 4.6. Insulin-Dependent Akt and GSK3β  Phosphorylation 
(A-C) Western blot analysis of insulin-induced protein phosphorylation in liver (A), soleus muscle (B), and 
epididymal fat (C) after IV saline or insulin injection in overnight-fasted or 4-hr- refed mice (n = 3 for 
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Figure 4.7. Hepatic Insulin Signaling  
(A) Western blot of insulin-induced protein phosphorylation in fasted or 4 hr-re-fed mice of each genotype. 
Each lane represents three pooled whole-liver extracts from a single cohort.   
(B-C) Densitometric analysis of Akt phosphorylation in Western blots from (A). Each point represents one 
of the two lanes for each genotype × feeding state combination.  
(D) Western blot of insulin-induced protein phosphorylation in 4 hr-refed mice matched for mean insulin 
concentration, noted below each genotype as mean insulin ± SEM. Each lane represents one liver extract 
from the indicated genotype.   
(E-F) Densitometric analysis of Akt phosphorylation in Western blots from (D). Each point represents one 
of the corresponding bands in (D).  
(G) qPCR analysis of Irs2 expression in either fasted or 4-hr-re-fed mice of each genotype (N ≥ 7 for each 
genotype). 
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Figure 4.8. Glucose Production in L-FoxO1 and L-DBD Primary Hepatocytes  
(A) Glucose production assays in cells incubated with glucose-production medium supplemented with 
(filled circles) or without (open circles) 0.1 M CPT-cAMP and 1 µM dexamethasone for 5 hr.  
(B) Quantification of the AUC from the data in panel A. Data in (A-B) represent mean ± SEM of three 
independent experiments performed in triplicate.  
(C-E) qPCR of G6pc, Pck1, and Ppargc1a levels in the presence or absence of cAMP/dex and insulin. 
Data are presented as mean ± SEM of a representative experiment of three, each performed in triplicate. 
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Figure 4.9. Lipid Metabolism in Mice and Primary Hepatocytes 
(A) Liver weight relative to body weight. Mice of each genotype were fasted overnight or fasted overnight 
and refed for 4 hr (N ≥ 10 for each genotype). 
(B) Liver TG content in fasted or 4-hr-refed mice, normalized to total liver weight (N ≥ 6 for each 
genotype).  
(C) Oral lipid tolerance test (OLTT) in 5-hr-fasted mice, administered by giving olive oil p.o. and drawing 
blood at the indicated time points (N = 6-9 for each genotype).   
(D) TG secretion assay in 5-hr-fasted mice (N ≥ 5 for each genotype). 
 (E) Area under the curve (AUC) of OLTT and TG secretion. Data are normalized to a representative 
control sample for each procedure.  
(F) Fatty acid oxidation in primary hepatocytes from control, L-FoxO1, and L-DBD mice. Data shown as 
average of three independent experiments performed in triplicate.  
Data in (A)-(F) represent means ± SEM. * p < 0.05 by Tukey’s post-hoc analysis following one-way 
ANOVA. 
(G) De novo TG synthesis in primary hepatocytes isolated from control, L-FoxO1, and L-DBD mice. Data 
shown are mean ± Satterthwaite-corrected SEM of three independent experiments performed in triplicate. 
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Figure 4.10. Expression of Genes Related to Hepatic Lipid Metabolism  
(A-F) Expression of lipogenic genes in livers from overnight-fasted or 4-hr-re-fed mice 
(G-J) Expression of bile-acid metabolic genes in livers from overnight-fasted or 4-hr-re-fed mice.  
Data represent mean ± SEM, N ≥ 7 for each genotype. * P < 0.05 as assessed by Tukey’s post-hoc 
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Figure 4.11. Studies on the Mechanism of Lipogenesis in Primary Hepatocytes  
(A-B) Gene expression in primary hepatocytes of indicated genotype serum-starved overnight and then 
treated for 5 h with or without 10 nM insulin. Data in (A) represent the mean of two (insulin) or three 
(vehicle) independent experiments performed in triplicate ± Satterthwaite-corrected SEM and in (B) are 
mean ± SEM representative of two independent experiments performed in triplicate. * p < 0.05 by 
unpaired, two-tailed student’s t test. 
(C) De novo lipogenesis in primary hepatocytes isolated from control and L-FoxO1,3,4 mice. Data 
presented are mean ± SEM representative of two independent experiments performed in triplicate. * p < 
0.05 by Bonferroni’s post-hoc test following two-way ANOVA. 
(D) Insulin signaling in primary hepatocytes treated with saline or with 1 nM insulin for 30 min following 
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Figure 4.12. Metabolic Characterization of Mice on Western-Type Diet 
(A-B) Liver weight relative to body weight (A) and liver TG content (B) in 5-hr-fasted or ad libitum-fed 
mice.  
(C) Hematoxylin and eosin staining of liver sections from WTD-fed mice. 
(D-G) qPCR measurements of hepatic Srebp1c, Fasn, Gck, and Scd1 in ad libitum-fed or 5-hr-fasted 
mice.  
Data represent means ± SEM (N ≥ 7 for each genotype). * p < 0.05 by Tukey’s post-hoc analysis 
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Figure 4.13. Studies of Liver Insulin Signaling in WTD-Reared Mice 
(A) Western blot of livers from ad-libitum fed or 5-hr-fasted mice. Each lane represents pooled liver 
homogenate from three mice of the same cohort.
(B-D) Densitometric analysis of phospho-Akt T308 (B), S473 (C) and GSK3β S9 (D). Bars represent the 
average value of the two lanes for each group and are calculated as the ratio of phosphorylated to total 






Figure 4.14. Transcriptomic Analysis of Livers by RNA-Seq   
(A) Genotypic comparisons of the numbers of genes significantly altered (p < 0.05) in the fasted (upper) 
and re-fed (lower) states.  
(B) Heat map illustrating the magnitude of differences in genes significantly altered in L-FoxO1 vs. L-DBD 






















































































































































Figure 4.15. Validation of Selected RNA-seq Candidate Genes 
(A) FPKM values of genes selected from RNA-seq to illustrate FoxO1’s roles as direct transcriptional 
repressor (Rgs16, left column), co-repressor (Hsd3b5, middle column), and co-activator (Enho, right 
column). 
(B-C) qPCR validation of the above gene targets in whole liver (N ≥ 7 for each genotype) (B) and primary 
hepatocytes (c). 




















Figure 4.16. Model of FoxO Action in GP vs. DNL 
Schematic diagram of insulin action on FoxO1 and FoxO3/4 with respect to G6pc expression à GP and 
Gck expression à DNL in (A) primary hepatocytes and (B) whole liver. Black type and strokes indicates 
that the indicated gene/protein or pathway is intact, while dark gray indicates partially intact and light gray 
indicates the absence of the indicated gene/protein or pathway. GP = glucose production, DNL = de novo 
























































Body weight (g)! Fed! 25.1 ± 0.7! 25.2 ± 0.4! 24.6 ± 1.1!
Lean mass %! Fed! 77.4 ± 0.6! 78.8 ± 1.2! 78.7 ± 0.7!
Fat mass %! Fed! 14.7 ± 0.5! 13.2 ± 0.3! 13.3 ± 0.6!
Fluid mass %! Fed! 7.9 ± 0.2! 8.0 ± 0.1! 8.0 ± 0.2!
Glucose (mg/dL)!
Fasted! 72 ± 2! 74 ± 4! 73 ± 3!
Re-fed! 200 ± 13! 204 ± 17! 177 ± 6!
Insulin (ng/mL)!
Fasted! 0.44 ± 0.08! 0.33 ± 0.04! 0.42 ± 0.08!
Re-fed! 1.06 ± 0.17! 0.96 ± 0.14! 1.03 ± 0.16!
Free fatty acids (mEq/L)!
Fasted! 1.66 ± 0.16! 1.65 ± 0.25! 1.75 ± 0.15!
Re-fed! 0.69 ± 0.07! 0.76 ± 0.13! 0.70 ± 0.08!
Triglycerides (mg/dL)!
Fasted! 70 ± 5! 57 ± 4! 60 ± 4!
Re-fed! 63 ± 5! 55 ± 5! 63 ± 6!
Cholesterol (mg/dL)!
Fasted! 97 ± 5! 83 ± 20! 93 ± 12!
Re-fed! 89 ± 4! 91 ± 1! 93 ± 3!
Table 4.1. Metabolic Features of Heterozygous Mice!
!











Free fatty acids (mEq/L)!
Fasted! 1.09 ± 0.19! 1.23 ± 0.09! 1.14 ± 0.13!
Re-fed! 0.19 ± 0.02! 0.20 ± 0.03! 0.21 ± 0.03!
Triglycerides (mg/dL)!
Fasted! 76 ± 6! 84 ± 4! 72 ± 12!
Re-fed! 102 ± 11! 92 ± 7! 121 ± 9!
Cholesterol (mg/dL)!
Fasted! 92 ± 4! 102 ± 5! 96 ± 6!
Re-fed! 92 ± 3! 85 ± 4! 90 ± 3!
Liver cholesterol (mg/g)!
Fasted! 1.66 ± 0.16! 1.56 ± 0.13! 1.75 ± 0.11!
Re-fed! 1.17 ± 0.10! 1.10 ± 0.07! 1.12 ± 0.13!
Table 4.2. Metabolic Features of L-FoxO1 and L-DBD Mice!
!














Fed! 33.2 ± 1.2! 34.9 ± 1.8! 38.0 ± 1.0! 36.0 ± 2.8!
Fasted! 33.7 ± 0.3! 33.3 ± 1.6! 34.3 ± 1.0! 33.3 ± 1.1!
Glucose (mg/dL)!
Fed! 218 ± 3! 223 ± 2! 190 ± 4! 203 ± 7!
Fasted! 241 ± 14! 242 ± 10! 214 ± 7! 220 ± 9!
Insulin (ng/mL)!
Fed! 2.87 ± 0.22! 2.43 ± 0.55! 4.22 ± 0.95! 6.66 ± 3.15!
Fasted! 2.58 ± 0.30! 2.11 ± 0.27! 2.68 ± 0.32! 2.25 ± 0.42!
Free fatty acids (mEq/L)!
Fed! 0.76 ± 0.04! 0.72 ± 0.08! 0.71 ± 0.05! 0.79 ± 0.06!
Fasted! 0.71 ± 0.06! 0.70 ± 0.05! 0.74 ± 0.05! 0.71 ± 0.07!
TG (mg/dL)!
Fed! 113 ± 11! 118 ± 12! 104 ± 7! 118 ± 7!
Fasted! 59 ± 6! 67 ± 6! 53 ± 3! 63 ± 9!
Cholesterol (mg/dL)!
Fed! 296 ± 21! 344 ± 27! 364 ± 28! 428 ± 42!
Fasted! 337 ± 34! 342 ± 27! 398 ± 31! 376 ± 55!
Table 4.3. Metabolic Features of WTD-reared L-FoxO1 and L-DBD Mice!
!




Gene Ontology Category! P value! No. of genes!
Lipid metabolic process! 2.1 x 10-7! 32!
Steroid metabolic process! 3.0 x 10-7! 15!
Oxidation-reduction! 1.0 x 10-6! 30!
Alcohol metabolic process! 1.3 x 10-6! 21!
Monocarboxylic acid metabolic process! 6.4 x 10-6! 17!
Oxo/carboxylic acid metabolic process! 8.6 x 10-5! 21!
Cellular ketone metabolic process! 1.2 x 10-4! 21!
Regulation of catalytic activity! 4.5 x 10-4! 19!
Sterol homeostasis! 7.2 x 10-4! 5!
Lipid metabolic process! 1.3 x 10-5! 26!
Oxidation-reduction! 6.2 x 10-5! 24!
Steroid metabolic process! 8.6 x 10-5! 11!
Monocarboxylic acid metabolic process! 3.8 x 10-4! 13!
Cellular lipid metabolic process! 4.2 x 10-4! 18!
Cholesterol metabolic process! 4.2 x 10-4! 7!
Brown fat cell differentiation! 6.6 x 10-4! 5!
Sterol metabolic process! 7.1 x 10-4! 7!




















Table 4.4. Gene Ontology Analysis: Control vs. L-FoxO1!
!
Analysis was performed using DAVID Bioinformatics Database.!
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Gene Ontology Category! P value! No. of genes!
Steroid metabolic process! 8.3 x 10-9! 17!
Alcohol metabolic process! 2.4 x 10-8! 24!
Sterol metabolic process! 4.6 x 10-7! 11!
Cholesterol metabolic process! 1.9 x 106! 10!
Lipid metabolic process! 3.3 x 10-6! 30!
Oxidation-reduction! 5.0 x 10-6! 29!
Oxo/carboxylic acid metabolic process! 1.2 x 10-4! 21!
Monocarboxylic acid metabolic process! 1.3 x 10-4! 15!
Steroid biosynthetic process! 1.5 x 10-4! 8!
Oxidation-reduction! 1.3 x 10-7! 28!
Lipid metabolic process! 3.2 x 10-6! 26!
Steroid metabolic process! 7.4 x 10-6! 12!
Monocarboxylic acid metabolic process! 9.7 x 10-6! 15!
Cholesterol metabolic process! 3.2 x 10-5! 8!
Antigen processing/present. via MHC-II! 4.3 x 10-5! 5!
Oxo/carboxylic acid metabolic process! 4.7 x 10-5! 19!
Sterol metabolic process! 5.9 x 10-5! 8!




















Table 4.5. Gene Ontology Analysis: Control vs. L-DBD!
!
Analysis was performed using DAVID Bioinformatics Database.!
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Gene Ontology Category! P value! No. of genes!
Steroid metabolic process! 7.6 x 10-9! 12!
Steroid biosynthetic process! 1.9 x 10-8! 9!
Sterol metabolic process! 3.6 x 10-8! 8!
Lipid metabolic process! 2.3 x 10-6! 18!
Alcohol metabolic process! 3.8 x 10-6! 13!
Oxidation-reduction! 2.8 x 10-5! 13!
Acute-phase response! 4.1 x 10-5! 5!
Sterol biosynthetic process! 4.1 x 10-5! 5!
Monocarboxylic acid metabolic process! 3.7 x 10-4! 9!
Acute-phase response! 2.2 x 10-6! 6!
Immune response! 7.3 x 10-6! 15!
Response to stimulus! 2.5 x 10-5! 36!
Immune system process! 5.0 x 10-5! 18!
Antigen processing/presentation! 1.9 x 10-4! 4!
Regulation of developmental process! 2.3 x 10-4! 14!
Negative regulation of signal transduction! 2.4 x 10-4! 8!
Defense response! 3.9 x 10-4! 12!




















Table 4.6. Gene Ontology Analysis: L-FoxO1 vs. L-DBD !
!
Analysis was performed using DAVID Bioinformatics Database.!
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Gene Ontology Category! P value! No. of genes!
Homeostatic process! 7.2 x 10-4! 15!
Regulation of biological quality! 9.3 x 10-4! 22!
Alcohol metabolic process! 1.4 x 10-3! 11!
Cellular amino acid derivative metabolism! 1.7 x 10-3! 7!
Regulation of catalytic activity! 2.8 x 10-3! 12!
Steroid metabolic process! 3.2 x 10-3! 7!
Lipid metabolic process! 3.7 x 10-3! 15!
Second messenger signaling! 4.1 x 10-3! 6!
Glycerolipid metabolic process! 6.0 x 10-3! 6!
Cholesterol metabolic process! 2.9 x 10-5! 6!
Sterol metabolic process! 4.6 x 10-5! 6!
Lipid metabolic process! 4.7 x 10-5! 14!
Monocarboxylic acid metabolic process! 6.7 x 10-5! 9!
Oxidation-reduction! 1.5 x 10-4! 13!
Cellular lipid metabolic process! 1.7 x 10-4! 11!
Steroid metabolic process! 1.7 x 10-4! 7!
Oxo/carboxylic acid metabolic process! 7.4 x 10-4! 10!




















Table 4.7. Gene Ontology Analysis: Transcription Factor Mode!
!
Analysis was performed using DAVID Bioinformatics Database using genes significantly!
altered in both L-FoxO1 and L-DBD relative to control but not to each other.!
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Gene Ontology Category! P value! No. of genes!
Oxidation-reduction! 4.2 x 10-4! 7!
Oxo/carboxylic acid metabolic process! 5.7 x 10-3! 5!
Cellular ketone metabolic process! 6.3 x 10-3! 5!
Monocarboxylic acid metabolic process! 7.8 x 10-3! 4!
Alcohol metabolic process! 1.7 x 10-2! 4!
Lipid metabolic process! 2.1 x 10-2! 5!
Immune system process! 3.1 x 10-2! 5!
Negative regulation of signal transduction! 5.0 x 10-5! 6!
Negative regulation of cell communication! 7.4 x 10-5! 6!
Negative regulation of biological process! 7.8 x 10-4! 11!
Immune response! 7.8 x 10-4! 7!
Negative regulation of cellular process! 1.5 x 10-3! 10!
Immune system process! 2.3 x 10-3! 8!
Neg. regulation of response to stimulus! 1.1 x 10-2! 3!
Regulation of developmental process! 1.1 x 10-2! 6!




















Table 4.8. Gene Ontology Analysis: Co-Regulatory Mode!
!
Analysis was performed using DAVID Bioinformatics Database using genes significantly!






























5.1. General Summary of Findings 
Through the work described in this thesis I have undertaken to enrich the current understanding of how 
the liver responds to insulin in both normal and pathophysiologic states. Specifically, my goal was to 
understand the etiology of selective insulin resistance – that is, the dissociation of insulin’s effects on 
hepatic glucose and lipid metabolism. I approached this question through the use of two distinct but 
related hypotheses.  
First, in Chapter 3, I surmised that selective IR represents not a pathogenic paradox, but rather a 
manifestation of the inherent differences in the insulin responsiveness of these processes. In order to test 
this hypothesis, I employed two models of insulin resistance in primary hepatocytes: chronic 
hyperinsulinemia (CHI) and acute competitive antagonism. CHI treatment in vitro showed that it is 
possible to recreate the uncoupling of insulin’s effects on glucose production and de novo lipogenesis 
within the context of the clinically relevant in vivo CHI that marks the run-up to type 2 diabetes. Next, 
treatment of hepatocytes with variable doses of S961, a peptide competitive antagonist of InsR, 
demonstrated that insulin’s suppression of GP and its stimulation of de novo lipogenesis (DNL) follow 
distinct dose-response patterns. The half-maximal dose of S961 to inhibit insulin’s effect on GP was about 
four times greater than its ability to halfway inhibit insulin’s effect on DNL. Taken together, these data 
suggest that hepatic IR in vivo may not only cause but also result from CHI, and that the causal 
relationship between CHI and IR occurs at least in part at the level of InsR itself. These findings 
contravene much of the conventional wisdom that intricate and arcane alterations in cellular metabolites 
or distantly related signaling pathways are required for the pathogenesis even of garden-variety IR [2, 51, 
65, 90, 362, 418, 419]. 
Second, in Chapter 4, I consider another possible culprit behind selective IR, FoxO1, the most 
distal insulin-regulated metabolic effector that is agreed to impact on both glucose and lipid metabolism. 
Despite much phenotypic evidence linking FoxO1 to insulin’s control of these processes, surprisingly little 
is known about the actual mechanisms FoxO1 uses to accomplish them. We therefore took an unbiased, 
genetic approach to the question by taking advantage of the fact that FoxO1 has been shown to act both 
as a transcription factor and as a transcriptional co-regulator. We therefore have developed mice (L-DBD) 
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that possess only DNA binding-defective FoxO1 (FoxO1-DBD) in its liver and compared their phenotype 
and gene expression to wild-type controls and to L-FoxO1 mice that completely lack the protein in 
hepatocytes. We found that FoxO1’s well-established role as an activator of hepatic glucose production 
requires its ability to bind to DNA (i.e., act as a transcription factor). On the other hand, while L-FoxO1 
mice exhibited increased liver TG levels, L-DBD mice were equivalent to controls in this regard. Thus, on 
the whole, FoxO1 regulates hepatic TG metabolism in co-regulatory mode. Interestingly, in spite of this in 
vivo conclusion, primary hepatocytes from both L-DBD and L-FoxO1 mice showed higher rates of DNL 
and lower rates of fatty acid oxidation. Thus, the ability of FoxO1-DBD to properly control liver TG 
metabolism in vivo either does not depend strictly upon regulation of hepatocyte-autonomous DNL or 
FAO or requires input from extrahepatic factors.  
Taken together, these results suggest that selective IR can be a phenomenon inherent to the 
hepatocyte and that FoxO1 may play a dual role in its development. This conclusion is further explored in 
the discussion that follows. 
 
5.2. Primary Hepatocytes: Limitations and Lessons 
5.2.1. Rationale for Using Primary Hepatocytes 
The liver exists at the center of a staggeringly complex web of metabolic regulation; extensive mouse 
genetic work emphasizes the particular importance of liver InsR action in the preservation of whole-body 
metabolic health. As discussed extensively in previous chapters, the liver Insr knockout (LIRKO) mouse 
develops diabetes due to unrestrained glucose production [273, 274]. Mice completely lacking Insr die in 
the perinatal period of extreme hyperglycemia and ketoacidosis. However, restoration of Insr expression 
only in liver and, to a lesser extent, in pancreatic β cells and certain brain regions (Ttr-Insr ; Insr-/- “L1” 
mice) largely reverses these effects [165]. Only about 30% of L1 mice go on to develop diabetes later in 
life versus 100% of neonatal mice with complete Insr knockout [164, 420, 421]. On the other hand, 
reconstitution of Insr expression in Glut4-expressing tissues including skeletal muscle and WAT (GIRKI 
mice) did not result in a notable prolongation of lifespan or reprieve from diabetes [422]. Moreover, rescue 
of Insr expression in neurons alone (NIRKI mice) also did not extend lifespan to adulthood or prevent 
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diabetes [422]. This finding further emphasizes the importance of Insr restoration in liver per se rather 
than in brain in the rescue of the L1 mouse [165, 420, 422]. 
  Despite the indubitable importance of liver insulin action in regulating global metabolism and 
preventing diabetes, studying the mechanisms of liver insulin action and resistance in vivo is fraught with 
complications. For example, L1 mice remain markedly hyperinsulinemic and are unable to normally 
suppress HGP during a hyperinsulinemic-euglycemic clamp in spite of normal Akt phosphorylation and 
G6pc/Pck1 expression [420]. It is therefore possible that this apparent defect in liver metabolism is due to 
defects in other, Insr-deficient tissues (e.g., unchecked WAT lipolysis, severely decreased skeletal muscle 
glucose uptake) rather than to primary defects in the liver itself [420]. We therefore undertook to address 
the liver-autonomous aspects of insulin action and resistance. We made extensive use of isolated primary 
hepatocytes to measure the production of glucose and lipids in response to insulin as well as associated 
changes in gene expression. Although we have made significant progress using this model, it is 
necessarily imperfect. In this spirit, our data indicate that the utilization of primary hepatocytes represents 
a double-edged sword; this system does not faithfully recapitulate many important facets of in vivo 
metabolism, but in certain cases this apparent disadvantage has actually proved educational.  
 
5.2.2. Primary Hepatocyte Studies of Glucose Metabolism 
The downsides of using primary hepatocytes, especially from mice, are many and varied, even aside from 
the obvious differences between the signaling and nutrient inputs available to hepatocytes in situ as 
opposed to in culture. If we first consider glucose production, for example, we mentioned in Chapter 1 that 
about 75% of glucose production over the first 16 h or so of fasting results from glycogenolysis and the 
rest from gluconeogenesis. In fact, the most acute effects of glucagon (analogous to cAMP treatment in 
our ex vivo experiments) are entirely attributable to enhanced glycogenolysis [423]. On the other hand, 
work form our laboratory using this glucose-production system has indicated that only about 10% of 
glucose production from primary hepatocytes results from glycogenolysis [370], similar to findings by 
other groups [424]. Whether or not this speaks to an inherent difference in the source of glucose for 
release between liver and primary hepatocyte or merely to the obvious differences in ambient conditions, 
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the conclusions we draw from these experiments are likely more germane to gluconeogenesis (i.e., the 
minor source of HGP in physiologic fasting) than to glycogenolysis.  
There are, however, several upsides to this complication. Although in human liver 
gluconeogenesis plays a minor role in HGP under normal conditions, both the relative and absolute rates 
of gluconeogenesis are significantly increased in patients with diabetes [103, 104, 106, 425]. Similar to 
the case of increased HGP in the L1 mouse, it has been unclear whether the increased gluconeogenesis 
of diabetes is attributable principally to mass action by increased influx of gluconeogenic precursors from 
other insulin-resistant tissues (i.e., a more passive role for the hepatocyte) or if there is some primary 
derangement in the liver’s handling of these substrates [126, 426, 427]. As our studies were performed 
within a milieu of constant glucose, lactate, and pyruvate levels, we can state that the derangement in 
gluconeogenesis in our cell-culture models of hepatic IR is inherent to the hepatocyte. Both CHI and 
acute InsR antagonism hinder the ability of insulin to blunt cAMP-induced glucose production.  Indeed, 
these experiments support an important role of insulin in the regulation of gluconeogenesis in hepatocytes 
even if not so readily in vivo. In fact, although several previous studies have found a similar effect as ours 
of glucagon mimetics on GP in primary hepatocytes, most of these do not remark on its suppression by 
insulin [145, 171, 424, 428, 429]. Several in vivo studies, mostly in dogs undergoing hyperinsulinemic-
euglycemic clamp, have cast doubt on the regulation of gluconeogenesis by insulin [94, 114, 399]. These 
reports have generally concluded that an effect of insulin on gluconeogenesis is transient and requires 
very high concentrations of insulin. Although these studies were performed with great rigor, they do not 
speak directly to processes in the hepatocyte itself. Even studies in whole liver in mice do not consistently 
reveal insulin suppression of gluconeogenesis [112]. The apparent inconsistency with our data may also 
stem from physiologic differences between rodents and large mammals [423, 430].  
Although our data support a dynamic regulation of gluconeogenesis by cAMP (i.e., glucagon) vs. 
insulin that can be perturbed by IR, the most important mechanisms remain unclear. The expression of 
G6pc and Pck1, the two rate-limiting enzymes of gluconeogenesis, are often used as a surrogate marker 
of HGP, but we found a poor correlation between transcript levels and observed GP. Although treatment 
of hepatocytes with InsR antagonist revealed a dose-dependent change in G6pc and Pck1 expression 
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that generally paralleled GP, the IC50 values for gene expression versus GP differed by an order of 
magnitude (Fig. 3.6). Despite this finding, one may still argue that the discrepancy between gene 
expression and GP is merely a quantitative matter. However, several other experiments revealed 
qualitative differences between the regulation of G6pc/Pck1 expression and GP, strongly suggesting that 
the dynamics of these processes are not synchronized within the temporal context of the experiment. In 
all of our GP experiments in both Chapters 3 and 4, cAMP treatment increases G6pc expression by at 
least 30-fold even as GP increases only by 50-100%. In our model of CHI, there was no alteration in 
basal or cAMP-induced GP even as the effect of insulin was nearly lost (Fig. 3.2A). On the other hand, 
both basal and especially cAMP-induced G6pc and Pck1 expression were markedly decreased, the latter 
by up to two thirds (Fig. 3.2B). Perhaps even more strikingly, primary hepatocytes from L-FoxO1 and L-
DBD mice exhibited a tenfold decrease in cAMP/dex-stimulated G6pc expression despite only a roughly 
25% decrement in GP (Fig. 4.8A-C). Interestingly, in vivo G6pc expression was decreased by about 25% 
in L-FoxO1 mice, commensurate with the decreased AUC of the glucose and pyruvate tolerance tests 
(Fig. 4.5). Further indicative of a dissociation between FoxO1-mediated GP and G6pc expression, we 
found G6pc expression to be decreased by about two thirds even in cells from Foxo1-heterozygous mice 
in spite of no defect in GP (Fig. 4.3A-C). As discussed earlier, FoxO1-associated GP has customarily 
been ascribed to its incontrovertible regulation of G6pc; that we have managed to quantitatively and 
qualitatively uncouple these events lends further credence to the hypothesis that FoxO1 affects 
gluconeogenic/glycolytic flux by as yet uncharacterized means.  
To reemphasize, we can be sure that FoxO1 is a key regulator of HGP, but we are skeptical of 
the idea that this occurs primarily through its regulation of G6pc. Finally, both our in vivo and primary 
hepatocyte data cast doubt on the importance of Ppargc1a expression for glucose production despite 
early enthusiasm in its favor [173, 372, 431]. Not only is expression of the gene in hepatocytes unaffected 
by insulin treatment – quite unlike its marked repression by re-feeding, and therefore also representing a 
dual drawback/benefit of primary hepatocytes – but its expression is not decreased in L-DBD mice even 
as GP is. 
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Overall, these conclusions regarding transcriptional regulation of gluconeogenesis are nicely 
concordant even with several in vivo models. As mentioned earlier, even liver-specific deletion of G6pc or 
Pck1 expression do not cause a physiologic impairment in glucose production due to compensation by 
other tissues [379, 380]. Moreover, although the expression of G6pc and Pck1 are clearly regulated by 
insulin, the activity levels of the enzymes are not well correlated with insulin action; flux through 
gluconeogenesis to G6P occurs even in the fed state [94, 114]. Even in the context of diabetes, when 
gluconeogenesis per se is elevated, studies of human liver samples did not reveal differences in G6pc or 
Pck1 expression [381]. It therefore appears that although G6Pase and PEPCK are essential to the 
biochemical process of glucose production, physiologic fluctuations in their mRNA levels may not be as 
important as once thought to the acute and subacute regulation of HGP. 
 
5.2.3. Primary Hepatocyte Studies of Lipid Biosynthesis 
The importance of differences between whole liver and primary hepatocytes with respect to de novo 
lipogenesis has already been extensively discussed in Chapter 4 and is revisited in Section 5.3.1 below. 
Aside from these phenomenological considerations, however, it is important to understand why these in 
and ex vivo differences occur. There are several different causes that are relevant to these studies. 
 First, as has been discussed, the major transcriptional control of lipogenesis by insulin occurs in 
vivo through the cleavage-induced activity of SREBP-1c [237, 276]. However, as discussed in Chapter 3, 
we found considerable variability in insulin’s regulation of SREBP-1c cleavage. This is not surprising, 
however, as mouse primary hepatocytes are generally considered a poor venue for the study of SREBP-
1c dynamics [218, 226]. Whereas SREBP-1c is the dominant SREBP-1 isoform in intact liver, in cultured 
cells including hepatocytes, SREBP-1a appears to predominate [226]. Even though SREBP-1a is far 
more powerful a driver of lipogenesis both in liver and primary hepatocytes than is the 1c isoform, its 
activity is not regulated by insulin [211, 226, 432]. Although we did not measure mRNA or protein levels of 
SREBP-1a in our studies, it is unlikely that 1a could account for the acute induction of DNL we observe 
following insulin treatment. Even the SREBP-1c that does remain in mouse hepatocytes loses its 
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responsiveness to insulin almost immediately after explantation, suggesting the requirement for 
extrahepatic inputs in regulating this system [218]. 
It is for these reasons that we proposed in Chapter 3 a modification to the Brown and Goldstein 
model of selective IR, in which the relative preservation of insulin-stimulated DNL proceeds via SREBP-1c 
activation [276]. That is, even though it may account for the slight increase in basal DNL in CHI-treated 
cells vs. control, it would not likely explain the retained acute increase in DNL, especially as we did not 
detect increases in expression of SREBP-1c target genes such as Fasn or Srebf1c itself over this time 
period [198]. We therefore hypothesize that insulin’s acute regulation of DNL in mouse primary 
hepatocytes proceeds via posttranslational modifications (such as of ACC1, PFK-2, and ACL) that affect 
carbon flux within the hepatocyte [48, 94, 158, 258]. Interestingly, however, rat hepatocytes differ from 
mouse in retaining a considerable degree of insulin-sensitive SREBP-1c cleavage [218]. Although several 
studies have modeled CHI in rat hepatocytes, none to date have directly studied the effect on SREBP-1c 
cleavage [285, 325, 432]. We have performed a pilot experiment in rat primary hepatocytes that showed a 
preservation of SREBP-1c cleavage in response to acute insulin following CHI treatment, however we 
have not yet assessed DNL in this system. 
Aside from SREBP-1c, there are numerous other potential confounders of insulin-stimulated DNL 
in mouse primary hepatocytes. As will be further discussed below, insulin induction of Gck expression via 
FoxO1 inhibition apparently requires some potentiating factor outside of the liver. One possibility in this 
vein is neuronal modulation, as acute infusion of insulin into the head arteries of dogs resulted in 
increased Gck expression in liver [433]. Furthermore, blockade of hypothalamic insulin signaling 
prevented insulin’s induction of Gck expression in liver [399]. Interestingly, this effect may be mediated 
through a downregulation of SHP (Nr0b2), a negative regulator of Gck expression that was identified as a 
FoxO1 target by our RNA-seq analysis and previous studies [168, 423, 434]. Additionally, our laboratory 
has shown that targeted deletion of Foxo1 in AgRP neurons decreases fasting Gck expression in liver 
[435]. Studies are currently underway in on mice lacking Foxo1 both in liver and in AgRP neurons. Finally, 
we have demonstrated that FoxO1 (and therefore, insulin) regulates lipid metabolism in part through 
modulation of bile acid signaling [168], a regulatory circuit not present in isolated hepatocytes.  
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5.2.4. Primary Hepatocyte Studies of Fatty Acid Oxidation 
Those considering the relationship between insulin action and hepatic lipid metabolism generally focus on 
lipid biosynthesis as the primary driver of liver lipid levels. However, as illustrated starkly by poorly 
controlled T1DM patients, insulin also plays an important role in the regulation of fatty acid oxidation. As 
mentioned in the introduction, however, it has been unclear whether the functional inhibition of FAO by 
insulin results primarily from blunted WAT lipolysis or due to direct effects on liver and/or skeletal muscle. 
By addressing this issue in primary hepatocytes, we have begun to parse out the relative contribution of 
liver itself in the absence of acute changes in FFA supply [436]. Specifically, we found that FoxO1 
ablation reduces FAO by over half, suggesting that insulin may exert a primary inhibition of FAO through 
FoxO proteins in the liver in addition to its well-documented effects on WAT lipolysis. Indeed, Insr-/-;  
l-Foxo1 mice have normal levels of β-hydroxybutyrate despite increased circulating FFA [145]. We did 
not, however, directly assess the effect of acute insulin treatment on FAO in primary hepatocytes. 
That insulin might suppress FAO directly in liver is also supported by tracer studies in humans 
with obesity and/or NAFLD that suggest increased rates of FAO [418, 437-440]. (Apparently, even though 
rates of FAO are increased in these patients, it is insufficient to lower liver TG levels to normal.) Although 
this may merely be due to increased delivery of FFA from WAT lipolysis, garden-variety IR is not strictly 
associated with tonically elevated fasting circulating FFA [441]. Indeed, adipocyte lipolysis is exquisitely 
sensitive to insulin – in fact, more so than any other major physiologic process [426, 442]. It is for this 
reason that even many patients with severe IR due to mutations in Insr do not develop DKA [65]. In a 
striking example of selective IR on a global scale, even moderate residual InsR action in these patients 
can evidently suppress lipolysis enough to keep FFA levels from creeping up into the danger zone [65, 
270]. Only in the most severe cases of absolute (e.g., untreated type 1 diabetes) or relative (e.g., Rabson-
Mendenhall syndrome) insulin deficiency does DKA arise, presumably due principally to unchecked 
lipolysis rather than to a primary defect leading to increased hepatic FAO [183, 443]. Going forward, it 
would be of interest to test the effects of CHI or S961 treatment on insulin inhibition of FAO in primary 
hepatocytes. CHI treatment especially may prove a useful model for teasing out the acute vs. chronic 
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effects of insulin on FAO as it would be expected to lead to derepression of FoxO1, thereby helping to 
elucidate its contribution to the process. 
5.3. Toward a Mechanistic Understanding… 
5.3.1. Identifying the True “Branch Point” in Selective IR 
Whether qualitative or quantitative, the defect in CHI-induced IR is at the level of InsR itself. Selective IR, 
on the other hand, has generally been attributed to postreceptor defects [65, 444]. Many different potential 
explanations have been invoked, generally focusing on identifying a discrete branch point beyond which 
the common upstream mediators of insulin signaling diverge to regulate disparate downstream metabolic 
processes [65, 90, 213, 218, 276, 295, 306]. These models generally posit that one branch (i.e., 
controlling hepatic glucose metabolism) becomes resistant to the effects of insulin while the other (i.e., 
controlling lipid metabolism) remains relatively sensitive, potentiated by hyperinsulinemia. Thus, in these 
cases, hyperinsulinemia is largely the result of altered glucose metabolism rather than a cause. These 
models generally ignore the precise mechanism whereby the sensitive vs. resistant pathways are 
differentially activated, although the implication is that this regulatory bifurcation requires signaling input 
from nebulous other pathways. Gonzalez, et al. [305] took a more sophisticated mechanistic approach by 
studying a model of CHI in cultured adipocytes, demonstrating that activation of downstream branches 
are selectively regulated by the different isoforms of Akt. Even this study, however, evaded the question 
of how exactly CHI induces IR in Akt1/2 activation and did not address the possibility of differential 
regulation of IRS1/2 or PI3K [305]. Another valid view that has been articulated posits that the concept of 
“selective IR” is somewhat misguided. That is, although insulin is certainly a key regulator of glucose 
homeostasis, its regulation of lipid metabolism requires a complex crosstalk between different tissues that 
is in some ways independent of insulin and therefore difficult to classify as “sensitive” or “resistant” [362].   
Our studies, on the other hand, have indicated that selective IR can be both hepatocyte-
autonomous and related directly to alterations in InsR number and/or function. Thus, selective IR does not 
require input from other signaling molecules or pathways; it also rebuts the implication that InsR plays a 
somewhat passive role in the development of selective IR [276]. Thus, rather than dividing IR along 
160 
receptor-level versus postreceptor lines, it behooves us to better understand how common mediators in 
both pathways may differentially regulate glucose vs. lipid metabolism. In this thesis we have employed 
three different models of hepatic insulin resistance; the data offer novel insights into the mechanism by 
which this altered InsR action translates into disparate effects on glucose vs. lipid metabolism. We 
therefore revisit our discussion of the proximal insulin-signaling pathway from Section 1.6.5 in order to 
integrate what we have learned from the experiments in this work. 
IRS1/2 
First, we consider the role of the signaling mediators most proximal to InsR, IRS1/2. Although 
investigators have suspected that IRS1 and IRS2 exert differential control over glucose vs. lipid 
metabolism, much of the data have been conflicting (see Section 1.6.5). Our studies unfortunately do not 
provide much in the way of reconciliation. Previous modeling of CHI in rat primary hepatocytes revealed a 
selective downregulation of IRS2 at the mRNA and protein levels, suggesting that intact insulin signaling 
to SREBP-1c proceeds largely via IRS1 [295]. In our model, however, we found decreases in protein 
levels of both IRS1 and IRS2, similar to findings by another group [303] and consistent with observations 
in the livers of several hyperinsulinemic animal models [303, 445]. Insulin can downregulate IRS1 by 
inducing its proteasomal degradation via a PI3K- and mTORC1-dependent mechanism [303, 446-448], 
although similar studies on IRS2 have yielded conflicting data [303, 449]. Downregulation of IRS2 by 
insulin appears to occur primarily at the transcriptional level [295, 303], although we did not find any 
difference on average in Irs2 mRNA levels in our CHI model. Overall, the similar decreases in both IRS1 
and IRS2 do not allow us to discern any functional differences in their roles in GP vs. DNL in this system. 
A further important aspect of IRS biology is its regulation by FoxO proteins. Our original study 
of the L-FoxO1 mouse demonstrated reductions in fasting-induced expression of Irs2, and FoxO1-
deficient primary hepatocytes exhibited reductions in both Irs1 and Irs2 expression [145]. This 
regulatory scheme suggests a homeostatic loop whereby increased insulin signaling inhibits FoxO1, 
thereby decreasing IRS levels and preventing overstimulation of downstream pathway components; the 
subsequent decline in insulin signaling through InsR leads to the derepression of FoxO1 allowing it to 
restore IRS levels [145, 
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247, 304, 360]. This therefore represents an additional feedback layer in insulin signaling on top of InsR 
downregulation. Our studies confirm a key role for FoxO1 in the expression of Irs2, as fasted L-FoxO1 
livers demonstrated a ~50% decrease in its mRNA. Moreover, Irs2 represents a direct transcriptional 
target of FoxO1, as Irs2 levels were equally decreased in fasted L-DBD livers. Interestingly, a study in 
MEFs deficient in either Irs1 or Irs2 indicates that the latter is required for the phosphorylation of Akt and 
FoxO1 while the former is dispensable, further substantiating an IRS2 à  FoxO1 à  IRS2 
homeostatic loop [304, 360]. 
Akt 
Our studies in primary hepatocytes verify that Akt signaling is required for mediating insulin’s 
effects on both glucose and lipid metabolism (Fig. 3.8), consistent with in vivo data [112, 158, 167, 306]. 
While data such as these have been used in the past to support a neatly bifurcating model of insulin 
signaling (i.e., glucose and lipid arms largely separate), our pharmacologic inhibition of Akt with Akti-1/2 
results in a total abrogation of Akt1/2 signaling [327]. It therefore remains possible that Akt1 and Akt2 
signal differentially to glucose vs. lipid metabolism, as proposed in Chapter 1 and buttressed by 
observations in an adipocyte model of CHI [305]. Nevertheless, the reliance of both glucose and lipid 
metabolism on the combined actions of Akt1 and Akt2 suggest that signaling pathways diverging 
upstream (e.g., MAPK pathway) do not play a critical role. This result has been suggested by previous 
studies [213, 218] but these prior reports do not report directly on GP or DNL. Another potential 
interpretation is that Akti-1/2 does not inhibit both isoforms with equal potency. 
Aside from potential isoform-specific actions of Akt, the kinase’s functional outputs may be 
differentially regulated on the basis of the relative phosphorylation levels of Thr 308 and Ser 473 (see 
Section 1.6.5). Indeed, we have determined in Chapter 3 that the phosphorylation of Akt at these two sites 
does display some differential sensitivity to insulin (Fig. 3.5). The calculated IC50 for the inhibition of Thr 
308 phosphorylation in response to 10 nM insulin by S961 treatment is 0.87 nM while that for Ser 473 is 
2.69 nM. Thr 308 phosphorylation is therefore approximately three times less sensitive to this dose of 
insulin than is phosphorylation at Ser 473. Thus, we expect processes that can be regulated efficiently by 
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Akt phosphorylated at Ser 473 but not at Thr 308 to proceed more potently while those requiring full 
activation of Akt at both sites would be stunted, an example of selective IR.  
Such a situation recalls the L-Pdk1KO mouse model, which interferes with Thr 308 but not Ser 
473 phosphorylation and exhibits deficient phosphorylation of FoxO1 and S6K while that of GSK3β 
remains mostly intact [319]. Interestingly, however, we observed largely the opposite pattern in our 
experiments. That is, phosphorylation of FoxO1 qualitatively paralleled that of Ser 473, such that at 10-9 M 
S961, both were nearly maximal. On the other hand, at that concentration of inhibitor, both 
phosphorylation of Thr 308 and GSK3β were less than half maximal. That FoxO1 phosphorylation 
appears to be relatively more responsive to insulin than other targets is consistent with the CHI model of 
Gonzalez, et al. [305] and in keeping with our own observations regarding the exquisite sensitivity of 
FoxO1 localization even to glancing doses of insulin [143, 149, 150, 450]. Such a conclusion is surprising 
given that FoxO1 in primary hepatocytes appears to be relatively exclusively a mediator of glucose and 
not lipid synthesis, while we found the latter to be more sensitive to insulin than the former. Again, we 
found very limited responsiveness of SREBP-1c cleavage to S961 treatment. Together, these 
observations suggest that the most important mediators of insulin’s acute effect on DNL in primary 
hepatocytes may be still more insulin-sensitive Akt target(s) that we have not assessed. 
As discussed above, FoxO1 participates in a homoestatic loop regulating insulin action via IRS; 
an obligate intermediate in this pathway is Akt. Indeed, FoxO1 induction of IRS2 would be expected to 
increase Akt phosphorylation, as observed. A constitutively active mutant of FoxO1 has been shown to 
increase basal Akt phosphorylation independently of its effects on IRS2, as this effect proceeds via a co-
regulatory mechanism [247] while we now know that its regulation of Irs2 expression does not (Fig. 
4.7G). Our previous work implicated FoxO1 inhibition of the pseudokinase tribble-3 (Trb3), a negative 
regulator of Akt phosphorylation, as the mechanism responsible [247, 451], although the regulation of 
Trb3 expression by FoxO1-DBD was not directly tested. Whether through IRS and/or Trb3, we expect 
Akt phosphorylation to be dampened in the absence of FoxO1. Consistent with this expectation, primary 
hepatocytes lacking FoxO1 do display a notable decrease in insulin-stimulated Akt phosphorylation. 
Interestingly, L-DBD primary hepatocytes have reproducibly shown a defect in Akt phosphorylation even 
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relative to L-FoxO1, suggesting either that Trb3 is not actually a FoxO1 co-regulatory target or that Trb3 is 
not the key mediator of the effect. That insulin’s induction of DNL in L-DBD hepatocytes remained normal 
in spite of the stark decrease in Akt phosphorylation serves as further evidence of the sensitivity of this 
process to insulin. 
The experiments contained in this work do not, however, speak to a functionally significant FoxO1 
à Akt connection in the healthy liver. Although re-feeding-induced Akt phosphorylation (at both sites) was 
decreased in L-FoxO1 and L-DBD livers (Fig. 4.7A-C), this difference disappeared after matching 
samples for mean insulin levels (Fig. 4.7D-F). Intravenous insulin injection also did not reveal any 
difference in hepatic Akt phosphorylation (Fig. 4.6). On the other hand, in the fasted liver, basal 
phosphorylation of Akt at Thr 308 but not at Ser 473 was higher in L-FoxO1 than in control or L-DBD mice 
(Fig. 4.7A-C); this is the opposite of our expectations based on Irs2 expression (Fig. 4.7G). It is tempting 
to speculate that the phenotypic correlation of this finding with differences in Gck expression and liver TG 
reflects differential Akt signaling on the basis of Thr 308 phosphorylation but we have no further data to 
imply causation. The potential importance of FoxO1 feedback may be magnified under conditions of IR, 
as Akt phosphorylation at Thr 308 and especially at Ser 473 were both decreased in the livers of L-FoxO1 
and L-DBD WTD-fed mice versus control. It would be of interest to assess whether the relative worsening 
of Ser 473 vs. Thr 308 phosphorylation produces functional consequences such as altered HGP, although 
we did not detect any significant changes in gluconeogenic gene expression (data not shown). 
Other Potential Mediators 
Other signaling elements downstream of InsR have also been invoked to explain selective IR. Semple, 
et al. (2009) [65] proposed, for example, that selective IR results from a branching downstream of IRS1/2 
wherein Akt signals to FoxO1 to regulate HGP while the path toward DNL proceeds via protein kinase C-λ 
(PKCλ) activation of SREBP-1c. This model is based on studies in demonstrating that overexpression of 
PKCλ increases SREBP-1c and Fasn levels in primary hepatocytes and liver [452, 453]. Liver-specific 
PKCλ-null mice, on the other hand, show decreased expression of SREBP-1c and its lipogenic targets as 
well as decreased TG content [419, 453]. The interpretation of these models, however, is complicated by 
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alterations in circulating insulin levels [90, 419, 453]. Moreover, we know both from experiments here and 
elsewhere using Akti-1/2 [213, 218] and from past studies in mice [112, 158, 167, 306] that Akt signaling 
is required for proper regulation of DNL in addition to HGP. The mechanism linking PKCλ to InsR also 
remains questionable [452, 454].   
Another possible mediator of selective IR is GSK3β. Although this enzyme has classically been 
envisioned as a negative regulator of glycogen synthesis, recent studies have found that both liver-
specific deletion of the protein [455] and expression of a constitutively active form [112] have no effect on 
hepatic glycogen metabolism in vivo, although in the former case this may be due to compensation by 
GSK3α [456]. (GSK3 activity appears to be more important for regulation of skeletal muscle glycogen 
metabolism [455, 457].) On the other hand, as described in Chapter 1, GSK3β may play a role in DNL via 
negative regulation of SREBP-1c stability [185, 215, 219, 220, 458]. Thus, a selective retention of insulin’s 
inhibition of GSK3β would be expected to enhance SREBP-1c signaling and thereby increase DNL 
especially in the face of hyperinsulinemia [185]. Potentially arguing against this mechanism, treatment of 
rat primary hepatocytes with a GSK3β inhibitor had little to no effect on Srebf1c mRNA, the expression of 
which is an indicator of SREBP-1c activity [213, 459]. In fact, the inhibitor had a greater effect to decrease 
Pck1 mRNA, suggesting more of an effect on the glucose than the lipid arm [213]. Furthermore, liver-
specific deletion of GSK3β revealed no metabolic abnormalities in terms of glucose or lipids [455]. We 
have a conducted pilot experiments to test this hypothesis in CHI by infecting cells with an adenovirus 
encoding a constitutively active GSK3β mutant but the data were not consistent with the hypothesis.   
Rather, the data reported in this thesis add considerably to the fund of knowledge regarding the 
dual regulation of hepatic glucose and lipid metabolism by FoxO1. We propose that FoxO1 (as well as 
other FoxOs) may itself be a key mechanistic link between the increased HGP and DNL of selective IR. In 
other words, again, rather than envisioning selective IR only as the product of a bifurcation in the InsR 
pathway, we see it potentially as arising parsimoniously at least in part from altered regulation of this 




5.3.2. FoxO1: A Bridge Not Quite Far Enough 
As discussed in Chapter 1, the prevailing model of insulin signaling anoints Akt as the most distal step in 
the InsR cascade at which insulin’s control of glucose and lipid metabolism are unified [90]. This view, 
however, is inconsistent with repeated observations from our laboratory and others demonstrating FoxO1, 
a substrate of the Akt kinase, as playing a role in both metabolic arms [2, 90, 155]. Indeed, the L-FoxO1 
mouse, completely lacking FoxO1 in hepatocytes, exhibits both decreased HGP and increased liver TG 
content, likely due to increased DNL and decreased FAO. Thus, in a reductionist sense, the phenotype of 
the L-FoxO1 mouse represents the inverse of the LIRKO mouse [202, 273, 274]; the pure IR of InsR 
deficiency could be wholly attributable to FoxO1 hyperactivity. Though oversimplified, the juxtaposition of 
L-FoxO1 and LIRKO models is salient in light of the demonstrated genetic epistasis between Foxo1 and 
Insr, Irs1/2, and Akt1/2 described in Chapter 1 [145, 166, 167]. Indeed, even in the model of acute, 
acquired IR via InsR antagonist treatment employed in this thesis reveals a close relationship between 
relative FoxO1 phosphorylation and the insulin responsiveness of GP and DNL (Fig. 3.2). 
These observations might lead one to redraw the typical diagram of the proximal InsR signaling 
cascade to include FoxO1 as well. Such a remodeling, however, may be a bit premature, for although 
FoxO1 represents a downstream bridge between the glucose and lipid arms, several caveats highlighted 
by this thesis currently imperil the crossing. As discussed in Chapter 1, insulin signaling regulates DNL 
both at the transcriptional and posttranslational levels. The effect of insulin to stimulate DNL in our 
experimental setup likely proceeds largely due to posttranslational effects alone, as lipogenic gene 
expression in mouse primary hepatocytes, including Srebf1c and Gck, is fairly unresponsive to insulin 
(see Section 5.3; Fig. 3.1E) [218, 226]. This explains, at least in part, why we generally see increases 
only of up to 70% in DNL in response to insulin in primary cells compared to the roughly fivefold increase 
in DNL due to re-feeding over a similar time period in vivo [253]. An exception may lie in the increased 
basal expression of Gck and Srebp1c following CHI treatment, consistent with the augmented basal DNL 
in CHI-treated cells (Fig. 3.1D-E); the normal insulin treatment in our DNL assays is for a fraction of the 
time and at one tenth of the dose of CHI treatment. Nevertheless, WTD feeding of wild-type mice (i.e., 
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driving CHI in vivo) results in constitutively increased Gck expression in liver with reduced fasting/feeding 
fluctuations. 
Unlike tampering with InsR function, dysregulation of FoxO1 does not appear to greatly impact 
upon normal regulation of DNL in isolated hepatocytes. CHI treatment, which results in a loss of insulin-
stimulated phosphorylation of FoxO1 and therefore unrestrained FoxO1 activity, was not associated with 
any defect in basal or insulin-stimulated DNL (Fig. 3.1A,D); in fact, both were higher following CHI 
treatment. Conversely, although in vivo studies indicate that loss of FoxO can enhance insulin-stimulated 
DNL [245], we find only a non-statistically significant ~35% increase in TG synthesis in L-FoxO1 primary 
hepatocytes compared to controls (Fig. 4.9G). Moreover, despite the higher baseline, L-FoxO1 (and L-
DBD) cells exhibit the same proportional DNL response to insulin as control cells. This implies that the 
posttranslational modifications activated by insulin treatment – and that appear to be part of what is 
paradoxically “preserved” in selective IR – are still operational in the absence of FoxO1. Thus, it appears 
that FoxO1’s major role in the regulation of DNL is at the transcriptional level, but that this comes into play 
mainly in the context of intact liver. The non-hepatocyte-autonomous nature of FoxO1’s transcriptional 
control of DNL is echoed by our observation that basal Gck expression is increased following CHI 
treatment (Fig. 3.1E), a time when FoxO1 activity is expected to be unrestrained (Fig. 3.1A). The slight 
increase in DNL in the absence of FoxO1 therefore likely reflects alterations that are cell autonomous, 
such as G6pc expression and/or even GP as a whole. Indeed, as discussed extensively in Chapter 4, we 
hypothesize that the discrepancy between in vivo and ex vivo hepatocellular lipid handling in the L-FoxO1 
mouse reflects on the nature of Gck vs. G6pc/GP regulation by insulin generally and FoxO1 in particular 
[253].  
Our understanding does remain incomplete, however, as liver-specific deletion of Akt2 decreases 
DNL and liver TG accumulation despite the expectation of increased FoxO1 activity [158]. Even 
simultaneous deletion of liver Foxo1, which on its own results in increased DNL and liver TG, does not 
overcome the decrease in DNL and liver TG content due to loss of Akt2 [158]. The decrease in DNL in the 
absence of hepatic Akt2 was proposed to be due in part to decreased activation of the mTORC1 à 
SREBP-1c pathway, but that this alone was not sufficient to explain the mouse’s phenotype [158]. Rather, 
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the authors of this study point to decreased Akt-mediated expression and phosphorylation of ATP citrate 
lyase (ACL) [158], an enzyme that participates in lipogenesis by facilitating the shuttling of acetyl-CoA 
from the mitochondrion to the cytosol [460]. 
The compendium of these data supports our hypothesis of a three-pronged control of hepatic 
lipogenesis by Akt (Fig. 5.1). First, as described in Chapter 1, insulin exerts posttranslational control over 
carbon trafficking through the hepatocyte, including via removal of phosphates placed by PKA and by Akt 
phosphorylation of ACL [158, 461, 462], among others. The inability to properly regulate these pathways 
in the absence of Akt2 may account for the aforementioned impairment in DNL [158]. We suspect that this 
pathway is largely responsible for insulin’s acute induction of DNL in primary hepatocytes and may be 
preserved in selective IR. Second, representing the now-classic pathway of transcriptionally controlled 
lipogenesis is stimulation of SREBP-1c cleavage and expression via Akt’s activation of mTORC1 and S6K 
[213, 215, 217, 218]. We believe that upregulation of this pathway underlies the increase in basal DNL we 
observe in CHI-treated primary hepatocytes and thus is also an important contributor to the phenotype of 
selective IR.  Finally, owing in large part to the work of Rebecca Haeusler [253], we now understand that 
Akt’s inhibition of FoxO facilitates DNL by reversing its dichotomous regulation of Gck and G6pc. This 
thesis extends our understanding of this process by indicating that the FoxO1 à ê Gck à ê DNL 
pathway is largely regulated by extrahepatic factors while the putative FoxO1 à é G6pc/GP à é DNL is 
intrinsic to the hepatocyte. Two of these mechanisms – posttranslational control of carbon flux and FoxO 
à Gck/G6pc – complement each other nicely in their ability to bridge the gap between insulin’s control of 









5.4. One Wonders 
Although the experiments presented in this thesis allow us new insights into hepatic insulin action and 
resistance, it brings up many more questions. Below are three of the more pressing issues and how we 
propose to test them. 
 
5.4.1. Acute vs. Chronic Effects of Insulin on GP and DNL 
We have proposed that selective IR operates both at the levels of acute and chronic insulin regulation of 
GP and DNL. Specifically, the former most likely proceeds via posttranslational modification of existing 
proteins while the latter hinges on de novo expression of new glucongeogenic/lipogenic enzymes. In 
order to test this hypothesis, we will treat hepatocytes with cycloheximide in order to inhibit new protein 
synthesis. We will then test the ability of insulin over the short term both to induce DNL and to inhibit GP. 
It is already known that the acute effect of glucagon on GP still proceeds even in the presence of 
cycloheximide [463], suggesting that the inhibition by insulin will be as well if it is merely a matter of 
reversing the acute effects of glucagon. We will also test the effect of cycloheximide on DNL in the setting 
of CHI treatment in order to assess whether the increase in basal Srebp1c and Gck expression are 
important in either increasing basal DNL or maintaining the acute insulin responsiveness of the process. 
Potential complication lies in our previous observation that cycloheximide treatment alone can increase 
basal Akt phosphorylation [247] and in an earlier report stating that cycloheximide treatment on its own 
can increase DNL in rats [464]. We will therefore be more concerned with the relative change (if any) with 
insulin compared to the cycloheximide/no insulin condition rather than compared to the vehicle/no insulin 
condition.  
 
5.4.2. FoxO1 Regulation of Gck Expression 
A key element of our proposed mechanism as to how FoxO1 mediates insulin’s effects on both lipid and 
glucose metabolism is its coordinate regulation of Gck and G6pc. In the case of the former, our new in 
vivo data suggest that Gck is at least partially a co-regulatory target of FoxO1. This possibility is not 
without precedent in the literature, as FoxO1’s regulation of Gck expression is mediated by interaction 
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with HNF-4α [179, 406]. We therefore are interested in directly testing whether FoxO1-DBD can indeed 
repress Gck expression. We have cloned the liver-specific Gck promoter into a luciferase vector and are 
currently performing reporter-gene experiments in isolated hepatocytes overexpressing FoxO1-WT and 
FoxO1-DBD. A determination that Gck is a bona fide co-regulatory target gene of FoxO1 would be a 
strong argument in favor of our model, as it would parallel the liver TG phenotype of L-DBD vs. L-FoxO1 
mice. We are also interested in pursuing co-immunoprecipitation experiments in order to determine the 
regulatory factors most important for FoxO1 regulation of Gck and other co-regulatory targets (e.g., 
Hsd3b5).  
 
5.4.3. Hepatocyte-Autonomous Regulation of FAO 
Our data provide evidence that insulin can regulate hepatocellular FAO at the transcriptional level through 
FoxO1 rather than only by affecting intracellular metabolite flux in the short term. Moreover, although FAO 
may be elevated in patients with hepatic IR or even NAFLD, the clinical approach to treatment of 
dyslipidemia includes treatment with fibrates, which act as PPARα agonists and thereby upregulate the 
FAO gene program to reduce steatosis and improve IR [465]. It is already well established that chronic 
treatment of primary hepatocytes with FFA induces IR [63, 466], but it is unclear whether the reverse 
holds. It would therefore be of interest to discern whether there is an alteration in FAO capacity in our 
hepatocyte model of CHI. We can test whether the selective IR of CHI affects FAO in the absence of 
confounding fluctuations in lipolysis, and then whether treatment of the cells with fenofibrate can reverse 
any adverse effects that arise. Studies have already demonstrated that treatment of primary hepatocytes 
with fibrates increases expression of genes not only involved in FAO per se but also those in glucose 
metabolism and various cell-stress responses [261, 467]. Indeed, the regulation of FAO in hepatocytes 
has been largely overlooked in favor of studying DNL, but it may well be an important contributor to the 






Type 2 diabetes and the metabolic syndrome are the great public-health crises of our day. Although we 
have learned much about their pathophysiology and treatment, even basic questions have remained. One 
of the most vexing of these has been the etiology of “selective” IR that contributes to the metabolic one-
two punch of excessive glucose production and hepatic steatosis. In this work, however, we have taken a 
step forward in unraveling this apparent paradox. Although important questions remain – especially 
regarding the relative importance of insulin’s acute vs. chronic regulation of glucose and lipid homeostasis 
in the liver – we now understand that FoxO1 biology can at least partially to bridge the gap. Discovering 






























Section 5.6:  
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